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 ABSTRACT  
Chronic kidney disease (CKD) is associated with a high infective burden and poorer 
vaccine responses. This thesis presents findings of a prospective observational study, 
where a non-biased approach was taken to systematically characterise the immune 
“landscape” in CKD and examine adaptive immune cell phenotypes associated with 
responses to two vaccines - seasonal trivalent influenza (TIV) and 23-valent 
pneumococcal polysaccharide (PPV23) - in older adults with and without CKD. 
Despite significantly higher rates of self-reported infections, reductions in humoral 
responses to vaccination in patients with CKD were subtle, but with evidence of 
hyporesponsiveness to repeat PPV23 vaccination. CKD patients had fewer circulating T 
and B lymphocytes than controls, greater proportions of “Th2-like” (CCR4+CCR6-
CXCR3-) and Treg cells (CD4+CD25+/highFoxP3+) and fewer Bregs 
(CD19+CD24highCD38high), but similar naïve/memory populations and “senescence”-
associated T cells (defined by loss of surface CD27/28 and/or gain of CD57/KLRG1). 
Unexpectedly, CMV was the main determinant of T cell phenotype in both study groups 
and was also associated with poorer responses to both vaccines. Examination of neutrophil 
function demonstrated reduced oxidative burst capacity, reduced NETs generation and 
impaired migratory accuracy to fMLP in patients with CKD.  
This study highlights the complexity of CKD-associated immune dysfunction and the 
important role played by CMV. 
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CHAPTER 1 
1 INTRODUCTION 
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1.1 The immune system in humans – an overview 
All mammals, including humans, exist in close association with microorganisms. 
Although the “rules of engagement” between host and microbe remain undefined, it is 
clear that microorganisms can have either a beneficial symbiotic relationship (as seen with 
bacterial colonisation of the intestine) or a damaging effect on the host, in which case 
these microorganisms are referred to as pathogens. Detrimental effects of host-microbe 
interaction have led to the evolution of a number of immune defence mechanisms to 
protect the host (1, 2).  
Three major immune defence mechanisms exist in humans: anatomical and physiological 
barriers e.g. skin and mucociliary clearance in the respiratory tract, together with innate 
and adaptive (also referred to as acquired) immune responses (3). A key feature 
distinguishing innate from adaptive immunity is the mechanism of pathogen recognition. 
Innate immunity relies on pattern recognition receptors (PRRs) – a limited repertoire of 
germline-encoded receptors with broad specificities, recognising highly conserved 
microbial structures or products of infection (1). This allows rapid (within hours) 
mobilisation of immune effector responses against pathogens. In contrast, the adaptive 
immune system relies on an extremely diverse repertoire of antigen receptors, but with 
narrow specificities, which arise from essentially random somatic recombination of 
germline gene segments (3). The trade-offs for the ability to recognise virtually any 
antigen are a time delay in generation of effective adaptive immune responses 
(approximately 5 days is required for clonal expansion of effector cells to clear pathogens) 
and the risk of inappropriate immune activation to self-antigens, or autoimmunity, which 
has led to the evolution of a number of tolerance mechanisms (1).  
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Another important distinction between innate and adaptive immune systems is the ability 
of adaptive immunity to generate antigen-specific immunological memory, with 
augmented effector responses upon pathogen re-encounter (3). This mechanism is the 
basis for vaccination as a therapy to reduce burden of infectious disease - discussed later 
in this chapter. 
 
1.2 The innate immune system 
The innate immune system has both cellular and humoral components, which are 
summarised in Table 1-1. Description of the function of all innate immune components is 
outside the scope of this Chapter, but the main features pertinent to pathogen clearance are 
described in the following sections.  
 
1.2.1 Innate immune system pathogen recognition mechanisms 
Three broad strategies for pathogen recognition are employed by the innate immune 
system (summarised in Table 1-2): the detection of “microbial non-self” or pathogen-
associated molecular patterns (PAMPs), detection of “danger” signals or damage-
associated molecular patterns (DAMPs) associated with infection and inflammation, and 
the detection of “missing self” – molecules present on healthy cells that are downregulated 
with infection (2). 
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Table 1-1 Summary of innate immune system components and their main functions.  
GI: gastrointestinal; NET: neutrophil extracellular trap; CRP: C-reactive protein; NK cell: natural 
killer cell. Compiled from references (2-4). 
 
Component	 Main function Location
Non-haematopoietic cells
Epithelial	 cells Barrier – physical	and	physiological	e.g.	
secretion	of	mucin,	low	pH	environment	of	
stomach;
Chemokine	and	cytokine	secretion;
Skin,	airways,	GI	tract
Haematopoietic cells	(myeloid	lineage)	
Monocytes Precursors for	tissue-dwelling	macrophages;
Phagocytosis	(poor);
Cytokine	&	chemokine	production;
Blood
Macrophages Phagocytosis
Cytokine	&	chemokine	production Tissue	resident	e.g.	Kuppfer cells	(liver)
Neutrophils Phagocytosis;
NETs generation;
Cytokine	production.
Blood	&	tissues;	
migrate	 to	site of	
injury	in	response	to	
chemotactic	signals
Dendritic	cells Antigen	presentation	to	T	cells
Cytokine	and	chemokine	production.
Tissue;	migrate	 via	
blood	&	lymph to	
secondary	lymphoid	
organs.
Eosinophils Helminth	defense – release	of	cytotoxic	
enzymes	&	proteins
Blood &	tissues;	
migrate	 to	site	of	
injury	in	response	to	
chemotactic	signals.
Mast	cells Allergy
Release	of	histamine, serotonin	à
vasodilation;
Leucotrienes,	prostaglandins	àincreased
vascular	permeability
Mucosal	and	
connective	tissues
Basophils Allergy
Anti-tumour responses Blood
NK cells Intracellular	pathogen	defense
Direct	cell	 lysis	(perforin/granzymes)
Cytokine production	(Type	1	interferons)
Blood
Humoral	components
Complement Opsonisation
Recruitment of	other	immune	cell	types
Direct	cell	 lysis
Blood
Acute phase	
proteins	e.g.	
CRP,	pentraxins
Opsonisation
Synthesised in	liver
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Table 1-2 Summary of innate immune system pathogen recognition receptors.  
PAMPs: pathogen associated molecular patterns; TLR: Toll-like receptor; NOD: nucleotide-
binding and oligomerisation domain; RNA: ribonucleic acid; DNA: deoxyribonucleic acid; 
DAMPs: damage-associated molecular patterns; NLRP3: nucleotide-binding domain leucine-rich 
repeat family, pyrin domain containing 3; RAGE: receptor for advanced glycation end products; 
MHC – major histocompatibility complex; KIR – killer cell immunoglobulin-like receptor. 
Adapted from reference (2) under the Creative Commons License.  
 
 
The best characterised class of PRRs is Toll-like receptors (TLRs) – a group of dimeric 
transmembrane proteins that recognise conserved microbial components, which can be 
located both on the cell surface membrane or localised intracellularly (e.g. on endosomes) 
(3). The TLR family consists of 10 different receptors (summarised in Table 1-3), each of 
which recognises a limited and different repertoire of “microbial non-self” PAMPs (3, 5). 
Intracellular signalling activated by TLR ligation leads to activation of transcription 
factors including nuclear factor kB (NFkB) and generates an inflammatory response. 
	 Receptor	types	
Detecting	microbial	“non-self”	
(PAMPs)	
	
	
	
	
	
	
	
Transmembrane:	
• TLR	
• C-type	lectin	(e.g.	dectin	1	fungal	PAMPs)	
	
Intracellular:	
• NOD-like	receptors	(e.g.	NOD1/2	-	bacterial	
peptidoglycans)	
• RIG-1,	MDA5	(viral	RNA)	
• DAI	(viral	DNA)	
Detecting	common	metabolic	
consequences	of	cell	
injury/infection	(DAMPs)	
• NOD-like	receptors		
(e.g.	in	NLRP3	inflammasome	activation)	
• RAGE	
Detecting	“missing	self”	 • MHC	class	1-specific	inhibitory	receptors	(e.g.	KIR	on	natural	killer	cells)		
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TLR-ligand interactions stimulate tissue-resident macrophages to secrete cytokines 
including tumour necrosis factor a (TNFa) and interleukins (IL) 1b and IL-6, which 
orchestrate local and systemic inflammation. Endothelial actions of TNFa and IL-1b 
induce vasodilation and increased vascular permeability, facilitating immune cell 
recruitment to the site of infection. Hepatocyte stimulation by IL-1b and IL-6 results in the 
production of various acute-phase proteins, including pentraxins and collectins, which 
opsonise microbes for phagocytosis by macrophages and neutrophils and also activate 
complement.  
 
Table 1-3 Toll-like receptors (TLRs) and their known ligands.  
Exogenous ligands denoted by black text, endogenous ligands highlighted in blue. dsDNA: 
double-stranded deoxyribonucleic acid; siRNA: small interfering ribonucleic acid; ssRNA: single 
strand ribonucleic acid. Adapted from reference (3) under the Creative Commons Licence. 
TLR Ligand(s)
TLR1 Lipopeptides, peptidoglycans
TLR2 Lipopeptides, lipotechoic acid,	glycolipids
TLR3 dsDNA, siRNAmRNA
TLR4 Lipopolysaccharide,	phosphorylcholineHeat shock	protein,	defensin 2,	fibrinogen
TLR5 Flagellin
TLR6 Lipopeptides
TLR7	/	8 ssRNA, resiquimodAutoantigen-containing	immune	complexes
TLR9 CpG DNAChromatin	complex
TLR10 unknown
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It is important to note that pathogen sensing occurs in both haematopoietic and non-
haematopoietic cells (e.g. endothelial cells) and the magnitude of the elicited 
inflammatory response (and the potential to cause tissue damage) can be determined by 
“where” the pathogen is sensed. For example, sensing of widely disseminated blood-borne 
pathogens stimulates a robust systemic inflammatory response, contrasted by only 
localised inflammation in response to pathogen sensing at an immunological barrier e.g. 
skin (6). 
 
1.2.2 Cellular effector mechanisms of the innate immune system  
The main innate immune cellular effector mechanism is phagocytosis – the recognition, 
engagement, engulfing and subsequent destruction of pathogens  - which can be 
performed by monocytes, macrophages, neutrophils and eosinophils – collectively termed 
“phagocytes” (4). Phagocytosis is essential for host defence against intra and extracellular 
bacteria, together with fungal pathogens. Innate immune cells also play a key role in co-
ordinating the adaptive immune response through antigen presentation, which will be 
discussed later.  
1.2.2.1 Phagocytic function of innate immune cells 
Phagocytes engulf pathogens by creating a membrane bound vesicle (phagosome) with 
projections of their cytoplasmic membrane (pseudopodia), which then fuses with 
cytoplasmic granules containing “killing machinery”, thus forming the phagolysosome. 
Two main killing mechanisms are employed: respiratory burst – an NADPH oxidase 
dependent process that yields the production of reactive oxygen species including 
hydrogen peroxide, and the action of non-oxygen-dependent toxic enzymes and cationic 
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proteins e.g. lysozyme and myeloperoxidase (7). Phagocytosis is facilitated by “marking” 
or opsonisation of microbes with products of the acute phase response, complement 
proteins and specific antibody. In addition to phagocytosis, neutrophils extrude 
intracellular DNA to form neutrophil extracellular traps (NETs), the function of which 
remains to be fully elucidated, but includes pathogen capture and thrombosis (8, 9).   
1.2.2.2 Humoral effector mechanisms of the innate immune system 
The main humoral component of the innate immune system is the complement system – a 
group of glycoproteins found in tissues and the circulation, the sequential activation of 
which is responsible for its 3 main functions: opsonisation, chemotactic activity and 
recruitment of phagocytes, together with direct cell lysis through formation of the 
membrane attack complex (MAC) (10). Figure 1-1 summarises the 3 pathways of 
complement activation and the main functions of individual components of the 
complement cascade.     
 
1.3 The adaptive immune system 
The hallmarks of adaptive immunity are immunologic specificity (with adaptive immune 
cells having an extremely diverse repertoire of antigen receptors with narrow 
specificities), discrimination of self and non-self (with the ability to remain inactive 
against self-antigens) and the ability to generate antigen-specific memory, with augmented 
effector responses upon antigen re-encounter (3).  
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Figure 1-1 Summary of complement cascade and pathways of activation  
Complement activation can occur through classical, lectin and alternative pathways, initiating the 
assembly of C3 convertases (C4bC2a, C3bBbp), which cleave C3 to generate C3b (opsonin) and 
C3a (anaphylatoxin). The activation pathways converge on a common terminal pathway with 
proteolytic activation of C5, which results in the formation of C5a (anaphylatoxin) and C5b. The 
latter forms the nucleus of the C5b-9 complex, which either remains in its soluble form (sC5b-9) 
or assembles in the membrane as the membrane attack complex (MAC). Complement activation is 
regulated by numerous inhibitors and at various levels of the cascade. Ab, antibody; Ag, antigen; 
CR1, complement receptor 1; C1INH, C1 inhibitor; C4BP, C4b-binding protein; DAF, 
complement-decay accelerating factor; MASP1, mannan-binding lectin serine protease 1; MBL, 
mannose-binding lectin; MCP membrane cofactor protein. Reproduced from reference (10) with 
permission from Springer Nature Limited.  
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1.3.1 Adaptive immune system cell types 
The main adaptive immune system cell types are T and B lymphocytes, which originate 
from haematopoietic precursors in the bone marrow (BM). Early T lineage progenitors 
migrate to the thymus during their development, whereas B cell progenitors remain in the 
BM. Lymphocyte activation and differentiation into mature effector cells occur at 
peripheral sites such as lymph nodes, spleen and mucosal- or gut-associated lymphoid 
tissues (MALT/GALT). The sites of lymphocyte development (bone marrow, thymus) are 
termed primary lymphoid organs and sites of activation are termed secondary lymphoid 
organs. The majority of lymphocytes are found in lymphoid organs, but migrate between 
them through blood and lymph (3, 7).  
 
1.3.2 Adaptive immune system pathogen recognition mechanisms 
As described earlier, the key feature of adaptive immune pathogen sensing mechanisms is 
the presence of a wide variety of highly specific antigen receptors, generated during 
lymphocyte development through random rearrangement of a small number of genes (V, 
D and J segments, see Figure 1-2), coupled with somatic hypermutation (3). Lymphocytes 
with “self-reactive” receptors are deleted from the repertoire during development. Both B 
cell receptors (BCRs) and T cell receptors (TCRs) are expressed on the lymphocyte 
surface and each lymphocyte has multiple copies of the same receptor, rendering them 
mono-specific (3). After appropriate stimulation with cognate Ag, lymphocytes undergo 
rapid clonal proliferation and differentiation into effector cells (detailed below). Over 
time, the repertoire of BCRs and TCRs therefore undergoes clonal selection, with 
expansion of populations recognising previously encountered antigens (1).  
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Figure 1-2 Diversification of lymphocyte receptor repertoire  
A – BCRs and TCRs have a similar structure. Each contains two distinct subunit chains (BCR: 
light and heavy chains); TCR (a and b chains). The variable regions of each chain (encoded by V, 
D, and J gene segments) form the antigen binding surface. B – diversification of antigen receptors 
is primarily established through rearrangement of V, D and J gene segments during lymphocyte 
development. A schematic of the BCR heavy chain is shown, but TCR mechanisms are similar, 
with exception of somatic hypermutation and class-switch recombination, which are mechanisms 
of BCR-specific secondary diversification. BCR: B cell receptor; TCR: T cell receptor; V, D and J: 
Variable, Diversity and Joining gene segments. Reproduced from (11) with permission from 
Elsevier. 
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1.3.2.1 The B cell receptor  
The BCR is a surface immunoglobulin or antibody – a Y shaped, flexible molecule made 
up of 2 heavy and 2 light chains (see Figure 1-2 A). The type of heavy chain defines 
antibody class and determines function (summarised Table 1-4). Both types of chains have 
constant and variable regions, the latter of which is the antigen binding site (3), 
recognising the 3-dimensional conformation of antigenic epitopes (7). 
Table 1-4 Summary of antibody class and function 
Ig: immunoglobulin. Adapted from reference (3) under the Creative Commons Licence. 
 
1.3.2.2 The T cell receptor 
The TCR consists of 2 chains (most commonly a and b, see Figure 1-2 A) and is 
associated with a membrane protein complex that propagates downstream signalling after 
TCR ligation, collectively known as cluster of differentiation (CD) 3 (12), which is 
frequently used as a lineage marker for T cells in phenotyping studies.  
Immunoglobulin	class	 Function	
IgG		
(subclasses:	IgG1-4)	
Major	form	of	circulating	antibody	
Secreted	during	secondary	
response	
IgA		
(subclasses:	IgA1,2)	
Major	form	of	antibody	in	mucosal	
immunity	
IgM	 Secreted	early	during	primary	
response	
IgE	 Triggers	immediate	allergic	
reactions	
IgD	 Exact	function	unclear	
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1.3.2.3 TCRs only recognise antigen presented with major 
histocompatibility molecules 
In contrast to the BCR, the TCR recognises linear antigenic peptides and only in 
combination with a major histocompatibility (MHC) molecule. As such, for TCR ligation 
to occur, the antigen first needs to be broken down by specialised antigen-processing cells 
(APCs) present at the site of injury/microbial invasion. Dendritic cells (DCs) are specialist 
APCs that fulfil this role (see Figure 1-3). Tissue-resident DCs actively internalise 
microbial products in their environment, presenting antigenic peptides on their cell surface 
in combination with either class I or class II MHC molecules. In the context of 
infection/inflammation, after “antigen capture” DCs migrate to secondary lymphoid 
organs where they interact with T lymphocytes (3). 
 
1.3.2.4 Costimulatory signals are required for T cell activation 
In contrast to pathogen sensing mechanisms in the innate immune system, T cells require 
additional information about the antigen they recognise before activation and 
differentiation occurs (1), as if to confirm that the antigen is truly associated with a 
pathological process (summarised in Figure 1-4). This is delivered through a number of 
co-stimulatory signals, in particular the ligation of T cell CD28 with APC-derived CD80 
or CD86. Other signals include interaction of T cell CD27, OX-40 and CD30 with their 
respective APC-derived ligands CD70, OX-40L and CD30L. The expression of these 
ligands is only induced on DCs after pathogen encounter, hence giving a distinct “action is 
needed” signal to cognate T cells (12). In the absence of co-stimulation, TCR ligation 
renders T lymphocytes anergic and unable to respond to subsequent stimuli. T cells also 
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express a number of inhibitory receptors that enable fine-tuning of the T cell response e.g. 
cytotoxic T lymphocyte antigen (CTLA)-4, which competitively inhibits CD80/86 binding 
to CD28 and also directly inhibits signalling downstream of the TCR (12). 
Costimulatory signals and the production of various soluble mediators after pathogen 
encounter that shape the differentiation of CD4+ T cells (described later) are ways that the 
innate immune system exerts control over the type of adaptive immune effector response 
that is induced (1, 6).  
 
Figure 1-3 Antigen presentation to T cells by dendritic cells.  
Antigens presented by dendritic cells in combination with MHC Class I molecules activate cognate 
CD8+ T cells – this can occur either through direct presentation of intracellular antigen by DCs or 
through cross-priming, which allows presentation of exogenous antigens to CD8+ T cells. 
Activation of cognate CD4+ T cells occurs after presentation of antigen combined with MHC 
Class II molecules. CD: cluster of differentiation; MHC: major histocompatibility complex. 
Reproduced from reference (13) with permission from Springer Nature Limited. 
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Figure 1-4 Signals leading to induction of T cell activation and differentiation.  
Recognition of antigen presented by APCs by naïve T cells represents the first signal, which is 
followed by ligation of costimulatory molecules e.g. CD28 by APC-derived CD80/86 (signal 2), 
necessary for full T cell activation. Finally, cytokines released by immune cells involved in the 
pathogen response enhance cellular expansion and induce differentiation into specific effector 
phenotypes (signal 3). MHC: major histocompatibility complex; CD: cluster of differentiation; 
TCR: T cell receptor; IL: interleukin; IL-2R: interleukin 2 receptor; DC: dendritic cell. 
Reproduced from reference (14) under the terms of the Creative Commons Attribution Licence.  
 
1.3.3 T lymphocyte effector functions  
T lymphocyte populations are primarily distinguished by surface expression of CD4 and 
CD8 molecules. The canonical function of CD8+ T cells is cytotoxicity. Naive CD8+ T 
cells recognise antigen bound only to class I MHC molecules, which are constitutively 
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expressed on all nucleated cells. CD8+ T cell effectors are the main players in the adaptive 
response to viral infections. Activated CD8+ T cells directly induce target cell death by 
perforin-mediated intracellular delivery of pro-apoptotic proteases (granzymes) and can 
also inhibit intracellular pathogen replication through the actions of secreted cytokines 
including Type 1 interferons (IFN) (3).  
Activated CD4+ T cells secrete a number of soluble mediators (cytokines) that help to both 
co-ordinate (“help”) and regulate the wider immune response. Naïve CD4+ T cells interact 
with cognate antigen bound to class II MHC molecules, the expression of which is 
restricted to immune cells (3, 7, 12).  
Current understanding of the diversity of the CD4+ T cell effector responses is 
summarised in Figure 1-5. The type of effector CD4+ T cell phenotype induced depends 
on the context of antigen encounter and the class of pathogen they recognise. 
Differentiation of naïve CD4+ T cells into various effector phenotypes is largely directed 
by cytokines released by innate immune cells (including DCs) during initial pathogen 
recognition, which control the expression of transcriptional master regulators including T-
bet, GATA-3 and RORgT (3).  
Individual CD4+ T helper (Th) phenotypes are characterised by a distinct pattern of 
cytokine secretion. For example, Th1 cells play a key role in defense against intracellular 
bacteria and protozoa through secretion of IFN-g and TNF-a. The innate pathogen 
recognition mechanisms for these microorganisms lead to the production of IL-12 by DCs, 
which drive differentiation of CD4 T cells into the Th1 phenotype through activation of 
the transcription factor T-bet (3). It has recently been shown that Th subsets can also be 
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distinguished by their surface expression of chemokine receptors, including CCR4, CCR6 
and CXCR3 (15, 16).  
Figure 1-5 CD4+ T cell differentiation into effector phenotypes. 
T cell-APC interaction and the different cytokines produced during the immune response to 
various pathogens stimulate CD4+ T cell differentiation into a number of effector phenotypes. T-
helper (Th) 1 cells promote immune responses directed against intracellular pathogens and secrete 
mainly interferon (IFN) g and tumour necrosis factor (TNF) a. Th2 cells are involved in helminth 
defence and secrete interleukins (IL) 4, 5 and 13. Th17 cells secrete IL-17 and IL-22, regulating 
local immune responses and are involved in autoimmunity. Follicular Th cells (fTh) interact with 
B cells to stimulate robust antibody production. Regulatory T cells (Treg) limit the extent of 
immune/inflammatory responses. Reproduced from reference (3) with permission from Elsevier. 
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1.3.4 Generation of T cell memory 
T cells downregulate their surface expression of CD45RA after encounter with their 
cognate antigen and this marker is frequently used to distinguish memory from naïve T 
cells (17). Once T cell activation has occurred, clonally expanded antigen-specific CD4 
and CD8 effectors migrate from secondary lymphoid organs to the site of infection, where 
they exert their functions.  
The primary T cell response typically peaks at 7-15 days after antigen exposure 
(summarised in Figure 1-6), roughly corresponding to the eradication of pathogen by a 
successful immune response (12). This is followed by a marked contraction of antigen-
specific T cells, leaving behind a relatively small pool of long-lived memory T cells. For 
both CD4+ and CD8+ T cells, memory cells can be divided into 2 main subclasses: central 
memory (TCM) and effector memory (TEM) (18). TCM cells have an enhanced potential for 
proliferation upon re-exposure to their cognate antigen and express high levels of the 
secondary lymphoid organ-homing chemokine receptors CCR7 and CD62L. In contrast, 
TEM cells have limited proliferative capacity after antigen re-encounter, but can rapidly 
mount effector functions e.g. granzyme and IFNg secretion. TEM cells lack the surface 
expression of CCR7 and CD62L and are, therefore, preferentially trafficked through non-
lymphoid tissues to peripheral sites of antigen encounter. A subset of TEM cells re-
expressing the marker CD45RA (usually associated with naïve T cells) - TEMRA -  are 
expanded with chronic viral infections e.g. cytomegalovirus (detailed later in this chapter). 
Initially thought to represent terminally differentiated, non-functional “exhausted” T cells, 
TEMRA exhibit potent cytotoxic effector activity (19).  
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Figure 1-6 Generation of T cell memory. 
Effector T cells (TEff) responding to antigen presented by dendritic cells (DCs) differentiate into 
various T helper (TH) subsets, examples of which are shown. Two main T cell memory subsets 
also develop: central memory (TCM) T cells that home to lymph nodes and effector memory (TEM) 
cells that migrate through non-lymphoid tissues. Memory T cells replicate and differentiate into 
TEFF populations upon antigen re-encounter. IL: interleukin; IFN: interferon; PNG: 
polymorphonuclear granulocyte. Reproduced from reference (13) with permission from Springer 
Nature Limited.  
 
1.3.5 Regulatory T cells 
Regulatory T cells (Tregs – CD25+FoxP3+ CD4 T cells) play an important role in immune 
tolerance by limiting the extent of the immune response and associated tissue damage 
through inhibition of the activity of APCs and effector lymphocytes (particularly Th cells) 
(3, 20). 
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1.3.6 B lymphocyte effector mechanisms  
The product of B lymphocytes – antibody - can neutralise antigen by preventing its 
binding to specific cellular targets and is able to recruit additional effector mechanisms for 
pathogen clearance through opsonisation of microbes and activation of complement (3). 
After activation through the BCR, naïve B cells differentiate into both antibody secreting 
cells (ASCs), termed plasma cells, and high-affinity memory B cells (summarised in 
Figure 1-7). 
 
Figure 1-7 B cell differentiation and generation of memory. 
B cells activated by cognate antigen (Bact) and helped by T cells (Th) differentiate into short-lived 
plasma cells, which produce the first wave of antibody (Ab) targeting pathogens. Germinal centre 
reactions involving Bact cells in secondary lymphoid organs (e.g. lymph nodes) generate long-lived 
plasma cells (which continuously secrete Ab) and high-affinity memory B cells (BM) that 
efficiently differentiate into high-affinity antibody secreting plasma cells upon antigen re-
encounter. Reproduced from reference (13) with permission from Springer Nature Limited. 
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1.3.7 Antigen-naïve B cell subsets 
Several naïve B cell subsets exist: follicular B cells (present in secondary lymphoid 
tissues), marginal zone (MZ) B cells (localised to splenic MZ) and B1 B cells, found in 
serous cavities including peritoneum and pleura (21, 22). Naïve B cells initially express 
immunoglobulins of the IgM and IgD isotypes, but are able to switch to secretion of IgG, 
IgA and IgE after activation.  
 
1.3.8 T-dependent B cell activation and the germinal centre response 
High affinity, class switched antibody is produced through activation of follicular B cells 
and their interaction with helper T cells in specialised cellular structures in secondary 
lymphoid organs, termed germinal centres (GCs) (21) – summarised in Figure 1-8. This 
process is dependent on the APC function of B cells: naive B cells that encounter their 
cognate antigen internalise and process it, and then present antigenic peptide fragments in 
conjunction with class II MHC to CD4+ T cells. In GCs, activated B cells undergo somatic 
hypermutation of their BCR genes, immunoglobulin class switch recombination (CSR or 
isotype switching), affinity maturation and clonal expansion (6, 23). CSR largely occurs in 
response to 2 signals: binding of follicular T helper cell (Tfh) CD40L to B cell-derived 
CD40 and secretion of distinct sets of cytokines (e.g. from Th1 and Th2 cells), which help 
to direct isotype and subclass selection (3, 6). Antigens eliciting such a response are 
termed T-dependent (TD) antigens. 
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Figure 1-8 T-dependent (TD) B cell activation.  
Follicular (FO) B cells are activated by relatively weak BCR crosslinking and costimulatory 
signals provided by cognate CD4+ T cells. These B cells first differentiate into germinal centre 
(GC) B cells and undergo class switch recombination and clonal selection, followed by generation 
of memory plasma cells (PC) or memory B cells. BCR: B cell receptor; CD: cluster of 
differentiation; BM: bone marrow. Reproduced from reference (21) with permission from Elsevier. 
 
 
1.3.9 T-independent B cell activation and the extra-follicular response 
Antibody production and generation of Ag-specific B cell memory can also occur in the 
absence of T cell help (see Figure 1-9). Such “T-independent” (TI) antigens can activate B 
cells either by concomitant ligation of TLRs and the BCR (e.g. lipopolysaccharide (LPS), 
flagellin – described as TI-1 antigens) or through extensive BCR crosslinking by a highly 
repetitive arrangement of antigenic epitopes, as is seen with bacterial polysaccharides (PS, 
described as TI-2 antigens) (1, 21). MZ and B1 B cells play a key role in responses to TI 
antigens (21). This extra-follicular B cell response results in the transient generation of 
low affinity antibody, most commonly of the IgM isotype, although class switch can also 
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occur as a result of canonical & non-canonical NF-kB signalling-induced activation-
induced cytidine deaminase (AID) expression that follows TLR ligation (6).   
 
Figure 1-9 T-independent (TI) B cell activation 
Marginal zone (MZ) or B-1 B cells are stimulated by strong crosslinking of the BCR (B cell 
receptor) by highly repetitive TI antigens e.g. polysaccharides (PS), together with accessory 
danger signals delivered via TLR (Toll-like receptor) stimulation by PAMPs (pathogen associated 
molecular patterns) or pro-inflammatory cytokines. Memory plasma cells are generated as a result 
of this extrafollicular response and home to bone marrow (BM) niches. Reproduced from 
reference (21) with permission from Elsevier.  
 
 
1.3.10 Generation of B cell memory 
ASCs “fight from a distance” - most plasma cells migrate to bone marrow (mediated by 
upregulation of the chemokine receptor CXCR4) to reside in uniquely supportive niches, 
where they produce large amounts of antibody that is carried in the bloodstream and by 
other bodily fluids to the site of infection (3, 23). The lifespan of plasma cells varies. 
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Short-lived (days) plasma cells are responsible for the acute phase of antibody secretion, 
whereas long-lived (years) plasma cells maintain circulating levels of antibody after 
pathogen clearance. Although both TI and TD antigens give rise to both short and long-
lived plasma cells, the effector quality of the latter is far superior from TD mechanisms 
than from TI (23).  
Memory B cells are largely generated from GC reactions and rapidly differentiate into 
high-affinity ASCs following repeat exposure to their cognate antigen, thus achieving 
faster pathogen clearance than the primary response. Different subtypes of memory B cells 
are identified by their different Ig isotypes (e.g. IgM and IgG or class-switched memory B 
cells) and levels of expression of costimulatory molecules (24).  Memory B cells can 
differentiate from responses to TI antigen, but appear to lack the canonical functions of 
memory - that is, enhanced sensitivity to Ag re-stimulation and lifespan compared to 
unstimulated cells (21). Importantly, reduced TI memory B cell responses to re-challenge 
with their cognate TI antigen has previously been reported (21, 25). This may be a 
regulatory response to antigens that biodegrade slowly e.g. polysaccharides (21), but the 
full biological significance of this remains unclear.  
 
1.3.11 Regulatory B cells 
A regulatory subset of B cells (Bregs) plays an integral role in maintaining immune 
homeostasis, through secretion of the cytokines IL-10, TGF-b and IL-35. Bregs direct T cell 
differentiation towards a Treg phenotype, inhibit the differentiation of Th1 and Th17 
phenotypes and induce anergy in CD8+ effectors, thus limiting tissue damage due to 
pathogen-induced inflammation (26).  
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1.4 Vaccination  
The principle of vaccination is to utilise the ability of the adaptive immune system to 
generate long-lived antigen-specific memory (with enhanced responses upon antigen re-
exposure) by using an agent that closely mimics natural infection with the pathogen of 
interest, but does not cause disease. The ideal vaccine closely mimics natural innate & 
adaptive immune activation to induce long-lasting humoral and cellular memory, without 
eliciting toxicity e.g. inflammation to a degree that would be damaging to the host.  
 
1.4.1 Types of vaccines currently used in humans 
Several broad groups of vaccines exist. Live attenuated vaccines (LAVs, consisting of 
weakened versions of pathogens e.g. smallpox, varicella, measles) generally elicit the 
most robust memory responses (even after a single vaccination) as they are the closest 
mimic to natural infection (27).  
“Non-live” vaccines use inactivated pathogens, antigenic protein subunits (e.g. HBV), 
inactivated toxins (toxoids e.g. DT/TT) or bacterial polysaccharides e.g. the 23-valent 
pneumococcal polysaccharide vaccine (PPV23) (27). Glycoconjugate vaccines, where 
bacterial polysaccharides (TI antigens that, alone, elicit weak memory responses) are 
covalently bound to a protein that engages with and stimulates T cell responses, thus 
enhancing the quality of the polysaccharide response, are an important tool used in 
eliciting immune responses to TI antigens in the immature immune systems of infants and 
young children (28).  
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1.4.2 Vaccine adjuvants 
As “non-live” vaccines generally elicit weaker immune responses compared to LAVs, 
they typically contain other substances that enhance the quality and diversity of the 
elicited immune response – adjuvants. The 3 common licensed adjuvants are summarised 
in Table 1-5. Adjuvant effects are largely elicited through activation of components of the 
innate immune system e.g. by enhancing pathogen recognition and presentation, 
stimulation of cytokine and chemokine secretion with resultant recruitment of immune 
cells to the site of vaccine delivery, together with inflammasome activation (29). In 
addition, adjuvants can mimic the different immune effector polarisation signals required 
for effective clearance of different types of pathogens (e.g. virus, bacteria). 
 
1.4.3 Assessing vaccine response 
Responses to vaccination are generally evaluated by the magnitude of the elicited humoral 
adaptive response (30, 31). Although vaccine induction of neutralising antigen-specific 
antibody is thought to be important in preventing disease (particularly for viruses), the 
amount of antibody required for this protection remains unclear for many pathogens. More 
recently, the polyfunctionality of antigen-specific T cells elicited by vaccination has been 
proposed as a key cellular read-out for the quality of vaccine response, particularly to viral 
antigens e.g. influenza (32). This is supported by the observation that live attenuated 
influenza vaccines can elicit far superior protection against infection, but with a lower 
magnitude of antibody response to their inactivated vaccine counterparts (33).  
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Table 1-5 Summary of common vaccine adjuvants licensed for use in humans.  
DT: diphtheria toxoid; TT: tetanus toxoid; Hib: Haemophilus influenzae b; Th: T helper; NLRP3: 
nucleotide-binding domain leucine-rich repeat family, pyrin domain containing 3; TLR: Toll-like 
receptor; DC: dendritic cell; APC: antigen-presenting cell. Adapted from reference (29) under the 
Creative Commons Licence. 
 
 
Adjuvant Mechanism of	Action	 Effect on	immune	response Licensed vaccines
Alum Induction of	local	cytokine	and	
chemokine	secretion
Immune	cell	recruitment	
(monocytes,	macrophages,	
eosinophils)
Enhanced	antigen	presentation
NLRP3	inflammasome activation
Independent	of	TLR	signalling
Enhanced antibody	
production
Polarisation towards	Th2	
effector	responses
Many vaccines	
including	DT/TT,	
Hib,	Hepatitis	B	
(Engerix B)
MF59 Induction of	local	cytokine	and	
chemokine	secretion
Immune	cell	recruitment	
(neutrophils,	monocytes,	
macrophages)
Enhanced	antigen	uptake	by	APCs
Enhanced	trafficking	of	antigen-
loaded	neutrophils	and	monocytes	
in	draining	lymph	nodes
Independent	of	TLR	signalling
Balanced	Th1	&	Th2	
responses
Influenza	vaccine	
(Fluad),	H1N1	
pandemic	vaccines
AS04 Induction of	local	cytokine	and	
chemokine	secretion
Immune	cell	recruitment	 (DCs,	
monocytes)
Enhanced	trafficking	of	antigen-
loaded	DCs	and	monocytes	in	
draining	lymph	nodes
TLR4 signalling to	activate	APCs
Enhanced	antibody	
production
Polarisation towards	Th1	
effector	responses
Human	papilloma
virus	(CervarixTM)
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1.5 Common respiratory pathogens in humans 
In the next section of this Chapter, I will briefly describe two common respiratory 
pathogens for which vaccines are commonly used in adults to reduce morbidity and 
mortality: influenza virus and Streptococcus pneumoniae. 
 
1.6 Influenza virus 
Influenza viruses are negative strand RNA viruses of the Orthomyxoviridae family and the 
3 main types known to cause human disease are summarised in Table 1-6 (34). Influenza 
A viruses are, to date, the only types to have caused pandemics (34), and, together with B 
viruses, are responsible for the majority of clinically significant influenza disease in 
humans (35).  
 
1.6.1 Epidemiology of influenza virus infections 
In climates with seasonal variation (away from the equator), influenza virus activity is 
increased during the colder months e.g. typically from December to March in the northern 
hemisphere (34). This variation has coined the term “seasonal influenza”. Although 
clinically significant influenza pandemics occur outside this variation, their description is 
outside the scope of this Chapter. Seasonal influenza represents an important global health 
problem. Influenza-related mortality is estimated at 4.0 to 8.8 per 100 000 individuals per 
year, which equates to 290 000 – 645 000 seasonal influenza-associated respiratory deaths 
worldwide (36).  
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Table 1-6 Summary of influenza virus types known to cause human disease. 
HEF: haemagglutinin-esterase-fusion protein. Table compiled from references (34, 35) under the 
Creative Commons Licence. 
 
 
1.6.2 Clinical features of influenza infection 
Influenza virus generally causes an acute respiratory disease and  
Figure 1-10 summarises the main clinical symptoms and complications of influenza virus 
infection. Virus transmission is typically through respiratory droplets and direct contact 
with infected (virus-shedding) individuals, with the incubation period lasting between 1 
and 4 days. Complications are more common in young children, healthy adults over 65 
years of age and immunocompromised adults e.g. with chronic diseases including chronic 
respiratory & kidney disease (discussed later). 
 
 
Influenza	
type
Subtypes Main	 reservoir At	 risk	groups
A Classification based	on	structure	of	
surface	haemagglutinin (H1-18)	and	
neuraminidase	 (N1-11)	antigens
Only	2	subtypes	currently	circulating:	
H1N1	and	H3N2.
Nomenclature	also	includes	natural	host	
species,	geographical	origin,	year	of	
isolation	and	strain	number
Acquatic birds,	
pigs,	horses, seals.	
All	ages;	severe	 disease	in	
immunocompromised	
individuals
B Classification	based	on	haemagglutinin
glycoprotein	structure
Humans Children	
C Only	one	glycoprotein (HEF) Humans All	ages,	but	generally	 causes	
mild	illness
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Figure 1-10 Summary of clinical symptoms, signs and complications of influenza virus 
infection.  
Symptoms and signs denoted by blue symbols, complications denoted by orange symbols. 
Reproduced from reference (35) under terms of the Creative Commons Attribution Licence.  
 
 
 
1.6.3 Immune responses to influenza infection 
Figure 1-11 summarises the immune response to natural influenza infection 
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Figure 1-11 Summary of immune responses to natural influenza virus infection.  
Compiled from (37). 
iNOS: inducible nitric oxide synthetase; TNF: tumour 
necrosis factor; Ab: antibody; HA: haemagglutinin; 
IFN: interferon; DC: dendritic cell; TLR: Toll-like 
receptor; NLRP3: nucleotide-binding domain leucine-
rich repeat family, pyrin domain containing 3; IL: 
interleukin; Th: helper T cell; CD: cluster of 
differentiation; NA: neuraminidase; Ig: 
immunoglobulin; Treg: regulatory T cells. Blue colour 
denotes innate responses; green colour denoted 
adaptive responses; purple colour denotes pathogen 
recognition mechanisms. 
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The influenza virus attaches to epithelial cells of the upper respiratory tract through 
haemagglutinin (HA) binding to sialic-acid residues on host membrane glycoproteins, 
which facilitates subsequent viral entry. Influenza neuraminidase (NA) is essential for 
intracellular viral propagation and release (34). 
 
1.6.4 Vaccination strategies against influenza 
Vaccination represents the most cost-effective way to prevent influenza disease and its 
associated complications. Current seasonal influenza vaccines are usually trivalent 
(derived from 2 influenza A strains and 1 B strain) and contain either live attenuated 
viruses or inactivated influenza antigens (summarised in Table 1-7).  
Table 1-7 Summary of common types of influenza vaccines. 
Ig: immunoglobulin; HA: haemagglutinin; NA: neuraminidase. Compiled from reference (38). 
Vaccine	type Antigenic	components Route	of	
administration
Patient	
group	
Immune	
responses
Live	
attenuated	
influenza	
vaccine	(LAIV)
Live	attenuated	influenza virus	
(trivalent)	– usually	propagated	in	
eggs.
Intranasal	
(mimics	natural	
infection route)
Children
and	adults	
(ages	2-49	
years)
Robust	mucosal	
IgA	 response
Cell-mediated	
response
Trivalent	
inactivated
influenza	
vaccine	(TIV)
Virus	initially propagated	 in	eggs.
Various compositions	and	structural	
organisation:
• Whole	inactivated	virus
• Virosomes (reconstituted	viral	
envelopes	consisting	of	HA,	NA	
and	viral	phospholipids)
• Split	antigen	 (virus	particles	
disrupted	by	diethyl	
ether/detergent;	 viral	 structural	
organisation and	ssDNA	lost)
• Subunit	antigen	(HA	and	NA	
proteins	only)
Intramuscular All	ages Neutralising
anti-HA	and	
anti-NA	
antibodies
Cell-mediated
response	less	
well	
characterised
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Although different methods of virus inactivation or TIV Ag composition may theoretically 
impact individual vaccine immunogenicity, this has not been borne out in meta-analyses 
(39, 40). Current vaccination strategies generally induce antibodies against HA and NA, 
the genes of which exhibit marked antigenic shift and drift. As such, neutralising 
antibodies generally lack cross-reactivity against non-matching influenza strains (34). 
Seasonal adjustments to vaccine strain composition are made in order to cope with this 
problem, based on WHO surveillance of prevalent influenza viruses (41). Table 1-8 
summarises the current recommendations for seasonal influenza vaccination in adults.  
Table 1-8 Current UK recommendations for influenza vaccination in adults. 
COPD: chronic obstructive pulmonary disease; HTN: hypertension; TIA: transient ischaemic 
attack; BMI: body mass index. Compiled from reference (42). 
Category Examples
All	adults	 aged	65 years	or	older
Adults <65	years	in	clinical	 risk	groups	(below)
Chronic	 respiratory	
disease
Asthma	requiring	 use	of	inhaled	 or systemic	steroids
COPD
Chronic	 heart	disease
Congenital	 heart	disease,	HTN	with	cardiac	complications,	 chronic
heart	failure,	 ischaemic heart	disease	requiring	 treatment	 or	
specialist	follow-up
Chronic	 kidney disease Stages	G3-5,	nephrotic	 syndrome,	kidney	transplantation
Chronic	 liver disease Cirrhosis,	 chronic	 hepatitis
Chronic	 neurological	
disease
Stroke/TIA;	clinically	vulnerable	individuals	with	 cerebral palsy,	
learning	disabilities,	 multiple sclerosis.
Diabetes	Mellitus All	types
Immunosuppression Chemotherapy	 recipients,	 bone	marrow	transplant,	 HIV	infection	 at	all	stages.
Asplenia/splenic
dysfunction Sickle	cell	disease
Pregnant	women Any	stage	of	pregnancy
Morbid	obesity BMI	≥	40kg/m2
Health	 &	social	 care	
workers	in	direct	contact	
with	 patients/clients
Hospital or	long-stay	care	facility staff,	main	carers of	an	elderly
person	whose	welfare	may	be	at	risk	if	carer falls	ill,	 individuals	 in	
receipt of	carer’s allowance.
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Recent Cochrane reviews concluded that seasonal inactivated influenza vaccination likely 
reduces the number of healthy and older (>65) adults that experience influenza infection 
and influenza-like illness, compared to unvaccinated individuals (43). However, the 
evidence of benefit in older adults, in particular with regards to influenza complications is 
limited. 
 
1.7 Streptococcus pneumoniae 
Streptococcus pneumoniae (pneumococcus, Pn) is a facultatively anaerobic encapsulated 
Gram-positive bacterium that frequently colonises the mucosal surfaces of the upper 
respiratory tract in humans (44). This extracellular pathogen is a highly adapted 
commensal with nasopharyngeal carriage rates of approximately 10% in adults, but as 
high as 65% in children (45). 
 
1.7.1 Clinical features of pneumococcal disease 
Pneumococci can cause varying degrees of local and systemic infection in its obligate 
human host through local spread (e.g. otitis media), aspiration (e.g. pneumonia) or 
bloodstream seeding (e.g. meningitis and/or septicaemia) (45). Indeed, pneumococcus is 
the most common causative organism of community-acquired pneumonia (CAP) 
worldwide (accounting for approximately 35% (46)). The term “invasive pneumococcal 
disease” (IPD) describes the presence of pneumococci in normally sterile sites e.g. blood 
or cerebrospinal fluid (47). Transmission is generally through respiratory droplet spread 
during close contact with pneumococcal carriers, but can also occur through fomites, as 
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pneumococcus can form hardy biofilms on inanimate objects that are resistant to the 
environment (44).  
 
1.7.2 Epidemiology of pneumococcal disease 
The burden of pneumococcal disease is high. Young children (under 5 years old) and older 
adults (over 65 years) are particularly affected. Estimated annual incidence of CAP in 
adults is 2-10 per 1000 individuals in western countries, markedly increasing with age 
(over 50 per 1000 person-years in individuals aged over 85) (47). The incidence of IPD is 
generally lower (estimates range from 10 to 50 per 100 000 person/years), but the case 
fatality rate is much higher (up to 30% in IPD versus approximately 10% in individuals 
hospitalised with CAP), again increasing with older age (47). Importantly, coinfection 
with pneumococcus is often seen during viral infections e.g. influenza, resulting in 
increased risk of morbidity (including incidence of IPD) and mortality, together with 
increased rates of pneumococcal transmission (47).  
 
1.7.3 Immune responses to pneumococcal infection 
Transformation of pneumococcus from commensal to pathogen mainly depends on the 
duration of colonisation, which is controlled by 2 main factors: competition with resident 
flora and host immune response competency (44). Figure 1-12 summarises the host 
immune response to natural pneumococcal infection.  
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Figure 1-12 Summary of immune responses to natural infection with Streptococcus 
pneumoniae. 
Compiled from references (44, 48, 49).  NET: neutrophil extracellular trap; IFN: interferon; NCR: 
natural killer cell activating receptor; TLR: Toll-like receptor; 
DNA: deoxyribonucleic acid; NOD: nucleotide-binding and 
oligomerisation domain; NLRP3: nucleotide-binding domain 
leucine-rich repeat family, pyrin domain containing 3; IL: 
interleukin; CD: cluster of differentiation; Th: T helper cells; 
TNF: tumour necrosis factor; Treg: regulatory T cells. Blue 
colour denotes innate responses; green colour denoted adaptive 
responses; purple colour denotes pathogen recognition 
mechanisms. 
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1.7.4 Pneumococcal host evasion and virulence factors 
Pneumococcus has a number of virulence and host evasion factors that promote invasion 
of respiratory epithelial cells and subsequent infection (summarised in Table 1-9).  
Table 1-9 Summary of pneumococcal virulence factors and effects.  
NET: neutrophil extracellular trap; Ig: immunoglobulin; DNA: deoxyribonucleic acid. Compiled 
from reference (44). 
 
Virulence	factor Effect/mechanism
Polysaccharide capsule • Promotes	 adherence	to	host	epithelial	 cells
• Inhibits pathogen	recognition,	 opsonisation,	 phagocytosis	
and	NETs	entrapment
• Evades	entrapment	 by	mucus	through	 electrostatic	
repulsion
Cell	 wall	components	
e.g.	peptidoglycan,	 lipoteichoic
acids,	wall teichoic	 acids.
• Resistance	to	action	 of	lysozyme
• Act	as	anchors	for choline-binding	 proteins
• Induce	inflammatory	response
Pneumolysin • Pore-forming	 toxin	 causes	host	cell	 lysis
• Promotes	 biofilm	formation
• Inhibits	phagocytosis
• Induces	inflammatory response
• Enhances	host-to-host	 transmission
Autolysin • Promotes	 nasopharyngeal	colonisation due to	release	of	
toxins	 e.g.	pneumolysin during	 cell	wall	degradation	
(bacterial	 autolysis).	
Pneumococcal	 surface	proteins
e.g.	choline-binding proteins,	
lipoproteins,	 non-classical	
proteins
• Promote	 adherence	to	host	epithelial	 cells
• Inhibit complement	 binding/activation
• Promote	 resistance	to	oxidative	stress
• Induce	inflammatory	response
Pili • Promote	 adherence	to	host	epithelial	 cells
• Inhibit	phagocytosis
IgA1	protease • Breaks	down	 human	IgA1	antibody	
• Inhibits mucosal	antibody-mediated	 defense
Hydrogen	peroxide • Damage	to	host	DNA
• Bacteriostatic effect	on	competition	 commensals
Pathogenicity	 islands • Parts	of	pathogenic	 bacterial	 genome coding	for	iron-
uptake	systems	&	proteins	 involved	in	adherence	to	host	
cells
Biofilms • Aggregates	of	bacteria surrounded	 by	extracellular	
polysaccharide	 matrix
• Promote	 bacterial	survival e.g.	through	enhanced	 gene	
transfer	 rates	(e.g.	to	promote	 antibiotic	 resistance)	and	
evasion	of	mucociliary clearance
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Of these, the pneumococcal polysaccharide capsule is the most important and is 
responsible for adherence to host cells, evasion of pathogen recognition, opsonisation and 
phagocytosis (44). The structure of capsule polysaccharides determines the pneumococcal 
serotype (over 90 are known) and the type of disease caused in the host e.g. serotype 1 is 
particularly associated with IPD, whereas 6C and 35B are associated with non-invasive 
disease (50). The ability of the host to produce antibody directed against specific capsular 
polysaccharides is a key feature of the host immune defence against pneumococcus (51). 
However, pneumococci can undergo “serotype switching” through mutations in capsule 
polysaccharide genes in response to selective pressures from antibiotic and vaccine use, 
further evading the immune response (44). 
 
1.7.5 Vaccination strategies against pneumococcus 
A number of vaccines have been developed in order to reduce the burden of pneumococcal 
disease in both adults and children – the 23-valent pneumococcal polysaccharide vaccine 
(PPV23) and pneumococcal conjugate vaccines (PCV) against 7, 10 or 13 serotypes. 
Current recommendations in the UK advocate the use of PCV13 in the primary childhood 
immunisation schedule and PPV23 in at risk adults (summarised in Table 1-10) (52). 
Although immune responses to PCV (TD) are superior to PPV23 (TI), the greater variety 
of serotypes contained in PPV23 may be an advantage in an adult population (with a 
mature immune system, able to respond to TI antigens) due to serotype replacement. 
Serotype replacement has been reported since the introduction of widespread childhood 
PCV vaccination, with the emergence of severe disease caused by non-vaccine strains e.g. 
paediatric 19A-associated IPD in the post-PCV7 era (53). The use of multivalent 
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conjugates in children may lead to the emergence of non-vaccine strains in adults through 
indirect herd immunity effects (51). Therefore, administration of the same vaccines as are 
used in the paediatric population may not confer extra benefit in adults.  
 
Table 1-10 Current UK recommendations for PPV23 vaccination in adults. 
COPD: chronic obstructive pulmonary disease; HTN: hypertension. Table compiled from 
reference (52). 
 
PPV23 is also used as a tool to assess humoral immune function in both children and 
adults. The American Academy of Allergy, Asthma and Immunology (AAAAI) guidelines 
for the diagnosis and management of primary immunodeficiency advocate the use of 
Category Examples
All	adults	 aged	65 years	or	older
Adults <65	years	in	clinical	 risk	groups	(below)
Chronic	 respiratory	
disease
Severe asthma	requiring	 repeated	 use	of	systemic	steroids
COPD
Bronchiectasis
Chronic	 heart	disease
Congenital	 heart	disease,	HTN	with	cardiac	complications,	 chronic
heart	failure,	 ischaemic heart	disease	requiring	 treatment	 or	
specialist	follow-up
Chronic	 kidney disease Stages	G4-5,	dialysis,	nephrotic	 syndrome,	 kidney	transplantation
Chronic	 liver disease Cirrhosis,	 chronic	 hepatitis
Individuals	 with	 cochlear
implants	 /	cerebrospinal	
fluid	 leaks
Vaccination should	not	delay	cochlear	 implantation;	 Cerebrospinal	
fluid	(CSF)	leaks	include	 those	following	trauma/major	 skull	surgery	
and	all	CSF	shunts.
Diabetes	Mellitus Excluding	 diet-controlled diabetes.
Immunosuppression Chemotherapy	 recipients,	 bone	marrow	transplant,	 HIV	infection	 at	all	stages.
Asplenia/splenic
dysfunction Sickle	cell	disease
Occupational risk Frequent exposure	to	metal	fume e.g.	welders
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PPV23 in individuals ages 2-65 as a tool in the diagnosis of antibody deficiencies, in 
particular selective antibody deficiency (SAD) - characterised by recurrent respiratory 
infections, normal total immunoglobulin and IgG subclass levels, but poor humoral 
responses to pneumococcal polysaccharides (54).  
 
1.7.5.1 PPV23 hyporesponsiveness 
PPV23 may have limited utility due to hyporesponsiveness reported with repeat 
administration - defined as the inability of an individual to mount an immune response 
upon re-exposure to antigen of at least the same or greater magnitude as that seen after 
primary exposure (51).  Although this has been reported in various adult cohorts (55-57), 
it is not a consistent finding (58-60) and the clinical impact of this remains under debate. 
Interestingly, hyporesponsiveness is also observed after natural exposure to 
pneumococcus, with reduced secondary responses in children to serotypes previously 
found colonising the nasopharynx (57).  
Several hypotheses have been postulated for the observed hyporesponsiveness to 
pneumococcal polysaccharides, including depletion of the memory B cell pool generated 
following primary exposure to polysaccharides (TI antigen) and chronic immune 
activation due to antigen persistence (25, 61). Further research is ongoing to discover 
conserved pneumococcal antigens that could both broaden vaccine coverage and enhance 
host immune responses (51).  
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1.8 Immune dysfunction with ageing  
Chronological ageing is associated with a decline in the effectiveness of immune 
responses as evidenced by increased susceptibility to infection (62), together with reduced 
immune responses to vaccines, including influenza (63-65) and pneumococcus (66, 67). 
Self-regulatory immune functions are also impaired, leading to a greater incidence of 
malignancy and autoimmunity (68, 69).  
 
1.8.1 Innate immune system alterations with older age  
A number of innate immune system alterations have been described with ageing that could 
explain these observations (reviewed in (70-72)). For example, age-related reduction in 
mucin secretion and cilia beat frequency may promote dissemination of respiratory 
pathogens such as influenza and pneumococcus (44). The phagocytic function of 
macrophages and neutrophils is impaired with older age (73), with neutrophils also 
exhibiting reduced killing ability and generation of NETs (74). Aged neutrophils also 
demonstrate impaired chemotactic accuracy, which, together with impaired migration to 
sites of infection, may result in overproduction of proteases, leading to increased local 
inflammation and tissue damage (75). These changes may be partly ascribed to defects in 
pathogen recognition mechanisms e.g. downregulation of TLR1 expression and reduction 
of TLR4 function seen with age (76, 77). Both NK cells and DCs have also shown to have 
globally reduced function with ageing (78). 
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1.8.2 Adaptive immune system alterations with older age 
The efficacy of the adaptive immune response also diminishes with increasing 
chronological age. Ageing is associated with a contraction of naïve T and B lymphocyte 
pools due to both a reduction in naïve cell generation (e.g. thymic involution) and/or 
impaired homeostatic maintenance mechanisms, together with differentiation into memory 
subsets with antigen experience, which results in the relative accumulation of memory 
lymphocytes with a restricted TCR/BCR repertoire (78). Numerical reduction of naïve 
lymphocytes theoretically reduces the capacity of the adaptive immune system to respond 
to novel antigens. Lymphocyte differentiation results in cell populations with limited 
replicative capacity (in part due to telomere shortening and accumulation of DNA damage 
(79)) – also described as “senescent” cells. Ageing is also associated with accumulation of 
highly differentiated lymphocytes that lose effector function – “exhausted” cells. 
However, it is increasingly recognised that replicative senescence and functional 
exhaustion do not go hand in hand, with populations of senescent cells shown to be highly 
functional and significantly contributing to the immune dysfunction seen with ageing.  
Indeed, the age-associated loss of the costimulatory molecules CD27 and CD28 on CD4 
and CD8 T cells is associated with reduced proliferative capacity, but also with gain of 
potent cytotoxic function (e.g. release of perforin, granzymes and IFNg) mediated in part 
by TCR-independent activation of upregulated NK-like receptors, including NKG2D (79, 
80). The late differentiated TEMRA population (characterised by the re-expression of 
CD45RA) exhibit potent cytotoxicity and secretion of pro-inflammatory cytokines, but 
with limited proliferative capacity, which is mediated by inhibition of protein kinase p38 
(81, 82). Late memory IgD-CD27- B cell expansions are associated with increasing age 
(83), and although they exhibit reduced mitogen-induced replicative capacity in vitro 
43 
 
(“senescence”) compared to naïve B cells, they are avid producers of pro-inflammatory 
cytokines (e.g. TNFa and IL-6) and microRNAs (83). Such pro-inflammatory cytokine 
production has been described as the “senescence-associated secretory phenotype” 
(SASP). SASP contributes to the low-grade chronic inflammation seen with older age, 
characterised by elevated levels of circulating CRP, IL-6 and TNFa (78). 
In addition to alterations in T cell responsiveness and function, the quality of antibody 
responses also declines with age. This results from a combination of defective B cell AID 
induction (a key enzyme involved in class switch recombination and somatic 
hypermutation) and reduced CD4+ T cell functionality after TCR ligation (due to reduced 
expression of miR-181a), with resultant reduction in B cell help (78).  
Alterations in adaptive immune regulation also occur with ageing. Although 
differentiation of regulatory T cells in the thymus and periphery declines with age, mature 
Tregs accumulate in the blood and secondary lymphoid organs through, as yet, 
incompletely understood mechanisms (84). Effector function of mature Tregs may cause 
excessive inhibition of otherwise useful immune responses, leading to poor pathogen 
clearance and increased susceptibility to infection. A reduced frequency and function 
(namely IL-10 secretion) of CD24highCD38high regulatory B cells has also been reported in 
older adults (85). This is associated with increased circulating autoantibody, suggesting a 
mechanism for reduced immune tolerance seen with ageing (85). 
 
44 
 
1.8.3  The role of cytomegalovirus in shaping the adaptive immune 
system  
Expansions of late differentiated T cells reported with older age have also been associated 
with chronic antigenic stimulation e.g. from persistent viral infections, calling into 
question their description as “age-related defects”. Cytomegalovirus (CMV) is 
increasingly recognised as having a potent role in modulating the “immune ageing” 
phenotype (86).  
A dsDNA betaherpesvirus, CMV establishes life-long persistent infection in humans after 
primary infection (often occurring in childhood) and periodically reactivates in response to 
stressors such as inflammation, infection or immunosuppression (87). These reactivations 
are usually subclinical and do not cause overt disease in the (otherwise) immunocompetent 
host. However, such chronic exposure to CMV antigens drives the expansion of CMV-
specific memory T lymphocytes, particularly of the CD28null and TEMRA phenotype (88, 
89). Latent CMV infection has been associated with a number of other adverse outcomes 
in humans, including increased morbidity and mortality from cardiovascular disease (90). 
Indeed, CD28null CD4+ T cells have potential for vascular endothelial toxicity (through 
expression of perforin/granzymes and endothelial homing markers CX3CR1, CD49d and 
C11b) and their expansions are independently associated with increased arterial stiffness 
(91, 92).  
The effect of latent CMV infection on B lymphocytes is less clear, with limited and 
variable literature on this subject to date (93, 94). However, the magnitude of the humoral 
response to CMV mirrors the T cell effects seen. Indeed, serum CMV-specific IgG levels 
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are considered a reasonable surrogate for the magnitude of CMV-associated T cell effects 
(95).  
Interestingly, the presence of latent CMV infection has also previously been associated 
with impaired responses to T-dependent vaccines in older adults (96) and a recent clinical 
trial demonstrated that suppression of CMV reactivation with valacyclovir could improve 
humoral responses to PCV13 in patients with vasculitis (97).   
Several elegant studies have identified enhanced p38 MAPK signalling in TEMRA 
populations as the mechanism for proliferative senescence and a potential therapeutic 
target to improve cellular function (81, 82, 98). However, the presence of highly 
functional and cytotoxic CMV-specific cells that are capable of controlling infection, but 
do not vigorously proliferate could actually be seen as a beneficial immune adaptation, 
rather than a defect (78), calling into question the potential therapeutic benefits of its 
reversal.  
Another important factor associated with increasing susceptibility to infection and poorer 
vaccine responses in older age is declining health status and the development of a number 
of chronic conditions, including chronic kidney disease, which I will describe in the next 
section of this Chapter. 
 
1.9 Chronic kidney disease (CKD) 
Chronic kidney disease (CKD) describes the end-point of a number of heterogeneous 
disease processes that irreversibly alter kidney structure and function over a period of 
months or years. Current international guidelines define CKD as the presence of reduced 
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kidney function (a glomerular filtration rate (GFR) of less than 60ml/min/1.73m2) or at 
least one marker of kidney damage (including proteinuria or other urinary sediment 
abnormality, histological or structural abnormalities) for a minimum of 3 months (99).  
 
1.9.1 Epidemiology of CKD 
CKD is an important global clinical problem. Although worldwide estimates of CKD 
prevalence and incidence are limited by heterogeneity in populations studied and CKD 
definition, it is consistently reported to affect approximately one in 10 individuals in high-
income countries e.g. UK and USA (100, 101). The prevalence of CKD varies within 
countries by social class and ethnicity. Individuals within the higher socioeconomic 
quartile have a 60% lower risk of progressive CKD than those in the lowest quartile (100). 
Hispanics in the USA and Black and Asian individuals in the UK have a significantly 
greater risk of developing CKD, which is not fully explained by differences in 
socioeconomic status (100). CKD prevalence increases markedly with advancing age, 
affecting more than 30% of individuals aged 75 years and over (102). As such, the 
prevalence of CKD is predicted to increase further with the expansion of the ageing 
population. 
CKD confers a significantly increased risk of all-cause mortality. Indeed, Global Burden 
of Disease Study estimates rank CKD as the 13th leading cause of death worldwide (103). 
CKD is also associated with significant morbidity (estimated age-adjusted global 
disability-adjusted life years (DALY) rate of 497.3 per 100 000 people in 2013 (103)) and 
associated economic burden, with CKD management accounting for approximately 1.3% 
of the 2009-2010 UK National Health Service (NHS) budget (£1.45 billion) (104).  
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Although global age-adjusted mortality and DALY rates due to non-communicable 
diseases in have been largely declining, this has not been the case with CKD. Infact, CKD-
related mortality rates have increased by approximately a third and DALY rates by 12% 
from 1990 to 2013 (103).  
 
1.9.2 Measuring kidney function 
Glomerular filtration is the passive process of creating an ultrafiltrate from blood as it 
passes through the glomerular capillary network (102). It cannot be measured directly, but 
can be assessed by measuring clearance of exogenous compounds or estimated from 
serum levels of endogenous filtration markers such as creatinine (a low molecular weight 
metabolite) or the serum protein, cystatin C (102). Estimated GFR (eGFR) is the most 
widely used in clinical practice and is calculated using regression equations. GFR varies 
with body mass, dietary protein intake, age, gender and ethnicity, therefore GFR 
estimation equations include parameters to account for this and also standardise GFR to 
average body surface area (BSA) – 1.73m2 (102, 105). Two creatinine equations are 
currently used in clinical practice in the UK – the MDRD Study equation (106) (updated 
for use with standardised serum creatinine in 2006) and CKD-EPI creatinine equation 
(2009, (107)) – Table 1-11. The CKD-EPI creatinine equation includes the same four 
variables as the MDRD Study equation, but uses a 2-slope linear spline to model the 
relationship between serum creatinine and eGFR. The CKD-EPI creatinine equation is 
more accurate than the MDRD Study equation at higher levels of eGFR 
(>60ml/min/1.73m2), resulting in lower rates of false-positive diagnoses of CKD (107). 
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Current guidelines advocate the use of CKD-EPI equation over that of the MDRD study 
(99).  
 
Table 1-11 Regression equations for estimation of GFR using serum creatinine.  
MDRD: Modification of Diet in Renal Disease study; CKD-EPI: Chronic Kidney Disease 
Epidemiology Collaboration; SCr – serum creatinine in mg/dl. Compiled from references (106) 
and (107). 
1.9.3 Classification of CKD severity  
CKD severity is classified by the degree of renal impairment (GFR) and proteinuria as a 
marker of kidney damage (urinary albumin/creatinine ratio, ACR), as shown in 
Table 1-12. When kidney function drops below 15ml/min/1.73m2 (CKD category G5), it 
is not sufficient to sustain physiological processes in the long term and is described as end 
stage renal disease (ESRD) (100). The risk of adverse patient outcomes increases with 
diminishing renal function and worsening proteinuria.  
MDRD	(2006)	 175	
x	SCr-1.154	
x	age-0.203	
x	1.212	[if	Black]	
x	0.742	[if	female]	
CKD-EPI	(2009)	 141	
x	min	(SCr/[0.9	if	male,	0.7	if	female],	1)[-0.411	if	male,	-0.329	if	female]	
x	max	(SCr/[0.9	if	male,	0.7	if	female],	1)-1.209	
x	0.993Age	
x	1.159	[if	Black]	
x	1.018	[if	female]	
	
49 
 
 
Table 1-12 Classification of CKD using GFR and ACR categories.  
GFR: glomerular filtration rate; ACR: albumin/creatinine ratio; CKD: chronic kidney disease. Red 
arrows denote increasing risk of adverse outcomes. Adapted from reference (99) under the 
Creative Commons License. 
 
1.9.4 Causes of CKD 
Causes of CKD include, but are not limited to, those listed in Table 1-13. Although the 
causes of CKD vary globally, diabetes mellitus (DM) and hypertension (HTN) are the 
main causes of CKD in high and middle-income countries (100). CKD prevalence 
increases with age, mirroring the age-associated increasing prevalence of DM and HTN.  
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Table 1-13 Causes of chronic kidney disease (CKD) – a summary. 
Ig: immunoglobulin; HIV: human immunodeficiency virus; NSAIDs: non-steroidal anti-
inflammatory drugs. Compiled from reference (100). 
 
HTN is common in CKD with a prevalence of over 80% in adults with non-dialysis CKD 
(GFR 15-60ml/min/1.73m2) (108) compared with just over a quarter of the general 
population (109). The pathophysiological relationship between hypertension (HTN) and 
CKD is bidirectional, with declining kidney function typically associated with a rise in 
blood pressure (BP) and chronically elevated BP associated with an increased risk of CKD 
progression (110). HTN in CKD arises from a combination of factors including retention 
of sodium and water associated with reduced GFR, inappropriate activation of the renin-
angiotensin-aldosterone system (RAAS) in the presence of a high sodium load, 
sympathetic nervous system activation and vascular endothelial dysfunction (111, 112). 
Treatment of HTN in CKD is often challenging and frequently requires the use of multiple 
anti-hypertensive therapies, including diuretics and RAAS inhibitors (113). 
Diabetes mellitus (DM), one of the main causes of CKD is also a major cardiovascular 
risk factor. Although diabetic nephropathy accounts for approximately a third of ESRD 
51 
 
requiring RRT (114), the prevalence of co-existing DM in CKD is often higher (115). The 
presence of DM in CKD is associated with worse patient outcomes, including increased 
risk of progression to ESRD and greater all-cause mortality (116).  
Although initial mechanisms of kidney damage differ, most chronic kidney diseases 
eventually result in renal fibrosis – the final stage of unsuccessful wound-healing, 
characterised histopathologically by glomerulosclerosis, tubular atrophy and interstitial 
fibrosis (100). The main goals of CKD treatment are to reverse potentially reversible 
pathologies (e.g. inflammation in glomerulonephritis), prevent deterioration of renal 
function (this includes the control of associated comorbidities e.g. HTN, DM), manage 
complications and, as disease progresses, prepare for RRT. 
 
1.9.5 Clinical manifestations of CKD 
Individuals with CKD are frequently asymptomatic until renal function is severely 
impaired and, as such, are often identified from routine screening tests. It is therefore 
difficult to estimate the true duration of CKD for most individuals.   
As kidney function declines, a number of substances, collectively termed uraemic 
retention solutes, accumulate and exert effects on nearly all organs and body systems 
(summarised in Table 1-14). Solutes that exert adverse biological effects are referred to as 
uraemic toxins and their control is a major focus of current research as a therapy to 
ameliorate CKD progression and/or symptoms. However, accumulation of uraemic toxins 
is not always predictable, with marked variation between individuals in their biological 
effects at different levels of GFR (100). 
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Table 1-14 Main clinical manifestations of chronic kidney disease. 
USS: ultrasound scan. Compiled from reference (100). 
 
 
1.9.6  Complications of CKD 
Table 1-15 summarises the main complications associated with CKD, several of which 
will be discussed in more detail below.  
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Table 1-15 Main complications of chronic kidney disease (CKD).  
ESRD: end-stage renal disease; K+: potassium; Na+: sodium. Compiled from reference (100). 
 
1.9.6.1 Progression to ESRD 
CKD progression is defined as a sustained drop in eGFR of 25% or more and a change in 
GFR category over 1 year, and/or a sustained drop in eGFR of >15ml/min over 1 year 
(113), and results from the progressive loss of functional nephrons. Risk factors for CKD 
progression include male gender, Black/Asian ethnicity, proteinuria and the presence of 
DM, HTN, cardiovascular disease and anaemia (117-119). Although prevalence of CKD 
increases with age, older adults with CKD generally show slower rates of progression than 
younger populations (120).   
ESRD is associated with the greatest risk of adverse outcomes and carries significantly 
increased risk of mortality compared to the general population (100, 121). Indeed, 1-year 
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mortality in patients with ESRD is typically greater than 10%, with cardiovascular disease 
and infection reported as the most common causes of death (114). 
Therapeutic options for individuals with ESRD are renal replacement therapy (RRT - 
dialysis or kidney transplantation) or conservative care with symptom management (100). 
The UK prevalence of RRT in 2016 was 962 per million population – an increase of 
approximately 3% from the previous year, with a median patient age of 59 years (118). 
Kidney transplantation accounted for just over half of prevalent RRT, with haemodialysis 
accounting for 40% and peritoneal dialysis for 6% (118).  
 
1.9.6.2 Anaemia 
Typically normocytic and normochromic, anaemia is common in CKD, with prevalence 
increasing as kidney function declines.  It arises from a combination of factors, including 
erythropoietin (EPO) deficiency through loss of cortical peritubular fibroblasts (the chief 
producers of EPO (122)), uraemia-associated reduced red cell survival and deficiency of 
haematinics such as iron and folate (100). Indeed, CKD is associated with excess 
circulating levels of hepcidin (123, 124), which impairs absorption of dietary iron.   
CKD-associated anaemia is an independent predictor of mortality and is associated with 
significant patient morbidity including reduced quality of life, more frequent hospital 
admissions and increased incidence of cardiac disease (125, 126). Treatment of CKD-
associated anaemia was revolutionised with the advent of recombinant human EPO 
(rhEPO) and its synthetic derivatives (collectively termed erythropoiesis-stimulating 
agents, ESAs) (127).  
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1.9.6.3 Disordered bone mineral metabolism 
The kidney plays a central role in maintaining calcium and phosphate homeostasis through 
interaction with parathyroid hormone (PTH), vitamin D and fibroblast growth factor 23 
(FGF23). CKD-associated alterations in bone mineral metabolism are summarised in 
Figure 1-13.  
Figure 1-13 Summary of alterations in bone mineral metabolism in chronic kidney disease 
(CKD). 
A – CKD is associated with vitamin D deficiency and retention of phosphate (P). High phosphate 
stimulates secretion of bone-derived fibroblast growth factor (FGF) 23, which suppresses 
activation of vitamin D to calcitriol. Elevated calcium-phosphate product (Ca-P) stimulates 
secretion of parathyroid hormone (PTH), which increases resorption of bone. B – prolonged 
parathyroid gland stimulation results in hyperplasia and secondary/tertiary hyperparathyroidism. 
Ca: calcium; VDR: vitamin D receptor. Reproduced from reference (128) with permission from 
Springer Nature Limited. 
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Disordered bone mineral metabolism in CKD results in abnormalities in bone 
mineralisation, turnover and strength, which can present clinically as increased bone 
fragility, bone pain and/or extra-skeletal calcification (100).  
 
1.9.6.4 Cardiovascular disease 
Cardiovascular disease (CVD) is the most common cause of death in CKD, accounting for 
1 in 4 deaths in prevalent RRT patients with ESRD in the UK (114). The risk of CVD-
associated mortality increases in a stepwise manner with worsening CKD severity, 
independent of traditional CVD risk factors (129). Increasing albuminuria is also 
independently associated with increased CVD mortality risk, without a threshold effect, 
suggesting that even small increases in ACR are clinically significant (129).  
The main early CKD-associated cardiovascular effects are left ventricular structural and 
functional abnormalities, together with arteriosclerosis (or vascular stiffening) (130). CKD 
is also associated with accelerated atherosclerosis (130), increased vascular calcification 
(131) and reduced coronary reserve and capillary density (132).   
Increased CVD risk can be partly explained by the higher prevalence of several major 
traditional CVD risk factors in CKD populations, including HTN and DM (133). CKD is 
also independently associated with dyslipidaemia (111, 134) and “obese sarcopenia” 
(where a relative increase of adipose tissue mass is seen with declining lean tissue mass 
(135)).  
However, CKD remains a strong independent risk factor for CVD mortality, even when 
traditional risk factors are taken into account (136). CKD-associated chronic low-grade 
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inflammation, increased oxidative stress and endothelial dysfunction are proposed 
explanatory mechanisms for this.  
 
1.9.6.5 Chronic inflammation, increased oxidative stress and endothelial 
dysfunction in CKD 
Albuminuria and reductions in GFR are associated with higher circulating biomarkers of 
inflammation, including C-reactive protein (CRP), tumour necrosis factor a (TNF-a) and 
interleukin-6 (IL-6) (137). Chronic low-grade inflammation is associated with worse 
outcomes in CKD, including progression to ESRD, the incidence of protein-energy 
malnutrition, anaemia and dysregulated bone mineral metabolism, together with 
cardiovascular and all-cause mortality (138, 139). 
Several mechanisms have been proposed to cause this chronic inflammatory state. For 
example, retention of uraemic solutes including advanced glycation end (AGE) products 
can induce inflammation in target cells (e.g. vascular endothelial/smooth muscle cells) 
through direct and indirect activation of NF-kB and subsequent formation of pro-
inflammatory cytokines (140). In addition to reduced renal clearance of reactive oxygen 
species (ROS), reductions in antioxidant factors such as superoxide dismutase and catalase 
(141) have also been reported. Endogenous production of ROS may also be increased in 
CKD through increased NADPH oxidase activity (141).   
Increased circulating levels of endotoxins, likely due to translocation of gut bacteria as a 
result of increased gut permeability, have been observed in ESRD patients and correlate 
with conventional inflammatory markers (142).  
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CKD-associated “obese sarcopenia” has also increasingly been shown to contribute to the 
inflammatory milieu via adipokines such as leptin, circulating levels of which are elevated 
in ESRD (143).  
Oxidative stress and chronic inflammation, together with retention of the nitric oxide 
synthesis inhibitor asymmetric dimethylarginine (ADMA), result in endothelial 
dysfunction in CKD. Inflammation, oxidative stress and endothelial dysfunction are key 
players in the accelerated atherosclerosis seen in CKD (141) and are also associated with 
non-atherosclerotic heart disease in non-dialysis CKD (144). 
The chronic inflammatory state associated with CKD has been likened to that seen in 
chronological ageing, suggesting that renal impairment may accelerate progression of 
“normal” ageing processes.  
 
1.10 The burden of infection in CKD 
Patients with CKD have a greater susceptibility to infections and associated morbidity and 
mortality (121, 145). This was first observed as a marked excess incidence of infection-
related death in patients with ESRD. Indeed, compared to the general population, ESRD 
treated with haemodialysis confers a 10-fold increased risk of death from pneumonia and 
80 to 100-fold increased risk of death from sepsis (146, 147). One-year mortality in 
prevalent RRT patients with ESRD is typically greater than 10%, with infection 
accounting for almost 1 in 5 deaths, second only to cardiovascular disease (114).  
The reported incidence of infections in patients with CKD is variable, but studies 
consistently show a graded increase in the risk of infection-related hospitalisation and 
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mortality both with reducing GFR (148-151) and increasing albuminuria, the impact of 
which is multiplicative (115). This is independent of potential confounders, such as age, 
gender, ethnicity, smoking/alcohol intake and prevalence of DM.  
The magnitude of risk associated with renal impairment also varies between studies. For 
example, Dalrymple et al reported a 25% increase in all-cause infection-related 
hospitalisation in individuals with CKD stage G3b/4 (eGFR 15-44ml/min/1.73m2) 
compared to those with an eGFR≥60 (149), whereas investigators from the Atherosclerosis 
Risk in Communities study (ARIC) reported at least a 2-fold increased risk (115).  
Acute infections are associated with higher rates of hospitalisation and longer duration of 
stay in patients with CKD (152). The most common types of infections are respiratory and 
genitourinary (both accounting for approximately 20-25%) (115, 149) and recurrent 
infections are more common with worsening CKD severity (115).  
Susceptibility to infection in CKD is not characterised by a predilection to any particular 
organism. Indeed, a study of bloodstream infection in a cohort of older adults with non-
dialysis CKD showed an increased incidence of infection with a variety of Gram positive 
and Gram negative bacteria with worsening GFR (150).  
Overall, infection-related hospitalisation episodes likely underestimate the true burden of 
infection in CKD. Factors associated with poor infection-related outcomes in patients with 
CKD include female gender (particularly in young haemodialysis patients), DM, CVD, 
hypoalbuminaemia, anaemia, and elevated inflammatory markers such as CRP (115, 147, 
153). Interestingly, excess risk of infection associated with CKD may decline with 
increasing age (151), with differences in susceptibility to infection more pronounced in 
younger adults. It is important to note that, in addition to the excess risk of mortality, the 
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incidence of infection in patients with CKD is independently associated with a higher risk 
of cardiovascular events, including ischaemia and heart failure (153).   
 
1.11 Vaccine responses in CKD 
Amongst the reasons for the observed increased susceptibility to infection is that public 
health measures to reduce infection, such as vaccination, are not as effective in CKD as in 
the general population. This is best characterised for the hepatitis B virus (HBV) vaccine 
(154), where studies in patients with ESRD have consistently shown lower seroconversion 
rates (155-157) and faster decline in protective antibody titres than in healthy individuals 
(156, 158, 159). Increasing age (160-163), hypoalbuminaemia (164, 165) and obesity 
(166) have been associated with poorer HBV vaccination responses in patients with 
ESRD. Interestingly, better response to HBV vaccination in patients with ESRD have been 
associated with lower mortality rates (167). 
Reflecting what is observed for the risk of infection, there is also a graded reduction in 
HBV vaccine responses with worsening renal impairment in non-dialysis CKD (168-171)  
and vaccination is currently recommended early in the disease to maximise humoral 
response (172). A number of other strategies have been employed in order to improve 
rates of seroconversion following HBV vaccination in CKD, including using higher 
vaccine doses (170) and increasing the number of doses given in a vaccination course 
(170, 173), but with variable effect (174, 175).  
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In addition to HBV, reduced responses in CKD/ESRD have also been reported for other 
TD vaccines e.g. influenza (176, 177) and also to TI vaccines including the pneumococcal 
polysaccharide vaccine (178, 179).  
Interestingly, the magnitude of the humoral antigen-specific response to vaccination in 
CKD may depend on when the antigen was first encountered. Our group have recently 
shown relatively preserved humoral memory directed against historical vaccine antigens 
(DT/TT) and antigens that are repeatedly encountered throughout life (Salmonella 
lipopolysaccharide, CMV), which suggests maintenance of long-lived plasma cell niches 
established before the onset of CKD (180). This is also supported by the findings of 
Tsouchnikas et al (181) of a more rapid decline of anti-HBsAg antibodies generated 
following vaccination than those generated through natural infection in a cohort of patients 
with ESRD.  
Collectively, the observations of increased susceptibility to infection and poorer vaccine 
responses in CKD have led to a dogma that these patients are immunodeficient and have a 
defective capacity to mount and maintain effective responses to antigens as compared to 
the general population. Although mortality from cardiovascular disease (CVD) in patients 
with severe CKD has markedly reduced over the past 20 years through innovations in 
diagnosis and patient management, mortality from infection remains largely unchanged 
(Figure 1-14) and the understanding of mechanisms behind poor immune responses in 
CKD remains incomplete.  
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Figure 1-14 Cause of death in prevalent renal replacement therapy cohorts by year.  
Adapted from reference (145) under the Creative Commons Licence. 
 
The next section of this chapter will summarise current understanding of the nature of 
immune defects in CKD, with a particular focus on chronic inflammation and dysfunction 
of neutrophils and lymphocytes. 
 
1.12 The nature of immune dysfunction in CKD 
The retention of various uraemic toxins has been proposed as a major driver of immune 
dysfunction in CKD (182). Host immune function in CKD has largely been studied in 
patients at the severe end of the disease spectrum (ESRD), who are receiving RRT, most 
commonly - haemodialysis. Immune function in less severe CKD has not yet been 
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comprehensively characterised, but, as renal disease is a continuum, it is potentially 
reasonable to suppose that alterations in immune function seen in ESRD start early in the 
course of CKD, just as other metabolic abnormalities associated with renal disease 
develop long before severe disease is established.  
 
1.12.1 Neutrophils in CKD 
A number of neutrophil functional defects have historically been identified in 
haemodialysis populations, including impaired phagocytosis (183, 184), reduced killing 
ability (185) and increased apoptosis (184). Neutrophils in patients with ESRD have also 
been shown to have features of spontaneous activation e.g. upregulation of TLR-2, TLR-4 
and integrins, enhanced ROS production and degranulation (186), which may enhance 
ESRD-associated oxidative stress. However, some studies in ESRD have also shown 
reduced neutrophil ROS production (187). 
Importantly, many of the neutrophil features seen in ESRD have been shown to be 
exacerbated following sessions of dialysis treatment (188, 189), particularly with the 
historical use of complement-activating cuprophane dialyser membranes (which also 
induced a potent transient neutropenia through neutrophil sequestration in the lung) (190-
192), and with ESRD treatment complications such as iron overload (187) that are now 
infrequently seen in current practice. These observations call into question the validity of 
ascribing such neutrophil dysfunction to renal impairment per se, rather than its treatment.  
A number of studies have examined neutrophils in non-dialysis CKD, with some findings 
directly conflicting the literature on ESRD. For example, ARIC study investigators 
showed a stepwise increase in circulating neutrophil numbers with reductions in eGFR 
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(193). Although neutrophil phagocytosis can be impaired in dialysis-treated patients, it has 
recently been shown to be comparable to controls in patients with less severe CKD (194). 
In this cohort, a stepwise increase in resting neutrophil oxidative burst was also seen with 
declining eGFR and responses to fMLP and E coli were reduced in patients receiving 
haemodialysis. However, in parallel to findings in ESRD populations, enhanced neutrophil 
apoptosis and increased expression of TLR2 and TLR4 with reducing eGFR have been 
reported in non-dialysis CKD (195-197). 
 
1.12.2 Lymphocytes in CKD 
Studies of lymphocyte populations in ESRD have reported reduced circulating total 
lymphocyte numbers (182, 186, 193). Lymphopenia, together with increased circulating 
neutrophils, results in an increased neutrophil/lymphocyte ratio (NLR). NLR may be a 
useful prognostic marker in ESRD, having been shown to predict cardiovascular and all-
cause mortality in both peritoneal and haemodialysis populations (198-201), together with 
increased arterial stiffness (202, 203). NLR has also been proposed as a low-cost surrogate 
marker for CRP (204-207). In non-dialysis CKD, NLR has been consistently shown to be 
significantly higher than in age matched controls, with a step-wise increase with 
worsening CKD stage and a significant negative correlation with eGFR (208-210). As 
with dialysis populations, an elevated NLR has also been associated with greater incidence 
of cardiovascular events/mortality and all-cause mortality in non-dialysis CKD (209, 211).  
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1.12.2.1 T lymphocytes 
Depletion of total circulating T cells has been reported in both ESRD and non-dialysis 
CKD populations (186, 212), together with variable reports of reductions in the CD4/8 
ratio (212-214). 
Increased T cell turnover and apoptosis have been observed in patients with ESRD, with 
resultant depletion of naïve (mirroring what is seen with immune ageing) and central 
memory T cells (214) that could reduce the capacity of the adaptive immune system to 
both recognise new antigens and respond to those previously encountered (186, 214, 215). 
Other T cell features consistent with immune ageing have been reported in CKD, 
including the expansion of terminally differentiated CD28null T cells, albeit in studies with 
variable controlling for the effects of latent CMV infection (216-219). Expansions of these 
CD4+CD28null T cell populations have also been associated with increased CVD risk in 
CKD (92, 220). The senescence-associated secretory phenotype (SASP) of aged immune 
cells may also be responsible for the chronic inflammation seen in CKD (215).  
T cell proliferation and functionality (characterised by activation-induced secretion of 
cytokines e.g. IL-2 and TNF-a (221, 222)) is reduced in ESRD (223). Indeed, Litjens et al 
demonstrated impaired HBsAg-specific T cell proliferation in samples taken from ESRD 
patients 2 weeks after HBV vaccination (which correlated with impaired serum antibody 
responses), together with impaired cytokine secretion (IL-2 and IFN-g) (222). Polarisation 
of CD4+ T cell effector responses towards the pro-inflammatory Th1 phenotype has been 
reported in ESRD as a putative driver of chronic inflammation (224) and a contributory 
mechanism to impairment of B cell function (through reduced Th2-mediated help) (225), 
but this is not a consistent finding (226, 227). Altered Treg function in the context of 
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chronic immune over-activation is another hypothesis that has been proposed to explain 
the increased susceptibility to infections seen in CKD (221, 228). Both increased (221) 
and decreased Treg numbers (229, 230) have been shown in dialysis-dependent CKD 
patients, together with increased Treg apoptosis and impaired suppressive function (228, 
231).  This crucial inhibitory T cell population warrants further investigation, especially in 
non-dialysis CKD.  
1.12.2.2 B lymphocytes 
The effect of CKD/ESRD on B cell populations and their function is less well understood. 
Several groups have consistently reported B cell lymphopenia in ESRD (232-234) and 
non-dialysis CKD (235, 236). Reduction in circulating numbers of CD27+ memory B cells 
has also been reported in paediatric patients with CKD (237).  
Increased B cell apoptosis has been postulated as a mechanism for the observed 
contraction of the B cell pool in ESRD (232, 233, 238), but this is not a consistent finding 
(239). Another hypothesis for reduced circulating B cell numbers is uraemia-induced 
resistance to the action of B cell differentiation and survival factors e.g. BAFF (B cell-
activating factor), that reduces the differentiation of transitional B cells into mature cells – 
Pahl et al recently identified reduced BAFF receptor expression on circulating transitional 
B cells in patients with ESRD, in the face of elevated circulating BAFF levels (239). 
Although numerous studies have demonstrated impaired antibody responses to vaccination 
in ESRD/CKD, literature characterising the nature of B cell function in vitro or in vivo is 
limited. In vitro studies of B cell function in ESRD have generally shown reduced 
proliferation and impaired immunoglobulin secretion in response to a variety of antigens 
(238, 240, 241), but not consistently (242). However, these effects may be mediated by 
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dialysis treatment, rather than renal impairment itself (243). Interestingly, several groups 
have shown PTH-associated inhibition of B cell proliferative capacity (244-246), and 
improved in vitro B cell function with EPO treatment (243), suggesting other possible 
mechanisms for the observed CKD-associated immune dysfunction. The characterisation 
of B cell effector phenotypes during in vitro differentiation of B cells or the evaluation of 
in vivo generation of ASCs following antigen exposure in patients with CKD or ESRD has 
not, to my knowledge, previously been performed.  
Overall, the immune phenotype reported in severe CKD is in keeping with a state of 
accelerated immune ageing. Indeed, immune cells in ESRD show greater telomere 
shortening compared to age-matched controls (247, 248) – a hallmark of replicative 
senescence. As such, CKD has been proposed as a phenotype of “unhealthy ageing”. 
However, complete characterisation of immune system alterations associated with renal 
impairment, rather than its treatment (dialysis) and other potential immunomodulatory 
confounders e.g. CMV, remains incomplete. Interestingly, features described in ESRD 
suggest a dysregulation of immunity, rather than an abject failure to mount immune 
responses. Without improved understanding of where the defects lie in the development, 
maintenance, regulation and implementation of immune functions, potential practical 
approaches to reduce the burden of infection in CKD patients cannot be identified.	 
 
1.13 Aims of thesis 
In this thesis I will describe the results of a prospective observational clinical study set up 
to test the hypothesis that older adults with mild-moderate renal impairment (CKD stage 
G3-4) have a dysregulated immune system compared to healthy age- and gender-matched 
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individuals. Two clinically recommended vaccinations (TIV and PPV23) were used as an 
in vivo antigen challenge and evaluation of multiple components/functions of both 
adaptive and innate immune systems was performed and compared between the groups.  
In this study I took a non-biased approach to systematically characterise the immune 
“landscape” in CKD and examine both innate and adaptive immune cell phenotypes 
associated with dysfunctional responses to vaccines.  
This study had 2 main aims: 
Aim 1 (cross-sectional): 
To investigate differences in the immune systems of patients with mild-moderate CKD 
and healthy individuals, in particular the relationship between innate and adaptive cell 
subsets and their function. 
Aim 2 (observational with clinically recommended intervention): 
To investigate differences in the response of adaptive immune system to external antigen 
challenge in patients with mild-moderate CKD compared to healthy individuals through 
real-time assessment of T-cell dependent pathways with seasonal influenza vaccination 
and T-cell independent pathways with pneumococcal polysaccharide vaccination. 
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CHAPTER 2 
2 MATERIALS AND METHODS 
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2.1 Clinical methods 
The study described in this thesis was approved by the Edgbaston Research Ethics 
Committee (reference: 15/WM/0057) and the full protocol is presented in the Appendix. 
 
2.1.1 Participants 
Study participants were recruited to two groups – patients with non-dialysis CKD (n=36) 
and healthy controls (n=30). Recruitment and exclusion criteria are summarised in Table 
2-1. Written informed consent was obtained from all participants in accordance with the 
Declaration of Helsinki.    
Table 2-1 Summary of SONIC study inclusion and exclusion criteria. 
	
INCLUSION	CRITERIA	
Any	gender	
Aged	65	years	and	over	
EXCLUSION	CRITERIA	
Aged	<	65	years		
Does	not	have	capacity	as	defined	by	Mental	Capacity	Act	
For	control	subjects:												eGFR	<60ml/min	OR	any	known	renal	disease	
For	CKD	subjects:																		eGFR	≤15ml/min	or	≥60ml/min	
Active	infection	and/or	fever	on	baseline	assessment	
Already	received	current	year’s	seasonal	influenza	vaccine		
Received	Pneumovax23©	within	last	5	years		
Any	contraindications	to	influenza	or	pneumococcal	vaccination	
Immunosuppressive	conditions	including,	
but	not	limited	to:	
• Malignancy	within	last	5	years	(except	non-
melanoma	skin	cancer)	
• Solid	organ	or	bone	marrow	transplant		
• Blood	borne	viral	infections:	HIV,	hepatitis	B	and	C	
• Autoimmune	disease	e.g.	vasculitis,	rheumatoid	
arthritis	
• Previous	removal	of	spleen	or	asplenia	from	any	
other	cause	
Immunosuppressive	medications,	including,	
but	not	limited	to:	
• Systemic	corticosteroids		
• Chemotherapy	
• Biological	therapies	within	preceding	12	months	
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2.1.2 Recruitment 
Study participants with CKD were recruited at the University Hospitals Birmingham NHS 
Foundation Trust (UHBFT) as summarised in Figure 2-1. 
 
2.1.3 Intervention 
Two seasonal vaccines – trivalent inactivated influenza and pneumococcal polysaccharide 
(Pneumovax 23©) – were used to examine immune responses to both T-dependent and T-
independent antigens in the same individual. Vaccination in this study formed part of 
routine clinical care and the vaccines were not assessed for efficacy or tolerability.  
The Pneumovax 23© vaccine (PPV23) manufactured by Merck (Philadelphia, USA) 
contained capsular polysaccharides for 23 Streptococcus pneumoniae serotypes: 1, 2, 3, 4, 
5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 
33F.  
Composition of the seasonal trivalent influenza vaccine (TIV) varied from year to year 
based on recommendations provided annually by WHO on prevalent circulating strains 
(41). The TIV compositions for all 3 seasons of the SONIC study are shown in Table 2-2. 
Both vaccines were administered intramuscularly into contralateral upper limbs at the 
recommended 0.5ml dose determined by the manufacturers.  
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Figure 2-1 Summary of recruitment methods for the SONIC study. 
A - participants with CKD. Controls: B – relatives of patients with CKD, C- Birmingham 1000 
Elders cohort.  
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Table 2-2 Composition of seasonal trivalent influenza vaccines used in SONIC study. 
 
 
 
2.1.4 Schedule of visits  
Participants were scheduled to attend a total of 4 study visits over 6 months – baseline 
(vaccination visit) and day 7, day 28 and month 6 after vaccination. Figure 2-2 
summarises clinical activity at each study visit.  
Demographics and baseline clinical information were sourced from electronic clinical 
records and patient interview at the baseline (vaccination) study visit. Vaccination history 
was obtained from primary care records requested as part of screening for study eligibility. 
Body mass index (BMI) was initially sourced from electronic records (within 6 months of 
baseline visit date), but this approach yielded a large amount of missing data for the first 
two vaccination seasons, so it was then recorded de novo at baseline for all study 
participants in the 2017-18 vaccination season.  
	
2015-2016	 2016-2017	 2017-2018	
Influenza	A	
strains	
A/California/7/2009	
(H1N1)pdm09-like	virus	
A/California/7/2009	
(H1N1)pdm09-like	virus	
A/Michigan/45/2015	
(H1N1)pdm09-like	virus	
A/Switzerland/9715293/2013	
(H3N2)-like	virus	
A/Hong	Kong/4801/2013	
(H3N2)-like	virus	
A/Hong	Kong/4801/2013	
(H3N2)-like	virus	
Influenza	B	
strains	
B/Phuket/3073/2013-like	
virus	
B/Brisbane/60/2008-like	
virus	
B/Brisbane/60/2008-like	
virus	
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Figure 2-2 Summary of SONIC study visit schedule and clinical activity at each visit.  
 
Structured patient interview and examination at day 7 identified vaccine-related adverse 
events. Patient interview and review of electronic health records identified medication 
changes and new health events, including incidence of infections. No clinical 
microbiology samples or data were collected as part of this study to confirm/type 
infections. As such, patient reporting of infections was subjective and liable to recall bias. 
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2.1.5 Study outcomes and sample size calculation 
The primary and secondary outcomes of the SONIC study were to identify the proportion 
of patients with CKD and controls that: 
1. achieved post-vaccination antibody titres above levels associated with protection 
from disease and/or an adequate response to TIV and PPV23; 
2. maintained “protective” antibody titre at 6 months’ post-vaccination. 
As such, the calculation of sample size was based on previous literature on humoral 
responses to the two study vaccines. Literature on humoral responses to PPV23 only was 
used as influenza literature was too heterogeneous due to yearly variations in vaccine 
composition. Few studies have evaluated responses to PPV23 in older pre-dialysis CKD 
patients. I therefore used studies of vaccination responses in healthy elderly individuals 
(249, 250) to estimate sample size by extrapolating the proportional reduction in response 
seen in studies of dialysis and renal transplant patients (251-254). Concentrations of 
antibody to pneumococcal polysaccharide (PnPS) are, by convention, reported as 
geometric means. A sample of approximately 50 individuals per group (total sample size 
100) was calculated to have 80% power to detect a 2-fold reduction in antibody titre 
difference in patients with CKD as measured using a logarithmic scale. 
Evaluation of the relationship between CKD and immune cell phenotype/function at 
baseline and after vaccination, together with the incidence of infectious disease requiring 
hospitalisation, GP consultation and/or antibiotics over a period of 6 months, were 
investigatory outcomes of the study.  
 
76 
 
2.1.6 Statistics 
Statistical analyses were performed using Prism (version 7, GraphPad, La Jolla, CA, 
USA), SPSS software (version 24, IBM, New York, USA) and Open Source 
Epidemiologic Statistics for Public Health (free open source online software for 
epidemiologic statistics, available at http://openepi.com). Continuous data were tested for 
Normality (using Shapiro-Wilk or Kolmogorov Smirnoff tests) and groups were compared 
using parametric (unpaired/paired t test, ANOVA) and non-parametric methods (Mann 
Whitney and Kruskall Wallis tests) as appropriate. Categorical data were compared using 
Fisher’s exact or Chi square tests. Differences in incidence rates were assessed using the 
mid P exact test. Correlations between continuous data were assessed using Pearson’s test 
(Normal/parametric data) and Spearman’s rank test (non-parametric data). Multivariate 
analysis on continuous data (Normalised as appropriate) was performed using linear 
regression modelling. In all statistical analyses, p < 0.05 was considered statistically 
significant. 
 
2.2 Laboratory methods 
At each study visit, approximately 50ml of venous blood was drawn peripherally using the 
Vacutainer® Safety-LokTM system (Beckton Dickinson, UK) into sterile Vacutainer® 
tubes (Beckton Dickinson, UK) with additives as listed in Table 2-3. Mid-stream samples 
of urine were also collected at each study visit into sterile 25 ml universal tubes without 
boric acid.  
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Table 2-3 Summary of blood samples collected at each study visit and the additives in 
Vacutainer collection tubes used.  
EDTA – ethylenediaminetetraacetic acid. 
Volume	
of	blood	
Vacutainer	
tube	
colour/name	
Additive	
36ml	 Green	 Sodium	
heparin	
6ml	 Red	-	clot	
activator	tube	
Micronised	
silica	
particles	
3.5ml	 Gold	-	serum	
separator	
tube	
Silica	gel	
4ml	 Purple	 EDTA	
 
Samples obtained at each study visit were either processed in the research laboratory 
within an hour of collection or sent for analysis to the Clinical Haematology and 
Biochemistry Laboratories at UHBFT as described later in this chapter. All Clinical 
Haematology samples were analysed on the day of collection. A minimum 5ml aliquot of 
urine collected at baseline was sent to Clinical Biochemistry on the day of collection for 
analysis of albumin/creatinine ratio (ACR). Serum samples were initially analysed by 
Clinical Biochemistry in batches from frozen serum prepared in the research laboratory 
(first two vaccination seasons, 2015-2017) in order to reduce processing costs. However, 
this proved inefficient and just as costly as sending fresh samples on the day of collection, 
so I reverted to the latter for the final vaccination season (2017-2018).  
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2.2.1 Samples for assay development from healthy volunteers  
Venous blood samples (maximum 50mls/donor) were collected from healthy young 
volunteers in the laboratory for the purposes of assay development. This was approved by 
the University of Birmingham Ethics committee (ref: ERN_13-0880) and written informed 
consent was obtained from all such donors in accordance with the Declaration of Helsinki.  
 
2.2.2 Serum preparation 
Whole blood was collected into clot activator (red) or serum separator tubes (gold), 
allowed to clot at room temperature for 1 hour (+/- 10 minutes) and then spun for 10 
minutes at 3000rpm, 4°C in a 5804R eppendorf centrifuge (Hamburg, Germany).  
 
2.2.3 Clinical laboratory measurements 
Clinical haematology and biochemistry measurements were performed by the Clinical 
laboratories at UHBFT using automated systems - Haematology Analyser (Beckman 
Coulter, CA, USA) and Roche/Hitachi 702 Analyser (Basel, Switzerland). Turbidimetric 
assays to determine serum concentrations of total IgG/A/M and IgG subclasses 1-4 were 
performed by the Clinical Immunology Service at the University of Birmingham using the 
cobas® (Roche/Hitachi, Indianapolis, USA) and SPAPLUS automated analyser systems 
(Binding Site, Birmingham, UK). 
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2.2.4 Highly sensitive C-reactive protein (hsCRP) measurement 
Serum concentrations of C-reactive protein (CRP) were determined using a high 
sensitivity enzyme-linked immunosorbent assay (ELISA) from IBL International 
(Hamburg, Germany), as per manufacturer instructions. Briefly, microtiterstrips pre-
coated with anti-CRP antibody were incubated with 100µl/well of diluted standard sera 
(1:100) and test sera (1:1000 in sample diluent). Each sample was run in duplicate. 
Covered microtiterstrips were incubated at room temperature (RT) for 30 minutes and then 
washed 3 times with kit phosphate-buffered Washing Solution at 200µl/well. In between 
washes, microtiterstrips were emptied by flicking contents into a waste container and 
blotting on absorbent paper. Kit Conjugate Solution (peroxidase-conjugated monoclonal 
anti-human CRP antibody) was then added at 100µl/well and incubated at RT for 30 
minutes. Washing was repeated as described above prior to addition of kit Chromogen 
Solution (tetramethylbenzidine, TMB) at 100µl/well and incubation for 10 minutes at RT, 
protected from light. The reaction was stopped by addition of 50µl kit Stop Solution (0.5M 
sulphuric acid) to each well. Absorbance at 450nm was read using a microplate reader 
(BioTek® Synergy, NorthStar Scientific Ltd, UK) within 30 minutes of assay completion. 
The minimal detectable concentration of the assay was 0.02µg/ml. 
 
2.2.5 Measurement of CMV-specific IgG  
Serum CMV-specific IgG titre was determined using a semi-quantitative in-house ELISA 
as previously described (255). Briefly, diluted cell lysate purified from CMV-infected 
fibroblast cultures and uninfected cells were used to coat a 96 well plate. Samples were 
added in a 1∶600 dilution together with standards for a calibration curve (pooled plasma 
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from three healthy CMV positive donors) and incubated for 30 minutes at RT. Secondary 
antibody (anti-human IgG-horseradish peroxidase, Southern Biotech, USA) was added 
after washing the plate with phosphate buffered saline (PBS)/0.05% Tween20, and 
incubated for a further 30 minutes at room temperature. The plate was developed with 
TMB solution and absorbance at 450nm was read using a microplate reader (BioTek® 
Synergy, NorthStar Scientific Ltd, UK). Optical density attributable to CMV-specific IgG 
was calculated by subtracting control lysate well values from the CMV lysate wells. A cut 
off of 10 arbitrary units was used to determine CMV seropositivity i.e. the presence of 
latent CMV infection.   
 
2.2.6 Measurement of IgG to pneumococcal polysaccharides and 
historic vaccine antigens 
This assay was performed by the Clinical Immunology Service at the University of 
Birmingham as previously described (256) using a mix of carboxylated fluorescent 
microbeads specific for distinct bead regions on a Luminex instrument (BioRad, CA, 
USA). The beads were conjugated to 1 of 14 different antigens (12 capsular 
polysaccharides: Streptococcus pneumoniae (Pn) serogroups 1, 3, 4, 5, 6B, 7F, 9V, 14, 
18C, 19A, 19F, 23F; 2 toxoids: Diphtheria and Tetanus; all sourced from ATCC, VA, 
USA). A dilution plate was made for each experiment prior to transfer to a 96-well filter 
microplate for incubation with the bead mix. Briefly, a series of 12 2-fold dilutions of 007-
SF standard serum (Food & Drug Administration, USA) starting at 1:100 was prepared in 
standard dilution buffer (PBS, 1%BSA, 0.05%Tween 20 and 5µg/ml pneumococcal cell 
wall polysaccharide). Test serum was then added at a dilution of 1:100 in standard dilution 
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buffer with 5µg/ml of serotype 22F polysaccharide (added to absorb non-specific 
antibodies). Four controls were run with every plate – 2 negative (sample dilution buffer; 
antibody-depleted healthy donor serum) and 2 positive (1 healthy donor serum and 1 mix 
of 3 healthy donors). The reported intra- and inter-assay variability for this IgG assay are 
8% and 31% respectively (256).  
 
2.2.7 Influenza haemagglutination inhibition assay 
The influenza haemagglutination inhibition (HAI) assay was performed by Rebecca Penn 
and Ruth Harvey from NIBSC laboratories (Potters Bar, UK) using a standard method as 
previously described (257). Briefly, sera were diluted 1:5 with receptor destroying enzyme 
(RDE), incubated overnight at 37°C and then heat inactivated at 56°C for 45 minutes. Sera 
were then added to a 96-well plate in a 2-fold dilution series in PBS with a final volume of 
100µl per well (final dilutions 1:10 to 1:1280). Test influenza virus (pre-diluted in PBS) 
was added at 50µl per well (dilution factor was determined by dividing the virus 
haemagglutinin (HA) titre by 8) and the plate incubated at RT for 60 minutes. Turkey 
erythrocytes in a 0.7% suspension in PBS were then added at 50µl per well and the 
samples left at room temperature for at least 20 minutes, until cell settling could be seen. 
The plate was read by tilting and evaluating the last dilution of serum with complete 
“streaming” of non-agglutinated red cells. The reciprocal of this dilution was taken as the 
“HAI titre” of that serum sample. Samples that failed to agglutinate the first dilution 
(1:10) were assigned a HAI titre of 5. All test sera were tested twice against the relevant 
vaccine strains from each vaccine season. RDE treated ferret antisera were used as 
positive and negative controls.  
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2.2.8 Peripheral blood mononuclear cell (PBMC) isolation  
Heparinised whole blood was diluted 1:1 with warm complete sterile Roswell Park 
Memorial Institute (RPMI) medium (RPMI 1640, 10% heat-inactivated fetal calf serum 
(HI FCS), 100U/ml penicillin, 100µg/ml streptomycin, all sourced from Sigma Aldrich, 
UK). PBMCs were isolated from diluted whole blood using gradient centrifugation with 
Ficoll Paque (GE Healthcare Life Sciences, IL, USA) and Leucosep tubes (Greiner-Bio-
One International, Austria) as per manufacturer instructions, and washed twice with 
complete RPMI (50ml/Falcon tube, spun at 300g for 10 minutes at 4˚C) prior to counting 
using a haemocytometer. The average yield of PBMCs from donors was 1x106 cells per 1 
ml whole blood. 
	
2.2.9 PBMC freezing and thawing 
For storage, PBMCs were resuspended in ice cold freezing solution (90% HI FCS, 10% 
DMSO, both Sigma Aldrich, UK) immediately after isolation at 5-10x106 cells/ml. Cells 
were transferred to cryovials and frozen initially at -80˚C using a Mr FrostyTM freezing 
container (ThermoFisher Scientific, MA, USA) or CoolCellTM (Biocision, CA, USA). 
Samples were then transferred to liquid nitrogen storage within 1-2 weeks for the first two 
years of the study. Unfortunately, PBMCs stored in liquid nitrogen had much greater 
variation in viability following thaw than cells frozen at -80˚C, so samples collected 
during the final year of the study were kept at -80˚C only.  
When required, frozen PBMCs were removed from storage and quickly defrosted by 
immersion in a 37˚C water bath for less than 5 minutes. Cells were washed once in 
warmed complete RPMI (50ml/Falcon tube, spun at 300g for 10 minutes at RT), then 
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resuspended in 2ml complete RPMI prior to addition of benzonase (Merck Millipore, MA, 
USA) at 1µl per 106 cells frozen. Cells were then incubated for 1 hour at 37˚C and washed 
a further 2 times in warmed complete RPMI prior to use (for flow cytometry viability 
staining, the last wash was performed in warmed sterile PBS). Cells were counted after 
defrosting using a haemocytometer. Average yield was 50-70% of cells initially frozen 
down. 
 
2.2.10 Neutrophil isolation from peripheral venous blood 
Heparinised whole blood was first incubated with dextran (2% w/v, reconstituted in 0.9% 
saline; Amersham Biosciences, Uppsala, Sweden) at a dilution of 1:6 in a sterile 50ml 
Falcon™ tube (BD Biosciences, UK) at RT for 30 minutes to allow red cell sedimentation 
to occur. Leucocyte-rich plasma was then carefully layered using a fine tip Pasteur pipette 
onto a sterile Percoll® (Sigma Aldrich, UK) density gradient consisting of 5ml 56% and 
2.5ml 80% Percoll® (diluted in 0.9% saline) in a sterile 15ml Falcon™ tube. Loaded 
gradients were spun at 1100rpm for 20 minutes with no brake at RT in an MR211i Jouan 
centrifuge (ThermoFisher Scientific, MA, USA). Neutrophils were then harvested from 
the 56-80% interface using a Pasteur pipette and transferred into a sterile 50ml Falcon™ 
tube. Cells were washed in RPMI-1640 medium supplemented with 1% 
penicillin/streptomycin (hereafter referred to as RPMI-PS) by spinning at 1600rpm, RT, 
for 10 minutes. After discarding supernatant, cells were resuspended in 1ml RPMI-PS 
prior to counting and determination of purity using an automated haematology analyser 
(Sysmex, UK). Cell populations containing ³95% neutrophils were accepted for further 
experiments and diluted to a final working concentration in RPMI-PS. 
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2.2.11 Lymphocyte immunophenotyping 
Flow cytometric phenotyping of T and B lymphocytes was performed using an LSR 
Fortessa instrument (BD Biosciences, UK) and results were analysed using FACSDiVa 
software version 8.0 (BD Biosciences, UK).  
 
2.2.12 Viability staining 
Viability staining was performed on all PBMC samples using an intracellular amine-
reactive dye (LIVE/DEADTM near IR Fixable Dead Cell Kit, ThermoFisher Scientific, 
USA) prior to surface and/or intracellular staining. Briefly, viability dye was defrosted and 
reconstituted with 50µl anhydrous DMSO per vial, as per manufacturer instructions. 
PBMCs were prepared as described above (section 2.2.8), washed once in PBS 
immediately prior to staining and resuspended at 106 cells/ml. 1µl of dye was added to 1ml 
of cell suspension and incubated at RT for 30 minutes, protected from light. Cells were 
then washed with 2ml MACS buffer (PBS with 1% HI FCS and 2mM EDTA, all from 
Sigma Aldrich), spun at 300g for 5 minutes and resuspended in 100µl BrilliantTM staining 
buffer (BD Biosciences, UK) for surface staining. Samples were excluded from final 
analysis if viability of the lymphocyte gate fell below 80%. 
 
2.2.13 Surface staining 
Titrated volumes of fluorochrome conjugated antibodies against cell surface markers were 
then added to the cell suspension in BrilliantTM staining buffer (BD Biosciences, UK) and 
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incubated at 4°C for 30 minutes, protected from light. After staining, cells were washed 
once with MACS buffer, and either stained for intracellular markers or prepared for 
analysis (resuspended in 300µl MACS buffer per tube and kept at 4°C, protected from 
light) - usually performed within an hour. To correctly and consistently identify “positive” 
populations of cells, a fluorescence-minus-one (FMO) control, where the marker of 
interest was substituted in the panel with an equivalent concentration of an isotype control 
antibody, was performed for each experiment. Table 2-4 shows the T lymphocyte and 
Table 2-5 the B lymphocyte immunophenotyping panels used in this study. Freshly 
isolated PBMCs were used for Panels 1 and 2 as staining for these markers was 
suboptimal on frozen samples during assay development. 
 
2.2.14 Intracellular staining for FoxP3 
Intracellular staining for FoxP3 was performed after surface staining using the 
eBioscience FoxP3/Transcription Factor Staining Buffer Kit, as per manufacturer 
instructions. Briefly, the kit Fixation/Permeabilization Concentrate (containing <5% 
paraformaldehyde) was diluted 4-fold with the kit Fixation/Permeabilization Diluent and 
added at 1ml per tube to the PBMC pellet after surface stained cells were washed with 
MACS buffer. Cells were incubated at RT for 30 minutes, protected from light. 2ml of 1X 
Permeabilisation Buffer (10x concentrate in kit diluted with deionised water) was then 
added to each tube, vortexed and spun at 300g, RT for 5 minutes. Supernatant was 
discarded and the cell pellet resuspended in the residual 1X Permeabilisation Buffer 
volume (approximately 100µl). The PE-conjugated anti-human FoxP3 antibody 
(eBioscience, USA) was added at 5µl per tube (106 PBMCs), the mixture was vortexed 
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and incubated at 4°C for 30 minutes, protected from light. PBMCs were then washed 
twice – first with 1X Permeabilisation Buffer (2ml/tube), followed by MACS buffer 
(2ml/tube), before being resuspended in 300µl MACS buffer per tube, ready for analysis. 
  
Table 2-4 T lymphocyte immunophenotyping flow cytometry panels used in this study.  
Red colour denotes intracellular marker. 
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Table 2-5 B lymphocyte immunophenotyping flow cytometry panels used in this study. 
 
 
2.2.15 Compensation method 
For all immunophenotyping experiments, single stain compensation samples were used to 
determine spectral overlap using the automated compensation option in FACSDiVa 
software (BD Biosciences, UK). Single stain compensation samples were prepared using 
ArCTM Amine Reactive and AbCTM Total Antibody compensation beads (Invitrogen) as 
per manufacturer instructions with pre-titrated volumes of fluorochrome-conjugated 
antibodies and viability dye. Adequacy of automated compensation was checked manually 
following data acquisition on the flow cytometer. 
 
88 
 
2.2.16 Measurement of neutrophil phagocytosis and reactive oxygen 
species production  
These functional parameters were assessed using PhagoburstTM and PhagotestTM assays 
(Glycotope GmbH, Berlin, Germany), as per manufacturer instructions.  
The PhagoburstTM assay quantitatively determines neutrophil oxidative burst in response 
to a number of stimuli, including N-formylmethyonine-leucyl-phenylalanine (fMLP), 
phorbol 12-myristate 13-acetate (PMA) and heat-killed opsonised Escherichia coli, though 
intracellular oxidation of dihydrorhodamine 123 (DHR-123) to its fluorescent product, 
rhodamine (258). Briefly, 100µl heparinised whole blood was transferred to a round 
bottom 5ml polystyrene tube (BD Biosciences, UK) - 1 tube was used for each of the 
following test conditions: wash buffer (negative control), fMLP (low biological control), 
PMA (positive control) and E coli (test condition). Samples were chilled on ice for a 
minimum of 10 minutes. Stimuli were added at 20µl per tube and samples were incubated 
for 10 minutes in a water bath at 37°C. The substrate (DHR-123) was then added at 20µl 
per tube and samples were incubated for a further 10 minutes at 37°C. Samples were 
incubated with 2ml 1x Fix/Lyse buffer for 20 minutes at RT, protected from light, and 
spun at 250g, 4°C for 5 minutes. Samples were then washed with 3ml/tube kit Wash 
Solution and spun at 250g, 4°C for 5 minutes, prior to addition of 200µl of DNA Staining 
Solution (propidium iodide) and incubation on ice for 10 minutes, protected from light.  
The PhagotestTM assay evaluates leucocyte phagocytosis by identifying neutrophils that 
have ingested FITC-labelled inactivated opsonised E. coli. Briefly, 100µl heparinised 
whole blood was transferred to a round bottom 5ml polystyrene tube (BD Biosciences, 
UK) - 1 tube was used for the test condition and 1 for a negative control. Samples were 
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chilled on ice for a minimum of 10 minutes. FITC-labelled heat-killed opsonised E. coli 
were added at 20µl per tube. The negative control remained on ice, but the test sample was 
transferred to a water bath at 37°C and incubated for 10 minutes. Fluorescence of 
extracellular bacteria was quenched using 100µl/tube kit Quenching Solution (trypan blue) 
and samples were then washed with 3ml/tube kit Wash Solution and spun at 250g, 4°C for 
5 minutes. Samples were then incubated with 2ml 1x Fix/Lyse buffer for 20 minutes at 
RT, protected from light, and spun at 250g, 4°C for 5 minutes. Another wash was 
performed prior to addition of 200µl of DNA Staining Solution (propidium iodide) and 
incubation on ice for 10 minutes, protected from light.  
All samples were analysed using a BD LSR Fortessa instrument within 30 minutes of 
assay completion (10,000 - 15,000 leucocytes recorded per sample), using a similar gating 
strategy for both assays, as summarised in Figure 2-3. Bacterial aggregates and debris 
were excluded by gating on DNA-stained cells (Figure 2-3A) and neutrophils were 
identified by forward and side-scatter characteristics (Figure 2-3B). Fluorescence in the 
FITC channel was then recorded for each test condition (both % and mean fluorescence 
intensity (MFI) of the neutrophil gate), with the negative control used to determine cut-off 
for FITC “positivity” (Figure 2-3C).  
The proportion of neutrophils defined as FITC positive by the above method were 
reported as “responding cells” in both assays. Phagocytic index (PI) was defined as the 
product of the phagocytosing neutrophil % and the FITC MFI of the neutrophil gate in the 
PhagotestTM assay, in line with previous studies (259). Oxidative burst capacity was 
defined as the FITC MFI of the neutrophil gate in the PhagoburstTM assay. The flow 
cytometer underwent repair after data acquisition for the 2015 cohort, hence FITC MFI in 
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data from this year is not directly comparable to subsequently acquired samples. In view 
of this, FITC MFI has been standardised across the entire study by dividing the MFI from 
stimulated samples by that of the negative control. 
Figure 2-3 Example gating strategy for PhagoTestTM and PhagoBurstTM assays.  
A – scatter plot demonstrating exclusion of bacterial aggregates/cell debris; B – scatter plot 
demonstrating selection of neutrophils; C – histogram of FITC fluorescence with representative 
data from study samples (PhagoBurstTM test conditions shown).  
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2.2.17 Quantification of neutrophil extracellular trap (NET) formation 
Unprimed neutrophils suspended at 1x106/ml in RPMI-PS were added to wells of a 96-
well flat bottomed plate (BD Biosciences, UK) at 200µl (2x105 cells) per well. Cells were 
then stimulated using PMA (final concentration 25nM diluted in RPMI-PS; Sigma 
Aldrich) or RPMI-PS as a negative control in replicates of 4 for each condition and 
incubated for 3 hours at 37°C in a humidified 5% CO2 atmosphere.  
Post-incubation, samples were transferred to 500µl microcentrifuge tubes (Sarstedt, 
Germany) and pelleted at 2200g for 10 minutes at 4°C in a pre-cooled microcentrifuge 
(Eppendorf, Germany). From each tube, 100µl of cell-free supernatant was then 
transferred into wells of a flat bottomed 96-well black plate (Corning, New York, USA) 
prior to addition of the cell-impermeable DNA binding dye SYTOX® Green (Life 
Technologies, UK) at 1µM concentration. A standard curve of l-DNA (ThermoFisher 
Scientific, UK) was run alongside each sample in a 1:2 dilution series (concentration range 
0-1000ng/ml). The plate was incubated for 10 minutes at room temperature, protected 
from light, and extracellular DNA content was then quantified by measuring fluorescence 
using a BioTek® Synergy 2 fluorimetric plate reader (NorthStar Scientific Ltd, UK) with 
a filter setting of 485nm (excitation) and 528nm (emission). Concentration of extracellular 
DNA was determined from the DNA standard curve and the mean of 4 replicates was 
reported for each sample.   
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2.2.18 Visualisation of NET formation using fluorescent microscopy 
2x105 neutrophils suspended in RPMI-PS were seeded onto 22mmx22mm square glass 
cover slips (VWR International, UK) and incubated for a minimum of 30 minutes at 37°C 
in a humidified 5% CO2 atmosphere to allow cells to adhere. Neutrophils were then 
stimulated with either RPMI-PS (negative control) of 25nM PMA (diluted in RPMI-PS) 
for 3 hours at 37°C, 5% CO2. Cells were fixed by addition of 4% paraformaldehyde and a 
further 30 minute incubation at 37°C, 5% CO2, then washed 3 times for 5 minutes in PBS 
at RT. Cells were permeabilised by incubation with 0.1% Triton X-100 for 1 minute at RT 
and then washed once in PBS as described above. DNA was stained using 1µM SYTOX® 
Green (Life Technologies, UK) dye (5 minutes, RT) and cells were washed a final time in 
PBS as described above. Specimens were then mounted in fluoromount medium and 
visualised using a LEICA DMI 6000 inverted microscope at x20 magnification.   
 
2.2.19 Assessment of neutrophil migration  
This was assessed using an Insall chamber (Weber Scientific International Ltd., 
Teddington, UK) as described previously (75, 260). This polymethyl methacrylate 
chamber consists of a central closed square chamber that is separated from a square outer 
chamber by two bridges of different thicknesses on opposite sides. This produces stable 
linear chemoattractant gradients of different steepness in a consistent and defined direction 
– the y direction (Figure 2-4). 
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Figure 2-4 Diagram representing neutrophil migration assay. 
Insall chamber was loaded with RPMI-PS and chemoattractant after neutrophils were adhered to 
coverslip. Top (thick) bridge of chamber was visualised using light microscopy and movement of 
neutrophils in the direction of increasing concentration of chemoattractant was recorded. 
 
Square glass 22mmx22mm coverslips were first coated with 400µl culture-tested 7.5% 
BSA (Sigma Aldrich, UK) and then with 400µl of a neutrophil suspension at 2x106/ml in 
RPMI-PS with 0.15% v/v 7.5% BSA. After a 20 minute incubation at room temperature, 
the coated coverslip was inverted onto an Insall chamber. The chamber bridges are 
designed to lie 20-30µm below the surface of the coverslip when it is in position, thus 
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allowing cells to move towards the test chemoattractant. The chamber was filled with 
RPMI-PS (negative control) or the test chemoattractant diluted in RPMI-PS: 10nM fMLP 
(Sigma Aldrich, UK) or 100nM interleukin 8 (IL-8/CXCL8, R&D Systems, Abbingdon, 
UK).  
Time-lapse recordings of cells at the wide chamber bridge were made using a LEICA DMI 
6000 inverted microscope at x40 magnification. Recordings lasted 12 minutes per 
experiment, with 36 images captured per film using LEICA software. Cell tracking 
analysis was performed on 10 randomly selected neutrophils in the field of view using 
ImageJ software and manual tracking plug-in (Wayne Rasband, National Institutes of 
Health, Bethesda, MD, USA). 
Neutrophil migration was assessed using 3 parameters as described in Table 2-6. 
Table 2-6 Description of neutrophil migration parameters calculated in this study. 
 
Chemokinesis	/	Speed	
(µm/min)	
Average	speed	of	cell	movement:	
distance	travelled	in	any	direction	
over	time	between	frames	
Chemotaxis	/	Velocity	
(µm/min)	
Average	velocity	of	cell	
movement:	speed	in	the	y	
direction	only	(towards	
chemoattractant)	
Chemotactic	index	/	
Accuracy	
Vector	analysis	of	cell	movement:	
cosine	of	angle	between	
orientation	of	cell	and	
chemoattractant	gradient	at	each	
frame	
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CHAPTER 3 
3 CHARACTERISATION OF THE 
STUDY COHORT: DEMOGRAPHICS 
AND CLINICAL RESULTS 
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3.1 Introduction 
The SONIC study was designed in order to evaluate immune system function in patients 
with CKD compared to age matched controls. Before moving on to describe differences in 
the immune system and its function, it is important to first describe the patient population, 
particularly with relation to severity of CKD. This chapter gives an overview of the 
demographic and clinical data of SONIC study participants (including comorbidities and 
medications), describes changes in participants’ health status over the 6 months of the 
study and defines clinical laboratory parameters of the cohort including CKD severity. As 
described in Chapter 1 (Introduction), several clinical features and changes in laboratory 
parameters are associated with CKD that may exert immunomodulatory effects in addition 
to renal impairment. Analyses in this chapter identify such differences between controls 
and patients with CKD that may confound analysis of CKD-associated immune effects.  
A total of 102 individuals (40 controls and 62 patients with CKD) were recruited to the 
SONIC study over 3 years (Figure 3-1), meeting the overall study sample size target. 
However, 36 participants (35%) were withdrawn from the study prior to vaccination with 
over a third due to patient choice (n=14, 39%). An unprecedented national shortage of 
PPV23 vaccines in the 2017-2018 vaccination season resulted in the withdrawal of 2 
participants for whom the vaccines were not available on the day of the baseline visit. 
Despite thorough screening of hospital records prior to recruitment, exclusion criteria were 
subsequently met for 12 individuals (33%) from GP records, repeat blood samples and/or 
patient interview by the research team. Eight individuals (22%) had already received the 
seasonal trivalent influenza vaccine (TIV) in the community prior to attending the baseline 
SONIC visit (6 of these were in the first study vaccination season) and were therefore 
withdrawn from the study. This was despite both verbal and written advice (PIS) by the 
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research team that TIV would be given as part of the study. A substantial amendment of 
the PIS that emphasised this message to participants, together with a GP letter of study 
participation to explain that TIV would be given as part of the study, was subsequently 
approved and used for the following SONIC study seasons (2016 onwards).  
A total of 66 individuals donated blood and urine samples at the baseline study visit (30 
controls, 36 patients with CKD), which were used for cross-sectional analyses. One 
control participant subsequently declined vaccination and was therefore withdrawn from 
further follow-up. One patient with CKD was lost to follow-up after the baseline visit. 
Samples from only 29 controls and 35 patients with CKD were, therefore, available for 
longitudinal analyses following vaccination up to and including day 28. A further 5 
patients with CKD and 1 control participant withdrew from the study prior to the month 6 
follow-up visit. 
 
3.2 Demographics and clinical parameters 
Healthy controls and patients with CKD were matched for age and gender, but were 
mainly of White ethnicity (Table 3-1).  
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Figure 3-1 SONIC study consort diagram - flow chart of participants and withdrawals. 
Blue colour denotes study flow, orange boxes denote withdrawn participants. 
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Table 3-1 Demographics of SONIC study participants.  
Median and interquartile range shown unless stated. P value <0.05 considered significant. aMann 
Whitney 2-tailed p value; bFisher’s exact 2-tailed p value. 
 
3.2.1 Aetiology of renal disease 
The most common identified cause of renal disease in patients with CKD in this study was 
ischaemic/hypertensive nephropathy (n=15, 42%). Five individuals had a diagnosis of 
diabetic nephropathy (14%), two individuals had obstructive uropathy (one of whom also 
had Fabry’s disease), one had a congenital single kidney and one lithium-induced 
nephropathy. None of the patients with CKD in this study had immune-mediated renal 
disease, as per study exclusion criteria. However, a third of patients with CKD (n=12, 
33%) in this study did not have a clearly defined aetiology for their renal disease. This was 
in the context of multiple comorbidities that are associated with renal impairment e.g. 
hypertension, atherosclerosis and diabetes. Patients with CKD had been under specialist 
nephrology follow-up for a median of 41 months (3.4 years) with a range of 3 months to 
23 years. 
 
3.2.2 Medical comorbidity and medications 
As expected, patients with CKD were significantly more comorbid than controls (Table 
3-2), with a significant excess prevalence of diabetes mellitus (DM), hypertension (HTN), 
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cardiac disease (ischaemic heart disease (IHD), congestive cardiac failure (CCF) and 
arrhythmias) and gastrointestinal conditions (mostly peptic ulceration and/or gastro-
oesophageal reflux).  
 
Table 3-2 Comorbidities of SONIC study participants.  
N and (%) shown unless stated. DM: diabetes mellitus; HTN: hypertension; IHD: ischaemic heart 
disease; CCF: congestive cardiac failure; AF: atrial fibrillation; PPM: permanent pacemaker; 
CVA: cerebrovascular accident; TIA: transient ischaemic attack; COPD: chronic obstructive 
pulmonary disease; OA: osteoarthritis; BPH: benign prostatic hypertrophy. P value <0.05 
considered significant. aMann Whitney 2-tailed p value; bFisher’s exact 2-tailed p value. 
 
101 
 
A total of 8 participants had a history of malignancy >5 years prior to study enrolment 
without evidence of recurrence/metastasis (2: prostate cancer, 2: breast cancer, 2: 
colorectal cancer; 2: melanoma). 
As expected with greater comorbidity, patients with CKD were prescribed significantly 
more medications per person than controls and the proportion of individuals with 
polypharmacy (an independent predictor of mortality/frailty (261, 262)) was significantly 
greater (Table 3-3). In parallel to a greater prevalence of cardiovascular disease and 
arrhythmias, significantly more patients with CKD were prescribed anti-platelet agents, 
anticoagulants and anti-anginal medications than controls. A slightly greater proportion of 
individuals with CKD were prescribed statin therapy than controls (known to modulate the 
immune system (263, 264)), but this did not reach statistical significance. Hypertensive 
individuals with CKD were prescribed a significantly greater number of anti-hypertensive 
agents per person than hypertensive controls, with a significant excess of second-line 
medications: diuretics, beta-blockers and doxazosin. This is not unexpected, as we know 
that renal impairment causes hypertension, which further worsens renal impairment in a 
positive feedback mechanism. Blood pressure control becomes more difficult with 
advancing renal impairment, frequently requiring a multiple anti-hypertensive medications 
and the use of less frequently used second-line agents. 
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Table 3-3 Medications prescribed for SONIC participants. 
Median and IQR shown unless stated. NOAC: new oral anticoagulant; HTN: hypertension; DM: 
diabetes mellitus; PPI: proton pump inhibitor; H2RA: histamine 2 receptor antagonist. P value 
<0.05 considered significant. aMann-Whitney 2-tailed p value; bFisher’s exact 2-tailed p value. 
 
A third of diabetic patients with CKD were taking oral anti-hyperglycaemics and 
approximately half were insulin-dependent, suggesting difficult glycaemic control and/or 
prolonged duration of disease. Almost half of all patients with CKD were prescribed a 
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gastric acid lowering treatment e.g. proton pump inhibitor or ranitidine, compared with 
only one control, mirroring the observed markedly greater prevalence of gastrointestinal 
comorbidity in patients with CKD. Significantly more patients with CKD were taking 
regular analgesics (paracetamol +/- opiates) than controls, mirroring the slightly increased 
prevalence of musculoskeletal comorbidities compared to controls. Moderate-severe renal 
impairment is associated with hyperuricaemia and just under a third of patients with CKD 
were prescribed anti-gout therapy at the start of the study.  
As discussed in Chapter 1 (Introduction) – CKD is also associated with anaemia, bone 
mineral disease and metabolic acidosis. Patients with CKD had significantly greater 
prescribing of oral iron than controls, but only one individual was prescribed ESA therapy 
at the start of the study. Just over a third of patients with CKD were prescribed 1-acalcidol 
(n=13, 36%) and 11% (n=4) were prescribed sodium bicarbonate.  
As per study exclusion criteria, none of the study participants had any active immune-
mediated disease or were taking immunosuppressive medications. 
 
3.2.3 BMI, smoking status and alcohol intake 
BMI was available for 33 patients with CKD (92%), but only 14 controls (47%). In this 
dataset, BMI was significantly elevated in patients with CKD, with almost two thirds of 
the CKD group classified as obese or severely obese (BMI≥30 kg/m2) – Table 3-4. 
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Table 3-4 Body mass index (BMI) of SONIC study participants.  
Median and IQR shown unless stated. P value <0.05 considered significant and highlighted in 
bold. aMann Whitney 2-tailed p value; bFisher’s exact 2-tailed p value. 
 
BMI significantly correlated with both CCI (Spearman’s correlation coefficient 0.52, 
p=0.0002) and medication burden (Spearman’s coefficient 0.35, p=0.02) in this study. 
Significantly more patients with CKD identified themselves as “ever-smokers” than 
controls (Table 3-5), but smoking exposure (measured in pack years) was equivalent 
between the groups. “Ever-smokers” had a significantly higher CCI than individuals that 
had never smoked (medians 3.5 and 1, respectively; Mann Whitney 2-tailed p=0.0002). 
 
Table 3-5 Smoking history of SONIC study participants.  
Median and IQR shown unless stated. P value <0.05 considered significant. aMann Whitney 2-
tailed p value; bFisher’s exact 2-tailed p value. 
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Smoking status and obesity (together with its’ associated metabolic syndrome) are known 
to be associated with greater cardiovascular disease risk (265-267), so it is not surprising 
that these features were more prevalent in patients with CKD. 
Control subjects had a significantly higher proportion of alcohol drinkers than patients 
with CKD (Table 3-6), but the degree of alcohol intake was equivalent between the 
groups. Interestingly, approximately 1 in 5 controls and patients with CKD identified as 
heavy drinkers (intake of over 14 units of alcohol per week), with a median of 20.5 
units/week in both groups.  
 
Table 3-6 Alcohol intake of SONIC study participants.  
Median and IQR shown unless stated. P value <0.05 considered significant and highlighted in 
bold. aMann Whitney 2-tailed p value; bFisher’s exact 2-tailed p value. 
 
“Current drinkers” had generally higher lower CCI than “tee-total” individuals, which 
approached significance (Mann Whitney 2-tailed p=0.07). This is in keeping with previous 
observations that older adults that report greater health-related quality of life and lower 
incident frailty consume more alcohol than their more comorbid counterparts (268, 269). 
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3.2.4 Self-reported health events 
Two-thirds of SONIC participants reported health events during 6 months of follow-up 
(n=43). These were defined as a new health condition (including infections) or diagnosis 
not previously known, an exacerbation of a pre-existing condition and/or any 
hospitalisation or medical procedure. A slightly greater proportion of patients with CKD 
reported health events than controls, but this did not reach statistical significance. 
Although the number of events reported by patients with CKD was almost twice that 
reported by controls (Table 3-7), time-adjusted incidence was not significantly different 
between the patient groups (rate ratio 1.5, 95% CI 0.91-2.59, mid P exact p=0.11). 
 
Table 3-7 Self-reported new health events by SONIC study participants.  
ENT: ear, nose and throat. P value <0.05 considered significant. aFisher’s exact 2-tailed value, 
.bmid P exact 2-tailed p value. 
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Overall, the majority of reported health events were respiratory (27 of 63 events, 43%) and 
infective in nature. Respiratory events made up a slightly greater proportion of health 
events reported in patients with CKD than controls. Patients with CKD reported a total of 
11 upper respiratory tract infections (URTIs, 55% respiratory events), 8 lower respiratory 
infections (LRTIs)/infective exacerbations of COPD or asthma (40% respiratory events) 
and 1 new diagnosis of metastatic lung carcinoma. Control participants reported 5 URTIs 
(71% respiratory events), 1 LRTI and 1 new diagnosis of pulmonary fibrosis. A quarter of 
health events reported by patients with CKD were skin/musculoskeletal/dental – slightly 
greater than in controls – with 5 episodes of acute gout and one each of exacerbation of 
chronic lower back pain, dental abscess, cryotherapy to skin lesion, infected leg ulcers, 
broken down abdominal hernia skin and severe sunburn requiring dressings. Of the 2 
events in this category reported by controls, one was a dental abscess and the other a new 
diagnosis of generalized eczema, treated with topical steroids.  
Control participants reported a slightly greater proportion of gastrointestinal/urological 
events than patients with CKD, with one episode each of gallstone pancreatitis requiring 
inpatient admission, elective inguinal hernia repair, altered bowel habit with subsequent 
negative endoscopy, urinary tract infection (UTI) treated with oral antibiotics, severe 
gastro-oesophageal reflux and traveller’s diarrhoea. One patient with CKD underwent an 
elective trans-urethral resection of the prostate (TURP) and one had an emergency hospital 
admission with priapism. 
Two individuals in both control and CKD groups reported cardiovascular health events, 
which were an ischaemic CVA (1 control, 1 CKD), a new diagnosis of hypertension (1 
control) and a new diagnosis of angina (1 CKD). Of the neurological/ENT events, 1 
control individual each reported new short term memory loss and a recurrence of benign 
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paroxysmal positional vertigo (BPPV) symptoms, and 1 patient with CKD reported 
recurrent epistaxis. Of the trauma events, 1 control sustained a deep cat bite requiring 
antibiotics and dressings, another control sustained a finger laceration necessitating A&E 
attendance and 1 patient with CKD was involved in a minor road traffic collision. One 
control participant was found to have an incidental iron deficiency anaemia on baseline 
study bloods, which was subsequently investigated further by their GP. Two patients with 
CKD had a new diagnosis of metastatic carcinoma (one of lung origin, one of unknown 
origin) during their 6-month follow-up and sadly passed away before the end of 3 years of 
study.  
The control individual that developed pulmonary fibrosis and the two patients with CKD 
who were diagnosed with metastatic carcinoma during the course of the study (thus 
fulfilling exclusion criteria) were subsequently excluded from analysis of immune 
function. 
 
3.2.5 Infective episodes 
Twenty-four participants reported a total of 33 infective episodes during the course of the 
study (Table 3-8). Patients with CKD reported over twice as many episodes as controls, 
with a slight excess of respiratory tract infections. The number and proportion of infective 
episodes that were treated with antibiotics and/or required hospitalisation were low and 
not significantly different between the two study groups. 
Time-adjusted reported incidence of infection in patients with CKD was almost twice that 
of controls and approached significance (rate ratio 1.9, 95% CI 0.9-4.1, mid P exact 2-
tailed p=0.09). However, when respiratory infections were considered separately, patients 
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with CKD had a significantly greater time-adjusted incidence than controls (rate ratio 2.4, 
95% CI 1.0-6.7, mid P exact 2-tailed p=0.05). Interestingly, individuals that reported any 
infections were significantly younger than those that did not (median 72 years (IQR 6) 
versus 78 (IQR 11), Mann-Whitney 2-tailed p=0.006) and this difference persisted when 
the study population was split by disease group. There were no significant differences in 
gender, CCI or laboratory parameters (Hb, WCC, eGFR, ACR, HbA1c, hsCRP or CMV 
IgG/CMV serostatus - described in detail later in this chapter) between individuals that did 
or did not report infections over 6 months. 
 
Table 3-8 Self-reported infective episodes by SONIC study participants. 
P value <0.05 considered significant and highlighted in bold. aFisher’s exact 2-tailed p value, 
bmidP exact 2-tailed p value. 
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3.3 Medication changes 
Over half of patients with CKD reported changes in medications over 6 months of follow-
up compared with just under a quarter of controls, with almost twice as many medication 
change events (Table 3-9). The most common class of medications altered was anti-
hypertensives, accounting for just over a third of medication change events in both 
controls and patients with CKD. Six patients with CKD commenced new treatments for 
anaemia during 6 months of follow-up (2 started IV iron, 2 oral iron, 1 vitamin B12 and 1 
ESA), compared with none of the controls. This is not unexpected, given the association 
of renal impairment with anaemia.  
 
Table 3-9 Medication changes reported by SONIC participants over 6 months.  
N (%) shown. P value <0.05 considered significant and highlighted in bold. aFisher’s exact 2-tailed 
p value; bMid-P exact 2-tailed p value. 
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3.4 Significant adverse events (SAEs)  
An SAE was defined as per the NHS Health Research Authority (HRA) guidance as an 
untoward occurrence that fulfilled one of more of the following criteria: 
• resulted in death 
• was life-threatening 
• required hospitalisation / prologation of existing hospital stay 
• results in persistent or significant disability / incapacity 
• was otherwise considered medically significant by the research team. 
10 SAEs were reported during the 3 years of the SONIC study, all of which were deemed 
unrelated to the study intervention. Eight events were reported for patients with CKD and 
2 events for controls (see Table 3-10). 
Two patients with CKD, but no controls died during the 6 months of study follow-up. A 
further 4 patients with CKD and 1 control participant who had died were identified when 
examining clinical notes during data collection/analysis at the end of the 3 years of study 
(August 2018). The difference in the mortality rate between controls and patients with 
CKD in this small study approached significance (Kaplan-Meier survival log-rank p=0.09, 
Figure 3-2). 
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Table 3-10 Summary of SONIC study SAEs by vaccination season.  
IV – intravenous, ERCP – endoscopic retrograde cholangio-pancreatography, LRTI – lower 
respiratory tract infection, PAF – paroxysmal atrial fibrillation, AKI – acute kidney injury. Blue 
text refers to CKD patients, black text refers to controls. 
 
Figure 3-2 SONIC study participant survival: Kaplan-Meier curve. 
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Of the patients with CKD who died, 3 suffered a cardiac arrest likely precipitated by an 
acute myocardial event and 2 died from metastatic carcinoma. One patient with CKD died 
from calciphylaxis, a life-threatening and rare syndrome typically associated with ESRD, 
characterised by intensely painful necrotic skin lesions that evolve as a result of 
microvascular ischaemia due to widespread vascular calcification (270). The control 
participant died from complications of pulmonary fibrosis diagnosed during their active 
participation in the SONIC study. 
3.5 Clinical laboratory parameters 
3.5.1 Haematology profile  
Table 3-11 summarises the baseline clinical haematology parameters for SONIC study 
participants. Patients with CKD were significantly more anaemic than controls and had a 
significantly greater total white cell count, with higher neutrophil, monocyte and 
eosinophil counts (Figure 3-3). Patients with CKD were also slightly lymphopaenic 
compared to controls, but this did not reach statistical significance. These features are 
expected, as anaemia is a known complication of CKD and renal impairment is associated 
with chronic inflammation, with expansion of white blood cells, particularly neutrophils 
(193). In line with previous literature (208-210), patients with CKD had a significantly 
higher neutrophil/lymphocyte ratio (NLR) than controls. Interestingly, there was no 
significant difference in NLR between patients with both DM and CKD and those with 
CKD only.  
The haematology profile of individuals was stable over a follow-up of 6 months, with no 
significant differences seen between measurements at baseline and month 6 in either 
controls or patients with CKD. 
114 
 
Table 3-11 Summary of baseline haematology parameters of SONIC participants.  
Median and IQR shown unless stated. Hb: haemoglobin; MCV: mean cell volume; WCC: white 
cell count. P value <0.05 considered significant and highlighted in bold. aMann Whitney 2-tailed p 
value, bunpaired t-test 2-tailed p value. 
 
3.5.2 Biochemistry profile  
Table 3-12 summarises the baseline clinical biochemistry parameters of SONIC 
participants. By design, patients with CKD had significantly higher urea and creatinine, 
mirrored by lower eGFR, than controls (Figure 3-4 – panels A-D). A small number of 
individuals had a calculated eGFR just below 15 at baseline, which was reported as 15 by 
the clinical laboratory (rounded up to 2 significant figures). As expected, proteinuria was 
significantly greater in patients with CKD (Figure 3-4 panel E) and increasing ACR was 
significantly associated with reducing eGFR (Spearman p<0.05). 
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Figure 3-3 Summary of haematology profiles of SONIC study participants – comparison 
between controls and patients with CKD.  
Hb shown for males (A) and females (B), together with total white cell count (WCC – panel C), 
neutrophil count (D), lymphocyte count (E), neutrophil/lymphocyte ratio (NLR – panel F), 
monocyte (G) and eosinophil counts (H). Dashed red lines denote limits of normal range. Error 
bars denote median and IQR. *denotes p<0.05. 
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Table 3-12 Summary of baseline biochemistry parameters of SONIC participants.  
Median and IQR shown unless stated. eGFR: estimated glomerular filtration rate; ACR: 
albumin/creatinine ratio; hsCRP: highly sensitive C-reactive protein; PTH: parathyroid hormone; 
TIBC: total iron binding capacity; HbA1c: glycated haemoglobin. P value <0.05 considered 
significant and highlighted in bold. aMann Whitney 2-tailed p value, bunpaired t-test 2-tailed p 
value. 
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Figure 3-4 Summary of renal profile of SONIC study participants – comparison between 
controls and patients with CKD.  
Urea (A), creatinine (B), eGFR (CKD-EPI in panel C, MDRD in panel D), albumin/creatinine 
ratio (ACR) – panel E. Dashed red lines denote limits of normal range. Error bars denote median 
and IQR. *denotes p<0.05. 
 
Over a third of patients with CKD had severe, G4A3 stage, disease (summarised in  
Table 3-13 and Figure 3-5).  
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Table 3-13 Classification of CKD disease in patients with CKD by eGFR and ACR. 
N and % shown. Grey text denotes classification based on CKD-EPI eGFR, black text denotes 
MDRD eGFR.  
 
Figure 3-5 Density plot summarising classification of CKD disease in SONIC patients 
with CKD. 
MDRD eGFR shown as representative.  
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There was no significant change in eGFR over 6 months in patients with CKD overall. 
Progression of CKD is defined as a sustained drop in eGFR of 25% or more and a change 
in GFR category over 1 year, and/or a sustained drop in eGFR of >15ml/min over 1 year 
(99). If these parameters are halved and applied to SONIC patients with CKD (assuming a 
constant rate in renal function decline), only one individual fulfils criteria for progression 
(Figure 3-6). This patient died of an acute myocardial infarction 18 months after 
completing SONIC study follow-up. 
 
Figure 3-6 Change in eGFR (MDRD shown) over 6 months.  
Purple colour denotes data from progressor patient. Adjusted baseline: mean taken of B and F1 
results to account for natural variability in eGFR; dashed red lines shown limits of eGFR for CKD 
G stages. 
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In keeping with the greater prevalence of diabetes in patients with CKD, HbA1c was also 
significantly higher in this patient group (Figure 3-7 A). As expected, hsCRP - a marker of 
inflammation, was significantly greater in patients with CKD than controls (Figure 3-7 B), 
mirroring the pattern seen with neutrophils and NLR. Albumin was significantly lower in 
patients with CKD than controls (Figure 3-7 C), in keeping with a chronic inflammatory 
process. Although calcium and phosphate levels were similar between patients with CKD 
and controls, median PTH in patients with CKD was above the reference range for 
normocalcaemic individuals, in keeping with what is known about bone mineral 
dysregulation with CKD. 
Interestingly, folate and iron levels (but not vitamin B12) were significantly lower in 
patients with CKD compared to controls, despite receiving supplementation (3 patients 
with CKD for folate, 6 for oral iron). 
 
3.5.3 Relationships between haematology and biochemistry parameters 
As expected, markers of renal disease severity were associated with markers of known 
complications of CKD. Significant negative correlations were seen between eGFR and 
markers of inflammation (WCC, neutrophil count, NLR and hsCRP) and bone mineral 
disease (alkaline phosphatase and phosphate). Significant positive correlations were seen 
between eGFR and markers of anaemia (Hb, folate, iron). The relationships seen with 
eGFR were mirrored by significant, but opposite relationships with ACR.  
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Figure 3-7 Measures of glycaemic control (A), hsCRP (B) and albumin (C) in patients 
with CKD compared to controls.  
Dashed red lines denote limits of normal range. Error bars denote median and IQR.  *denotes 
p<0.05.  
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Figure 3-8 Summary of serum vitamin B12 (A), folate (B) and iron (C) in SONIC study 
participants – comparison between controls and patients with CKD.  
Dashed red lines denote limits of normal range. Purple colour denotes data from individuals 
receiving supplementation. Error bars denote median and IQR.  *denotes p<0.05.  
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3.6 Serum clinical immunology profile 
3.6.1 Total immunoglobulins 
Quantifying total circulating immunoglobulins (IgA, IgM and IgG) is an important means 
of assessing the immune system. Deficiency in any and all of these immunoglobulin 
classes are associated with a number of clinical syndromes of increased susceptibility to 
infection as described in Chapter 1 (Introduction).  
Baseline serum samples from SONIC study participants recruited during the 2015/16 and 
2016/17 vaccination seasons (20 controls, 25 patients with CKD) were tested for total 
immunoglobulins. No significant differences in total IgG, IgA and IgM serum 
concentrations were seen between controls and patients with CKD (Figure 3-9). Just over 
a third of controls and patients with CKD had low serum total concentrations of IgM 
(Table 3-14), which is expected as IgM is known to decline with age (271). Interestingly, 
3 patients with CKD, but no controls, had low total serum IgG concentrations, and this 
class deficiency was not isolated - 2 individuals also had low total IgM, but normal IgA 
and 1 had low total IgA, but normal IgM.  
In view of these finding, we then examined IgG subclass concentrations in a small subset 
of SONIC participants (11 controls, 14 patients with CKD – 2 of whom had low total 
IgG). There were no significant differences in serum concentrations of IgG1-4 between 
patients with CKD and controls (Figure 3-10). 
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Figure 3-9 Total serum immunoglobulins in SONIC study participants – comparison 
between controls and patients with CKD. 
Serum concentrations of total IgA (A), IgM (B) and IgG (C). Dashed red lines denote limits of 
normal range; error bars denote median and IQR.  
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Table 3-14 Summary of SONIC participants with low total serum immunoglobulin levels. 
N (%) shown unless stated, Fisher’s exact p shown. P value <0.05 considered significant. 
 
 
Figure 3-10 Serum concentrations of IgG subclasses in sample of SONIC study 
participants – comparison between patients with CKD and controls. 
Blue symbols denote data from patients with CKD, unfilled symbols denote data from controls. 
Error bars denote median and IQR. 
 
3.6.2 Anti-TT/DT IgG 
Our group has previously shown that antibody responses to several historic antigens in 
patients with CKD can be at least equivalent to healthy controls, which suggests that renal 
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impairment may not induce a global immunodeficiency state, but one that reflects the 
timing of antigen encounter (180). As such, I examined the impact of renal impairment on 
already established humoral immune memory in the SONIC cohort, by evaluating humoral 
responses to several antigens typically encountered by early adulthood: tetanus and 
diphtheria toxoids (TT and DT – vaccine antigens), and cytomegalovirus (CMV).  
Tetanus/diphtheria (TT/DT) vaccination history was available for 29 controls and 31 
patients with CKD (91% total study population). Eighteen SONIC study individuals 
(30%) had a TT/DT booster vaccination in the 10 years preceding their participation in the 
study and there was no significant difference in TT/DT coverage between patients with 
CKD (n=8, 26%) and controls (n=10, 34%). No significant differences were observed in 
anti-TT or anti-DT IgG titres between patients with CKD and controls (Figure 3-11) and 
this was unchanged if data from individuals with undetermined vaccination history were 
included. As expected, control participants that had received a TT/DT vaccine in the 
preceding 10 years had significantly higher anti-TT and anti-DT IgG titres than controls 
that had not had a booster vaccine. This pattern, however, was not seen in patients with 
CKD. 
When clinical correlates of protection were considered, 22 patients with CKD (61%) had 
levels of anti-TT IgG above the WHO-defined threshold associated with tetanus protection 
(0.1µg/ml (272)) - hereafter referred to as “protective titre”, compared to 24 controls 
(80%, Fisher’s exact 2-tailed p=0.11). Only 2 patients with CKD (8%) and no controls 
(Fisher’s exact 2-tailed p=0.49) had levels of anti-DT IgG above the protective titre as 
defined by WHO (0.1µg/ml (273)).   
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There were no significant correlations between anti-TT IgG titres and measures of renal 
disease severity – eGFR and ACR - in all SONIC participants or when controls and 
patients with CKD were considered separately. Interestingly, anti-DT IgG significantly 
correlated with eGFR, but not ACR, in patients with CKD (Spearman’s rank 2-tailed 
p=0.04, correlation coefficient 0.41), but no significant relationships were seen in controls.   
 
Figure 3-11 Serum concentrations of anti-TT and DT IgG in SONIC study participants – 
comparison between controls and patients with CKD. 
A - TT, B – DT: comparisons between controls and patients with CKD. C – TT and D – DT: 
comparisons between patient groups split by recent booster vaccination status. Error bars denote 
median and IQR, unfilled symbols denote data from controls, blue symbols denote data from 
patients with CKD. Dashed red line denotes WHO protective titre. *denotes p<0.05, ns – not 
significant. 
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3.6.3 CMV-specific IgG 
Serum levels of CMV-specific IgG were determined by ELISA at baseline for all SONIC 
participants and a titre of 10 AU or greater was used to determine CMV seropositivity.  
Although patients with CKD had an excess of seropositive individuals compared to 
controls that approached significance (19 controls (63%) versus 30 patients with CKD 
(83%), Fisher’s exact 2-tailed p=0.09), absolute titres of seropositive individuals were not 
significantly different between the two disease groups (Figure 3-12 A, B). However, a 
significantly greater proportion of male patients with CKD were seropositive for CMV 
than male controls (n=7 (47%) and n=22 (92%) respectively, Fisher’s exact p=0.003) and 
seropositive females generally had higher titres than seropositive males (Figure 3-12 C). 
Interestingly, there were no significant differences in measures of multimorbidity (CCI, 
medication burden) when comparing male and female SONIC participants either as a 
whole study cohort or when split by disease group. However, male study participants had 
a significantly higher weekly alcohol intake than females overall (median 6 units (IQR 
18.5) and median 3.5 (IQR 7), respectively, Mann Whitney 2-tailed p=0.009). 
Haematology and biochemistry laboratory parameters were also similar between SONIC 
study males and females, except for platelet and monocyte counts, where female 
participants had significantly higher platelet counts (median 240.5 (IQR 39) versus median 
184.5 (IQR 54) for males, Mann Whitney 2-tailed p=0.002) and lower circulating 
monocytes (median 0.4 (IQR 0.2) versus median 0.6 (IQR 0.3) in males, Mann Whitney 2-
tailed p=0.01) than males. 
 
 
129 
 
Figure 3-12 Serum CMV-specific IgG titre in SONIC study participants. 
Comparison between controls and patients with CKD: A – all participants; B – CMV-seropositive 
only; C – CMV-seropositive individuals split by gender (rose colour denotes females). Error bars 
denote median and IQR. Dashed red line in panel A denotes threshold for CMV seropositivity. 
*denotes p<0.05. 
 
 
3.7 Discussion 
This Chapter characterises the demographic, clinical and basic laboratory parameters of 
the SONIC study population. This study has several strengths. Overall, the CKD and 
control groups were matched for age and gender. The CKD group was also broadly 
representative of the wider population of moderate/severe CKD patients, with a median 
eGFR of 23 ml/min and approximately a third of individuals classified as CKD G4A3 
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(moderate/severe renal impairment with severe proteinuria). The exclusion of dialysis 
therapy and immune-mediated/malignant health conditions in this study allows for a 
“cleaner” analysis of immune system phenotype and function in CKD than previous 
studies. However, study participants recruited were mainly of White ethnicity, and, as 
such, results may not be entirely applicable to the wider, more ethnically diverse CKD 
population.  
Although the recruitment target of 100 study participants was reached by the end of the 3 
years of the SONIC study, a large number of individuals were withdrawn prior to 
vaccination, resulting in a smaller sample size than planned – the main weakness of this 
study. However, this sample size approximates several other studies of immune function 
and phenotype in populations with renal disease (239, 274).  
The majority of CKD patients had a diagnosis of ischaemic/hypertensive or diabetic 
nephropathy – the two most common non-immune causes of CKD in adults (100). In 
keeping with previous literature, patients with CKD in this study reported slightly more 
health events and significantly more respiratory infections than controls in a period of 6 
months. Over the course of the 3 years of study, the CKD group also had a slightly higher 
mortality rate than controls.  
As expected, patients with CKD were significantly more comorbid than controls with a 
greater prescribing of anti-hypertensive and other “cardiac” medications. However, there 
was a significantly greater prevalence of DM in the CKD group than expected (67% 
versus approximately 30% in the wider CKD population (114)). This is likely due to the 
study selection criteria of older adults, as DM prevalence (like CKD) increases with age 
(115). Interestingly, the control study participants were really very “well”, with a median 
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CCI of 1 and hypertension, hypercholesterolaemia and musculoskeletal conditions e.g. 
OA/gout being the main comorbidities reported. As such, multimorbidity and, specifically, 
the presence of DM, are potential confounders in the subsequent analysis of CKD impact 
on immune system phenotype and function in this study.   
Patients with CKD had clinical laboratory features in keeping with known complications 
of CKD – anaemia (with low serum iron and folate) and elevated inflammatory markers 
(neutrophilia, high NLR ratio and hsCRP). No significant differences were seen between 
controls and patients with CKD in total immunoglobulins and IgG titre to the historic 
vaccine antigens, TT and DT. A slightly greater proportion of patients with CKD had 
evidence of latent CMV infection compared to controls (83% versus 63%), but the CMV-
specific IgG titre was equivalent between the groups in CMV seropositive individuals. As 
CMV infection is known to modulate the adaptive immune system (see Chapter 1, 
Introduction), this is another potential confounder in the analysis of CKD impact on the 
immune system in this study.  
Multiple comparisons have been made between data from patients with CKD and controls 
in this chapter and although some of the significant findings may represent type I errors 
(false positive), most are probably due to genuine differences between the disease groups. 
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CHAPTER 4 
4 VACCINE RESPONSES IN 
PATIENTS WITH CKD 
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4.1 Introduction  
The presence of CKD and ESRD/dialysis therapy have previously been associated with 
impaired vaccine responses, particularly for hepatitis B, with studies consistently 
demonstrating lower peak antibody titre, lower seroconversion rates and faster decline in 
protective antibody titres than healthy individuals (157, 181, 253).  
The effect of renal impairment on immune responses to various vaccines in older adults 
has not previously been systematically interrogated. The clinical study described in this 
thesis was designed to comprehensively evaluate the immune system in older patients with 
CKD, with a particular focus on adaptive immune function, where administration of 
clinically recommended seasonal vaccines (T-dependent seasonal trivalent influenza 
vaccine, TIV, and T-independent 23-valent pneumococcal polysaccharide vaccine, 
PPV23) acted as an in vivo antigen challenge. These vaccines were chosen specifically to 
examine both T-dependent and T-independent immune responses in the same individual. 
Responses to seasonal influenza vaccines are generally lower in older adults than those 
seen in young adults (64, 275). Despite this, influenza vaccination in the elderly is 
generally associated with reduced winter morbidity/mortality on a population level (276). 
Seasonal influenza vaccine responses in adults with CKD (including those treated with 
dialysis) are variable (176, 277, 278) and vaccine efficacy in ESRD is unclear (279). 
However, given the significant negative effects of influenza disease in this vulnerable 
patient population, annual vaccination is recommended (42). 
As with TIV, PPV23 responses in older and/or comorbid adults are generally lower and of 
poorer quality than in young adults (280) and vaccine effectiveness in these vulnerable 
populations is unclear (281). As described in Chapter 1 (Introduction), 
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hyporesponsiveness to repeat PPV23 vaccination (defined as the inability to mount an 
immune response upon re-exposure to antigen of at least the same or greater magnitude as 
that seen after primary exposure) is also a potential concern in this population as the 
inability to boost immune responses may limit both the effectiveness and the utility of the 
vaccine. Although PPV23 hyporesponsiveness has been observed in older adults (55, 56), 
its clinical impact remains under debate, particularly with evidence of vaccine efficacy in 
preventing the incidence of pneumococcal disease, even in adults aged over 50 years 
(282). 
In this Chapter I will describe the humoral response elicited by TIV and PPV23 in patients 
with CKD compared to age and gender-matched controls. The conventional method of 
evaluating responses to vaccines is to measure circulating antigen-specific antibody before 
and after vaccination, with increases in concentrations attributed to vaccine-induced 
immune activation. Antigen-specific antibody titres are, by convention, reported as 
geometric means in population studies of vaccine response. 
The gold-standard method of measuring humoral responses to TIV is by the 
haemagglutination inhibition assay (HAI, as described in Chapter 2, section 2.2.7) at 
baseline and day 28 post-vaccination for the specific influenza strains contained in the 
vaccine. This is a functional assay that evaluates the ability of antibody to haemagglutinin 
(HA – a surface protein of the influenza virus) to prevent erythrocyte agglutination by 
blocking HA binding to erythrocyte cell surface receptors. “HAI titre” is defined as the 
reciprocal of the highest serum dilution that completely inhibits haemagglutination in this 
assay. A variability in immunogenicity (the capacity to induce a robust immune response) 
can exist between different influenza strains from different vaccination seasons (283).  
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The gold-standard for PPV23 response assessment is the measurement of concentrations 
of anti-pneumococcal polysaccharide (PnPS) IgG at the same timepoints as for TIV (31). 
By convention, both HAI titres and anti-PnPS IgG concentrations are reported as 
geometric means when comparing responses between populations. Although PPV23 
contains capsule polysaccharides from 23 different pneumococcal serotypes, there is little 
consensus on how many or which serotypes should be measured to examine vaccine 
response. The humoral response to PPV23 can be used in children and adults as a tool for 
diagnosis of antibody deficiencies (54) and guidelines for this recommend measurement of 
responses to a minimum of 4 serotypes, accepting that most centres examine between 12 
and 14 (284). In this study we used an established clinical assay that was developed for 
assessment of immunodeficiency to examine responses to PPV23 (256) – see Chapter 2, 
section 2.2.6. This multiplexed assay measures IgG concentrations against 12 
pneumococcal serotypes: 1, 3, 4, 5, 6b, 7f, 9V, 14, 18c, 19A, 19F and 23F.  
The analysis presented here will address both the primary and secondary outcomes of the 
SONIC study: the proportion of CKD patients having adequate response and protective 
antibody titres following vaccination with TIV and PPV23 compared to healthy controls 
and the proportion of vaccinated individuals maintaining protective antibody titres 6 
months following vaccination. For clarity, only data from baseline, day 28 and month 6 
post-vaccination timepoints are presented. Day 7 antigen-specific HAI and IgG data was 
collected, but did not alter the patterns observed in humoral responses at day 28 and month 
6 and is therefore not included in this Chapter. 
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4.2 Vaccination history 
Coverage with the preceding season’s TIV was high and similar between controls and 
patients with CKD across the 3 study seasons (Table 4-1).  
 
Table 4-1 Preceding season’s TIV coverage – controls v CKD.  
Fisher’s exact 2-tailed p values shown. Significance defined as p<0.05. 
 
However, coverage with PPV23 was significantly lower in controls than patients with 
CKD (Table 4-2). Median time from previous PPV23 was approximately 10 years and not 
significantly different between the two study groups.  
137 
 
Table 4-2 PPV23 vaccination history of SONIC study participants. 
Median and IQR shown unless stated. PPV23: 23-valent pneumococcal polysaccharide 
vaccine; aFisher’s exact 2-tailed p value, bMann Whitney 2-tailed p value; significance 
defined as p<0.05. 
 
4.3 Vaccination-related adverse events 
There were no significant differences in the number of individuals reporting vaccination-
related events or the total number of such events between patients with CKD and controls 
in this study. A total of 20 individuals (33%) reported adverse events within 7 days of 
vaccination (11 controls, 9 patients with CKD), with less than 10% reporting 2 or more 
events (Table 4-3). The majority of these were local injection site reactions including pain, 
redness and swelling, all of which had completely resolved by the second follow-up 
timepoint (day 28).  
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Table 4-3 Vaccination-related adverse events reported within 7 days.  
N and (%) shown unless stated; amid P 2-tailed p value; bFisher’s exact 2-tailed p value; 
significance defined as p<0.05. 
 
 
4.4 Humoral responses to TIV antigens are similar between 
older patients with CKD and controls 
To systematically interrogate the humoral response to TIV, I first evaluated pre-
vaccination (baseline) strain specific influenza HAI titres. Due to heterogeneity in the 
composition of TIV across the 3 seasons of this study, I initially examined each season in 
turn. At baseline, the only difference seen between the patient groups was a significantly 
higher HAI GMT to the A/H3N2/Switzerland strain in patients with CKD than controls in 
the 2015-2016 vaccination season (Table 4-4). However, significance was lost when 
previous exposure to the antigen (e.g. through the previous year’s TIV) was taken into 
account (p=0.07). 
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Table 4-4 Baseline influenza HAI GMTs – study participants split by disease group and 
vaccination season.  
Geometric mean titres and 95% confidence intervals shown. Unpaired t-test on log-transformed 
data 2-tailed p value shown, p<0.05 considered significant and significant results highlighted in 
bold.  
 
 
Patients with CKD and age matched controls had similar baseline strain-specific HAI 
GMTs prior to first and repeat exposures to vaccine influenza strains (Table 4-5 and Table 
4-6, respectively). 
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Table 4-5 Influenza HAI GMTs for first exposure to listed strains – study participants split 
by disease group.  
ARR: geometric mean of antibody response ratio, AMR: geometric mean of antibody maintenance 
ratio. * - p<0.05 2-tailed paired t test on log transformed data: comparison of Day 0 and Day 28 
titres within controls/patients with CKD; ~ - p<0.05 2-tailed paired t test on log transformed data: 
comparison of Day 28 and Month 6 titres within controls/patients with CKD; # - p<0.05 2-tailed 
paired t test on log transformed data: comparison of Month 6 and Day 0 titres within 
controls/patients with CKD. 
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Table 4-6 Influenza HAI GMTs for repeat exposure to listed strains – study participants 
split by disease group.  
ARR: geometric mean of antibody response ratio, AMR: geometric mean of antibody maintenance 
ratio. * - p<0.05 2-tailed paired t test on log transformed data: comparison of Day 0 and Day 28 
titres within controls/patients with CKD; ~ - p<0.05 2-tailed paired t test on log transformed data: 
comparison of Day 28 and Month 6 titres within controls/patients with CKD; # - p<0.05 2-tailed 
paired t test on log transformed data: comparison of Month 6 and Day 0 titres within 
controls/patients with CKD. 
 
Baseline HAI GMT against A/H3N2 strains correlated significantly with baseline titres to 
influenza B strains (Pearson R: 0.48, p<0.001), but not A/H1N1 strains. Increasing age 
was also significantly associated with higher baseline HAI GMT to A/H3N2 (Pearson R: 
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0.37, p=0.004) and B strains (Pearson R: 0.31, p=0.02), but not A/H1N1. There were no 
significant relationships between baseline HAI GMTs to any influenza vaccine strains and 
measures of renal disease (eGFR, ACR), multimorbidity (CCI, medication burden), 
glycaemic control (HbA1c), latent CMV infection (CMV-specific IgG titre) or 
inflammation (hsCRP).  
In order to compare vaccine-induced humoral responses in a “like-for-like” manner, first 
and repeat exposures to different influenza strains were, in the first instance, analysed 
separately. Table 4-5 and Table 4-6 summarise HAI GMTs and 95% confidence intervals 
at day 0, day 28 and month 6 study timepoints, together with the statistical differences 
within this data.  
Both patient groups generally increased HAI titres following 1st exposure to 
A/H1N1/California and A/H3N2/Switzerland. However, subject numbers were too small 
for meaningful statistical comparisons (maximum n=2), so these data are excluded from 
subsequent analysis. Controls and patients with CKD were able to significantly increase 
strain-specific HAI titres between day 0 and day 28 post-vaccination upon first or repeat 
exposure to A/H1N1 strains (Table 4-5, Table 4-6, Figure 4-1 A,E and Figure 4-2 A,E). 
The response to A/H3N2 strains was more variable. On first exposure to the 
A/H3N2/Hong Kong vaccine antigen, controls had a significant increase in strain-specific 
HAI titres, but patients with CKD did not (Figure 4-1 B,F). However, both controls and 
patients with CKD had a robust increase in HAI titres after repeat exposure to 
A/H3N2/Switzerland (Figure 4-2 B,F), but not A/H3N2/Hong Kong (Figure 4-2 C,G). 
This is likely to reflect some differences in immunogenicity of Switzerland versus Hong 
Kong strains of influenza A/H3N2 and also the small sample size in this like-for-like 
analysis.  
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Figure 4-1	Primary response to TIV antigens. 
Strain-specific HAI titres shown at baseline and day 28 after vaccination for individual controls 
(A-D) and patients with CKD (E-H). * p<0.05 – paired t-test on log transformed titres. 
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Figure 4-2 Secondary response to TIV antigens. 
Strain-specific HAI titres shown at baseline and day 28 after vaccination for individual controls 
(A-D) and patients with CKD (E-H). * p<0.05 – paired t-test on log transformed titres. 
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Responses to B strains were generally poor in all study participants. In controls, a 
significant increase in HAI titres post-vaccination was seen only on first exposure to 
B/Phuket (Figure 4-1 C) and not on first or repeat exposure to B/Brisbane (Figure 4-1 D, 
Figure 4-2 D). Patients with CKD generally increased titres after first exposure to both 
B/Phuket and B/Brisbane (Figure 4-1 G, H), but this fell short of statistical significance 
(paired t-test on log transformed data 2-tailed p=0.06). Repeat exposure to B/Brisbane, 
however, did yield significant increases in HAI titre in patients with CKD (Figure 4-2 H). 
The magnitude of humoral responses to individual influenza strains, as measured by the 
antibody response ratio (geometric mean of Day 28/Baseline titre; ARR), was greatest for 
first and repeat exposures to A/H1N1 strains and repeat exposure to A/H3N2/Switzerland 
(Table 4-5 and Table 4-6). The ARR was generally lower in patients with CKD than 
controls on first or repeat exposure to most strains, but this did not reach statistical 
significance.  
As there was little difference between patients with CKD and controls when individual 
influenza strains and previous exposures were considered separately, data were then 
combined to give representative results for responses to all strains of A/H1N1, A/H3N2 
and B influenza (Table 4-7 summarises HAI GMTs, 95% confidence intervals and 
statistical differences within the data). This method also increased the sample size and 
hence, power, of statistical analysis. 
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Table 4-7 Influenza HAI responses by strain and disease group – combined data.  
ARR: geometric mean of antibody response ratio, AMR: geometric mean of antibody maintenance 
ratio. * - p<0.05 2-tailed paired t test on log transformed data: comparison of Day 0 and Day 28 
titres within controls/patients with CKD; ~ - p<0.05 2-tailed paired t test on log transformed data: 
comparison of Day 28 and Month 6 titres within controls/patients with CKD; # - p<0.05 2-tailed 
paired t test on log transformed data: comparison of Month 6 and Day 0 titres within 
controls/patients with CKD.  
 
Overall, both controls and patients with CKD significantly increased HAI titres to all TIV 
strains at day 28 post-vaccination and by an equivalent magnitude (Table 4-7 and Figure 
4-3).  
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Figure 4-3 Summary of humoral response to TIV antigens- comparison between controls 
and patients with CKD.  
Strain-specific HAI titres shown at baseline and day 28 after vaccination for individual controls 
(A-C) and patients with CKD (D-F), together with strain-specific antibody response ratios (ARR) 
– panels G-I. *p<0.05 – paired t-test on log transformed titres. Error bars show geometric mean 
and 95% CI. 
 
 
Influenza A strains (in particular H1N1) elicited a greater magnitude of HAI titre increase 
at day 28 than B strains. Increases in influenza A strain ARR were significantly associated 
with lower baseline HAI titres (Pearson R: -0.38, p=0.002 for A/H1N1 strains; R: -0.48, 
p<0.0001 for A/H3N2 strains). This was not the case for influenza B strains. However, as 
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seen with baseline HAI titres, higher A/H3N2 strain ARR was significantly associated 
with higher ARR to B strains (Pearson R: 0.30, p=0.02).  
Increasing age was significantly associated with lower ARR to A/H1N1 (Pearson R: -0.35, 
p=0.006) and A/H3N2 strains (Pearson R: -0.32, p=0.01) and approached significance for 
influenza B strains (Pearson R: -0.22, p=0.09). However, as seen with baseline HAI titres, 
there were no significant associations between ARR to any of the vaccine influenza strains 
or measures of renal disease (eGFR, ACR), multimorbidity (CCI, medication burden), 
glycaemic control (HbA1c), latent CMV infection (CMV-specific IgG titre) or 
inflammation (hsCRP).  
Older age (p=0.02) and higher baseline HAI titres against A/H1N1 strains (p=0.004) were 
significant predictors of lower A/H1N1 ARR in a linear regression model that also 
included gender, CKD status and CMV serostatus. Higher baseline A/H3N2 HAI titres 
(p=0.001) also emerged as a significant predictor of lower A/H3N2 ARR when the same 
model was applied to this vaccine strain. However, no significant predictors of influenza B 
strain ARR were identified on multivariate analysis.  
In summary, influenza A strains (particularly H1N1) elicited a greater increase in 
neutralising strain-specific HA antibody after vaccination with TIV than was seen for B 
strains in this study of older adults with and without chronic disease. No differences in the 
absolute HAI GMTs or the magnitude of HAI titre increase post-vaccination (ARR) was 
detected when patients with CKD were compared with age-matched controls. Only age 
and pre-vaccination strain-specific HAI titres emerged as significant predictors of the 
magnitude of influenza A strain HAI increase at day 28 post-vaccination (ARR).  
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4.5 Maintenance of TIV response 
When primary and secondary responses to different influenza strains were analysed 
separately, significant reductions in strain-specific HAI titres at month 6 post-vaccination 
were seen in both controls and patients with CKD following primary and secondary 
exposures to A/H1N1 strains and repeat exposure to A/H3N2/Switzerland (summarised in 
Table 4-5 and Table 4-6, data also shown in Figure 4-4 A,E and Figure 4-5 A,B,E and F). 
No significant reductions in HAI titre from levels reached at day 28 were seen at month 6 
following first exposure to A/H3N2/Hong Kong in either controls or patients with CKD 
(Figure 4-4 B,F), but controls exposed to this antigen a second time did demonstrate a 
significant reduction in titre from day 28 to month 6 after vaccination (Figure 4-5 C). The 
patterns seen with influenza B antigens were variable, with significant reductions in titre at 
month 6 observed in controls only following first exposure to B/Phuket (Figure 4-4 C) and 
patients with CKD only following first exposure to B/Brisbane (Figure 4-4 H). 
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Figure 4-4 Maintenance of responses following first exposure to TIV antigens. 
Strain-specific HAI titres shown at day 28 and month 6 after vaccination for individual controls 
(A-D) and patients with CKD (E-H). * p<0.05 – paired t-test on log transformed titres. 
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Figure 4-5 Maintenance of responses following repeat exposure to TIV antigens. 
Strain-specific HAI titres shown at day 28 and month 6 after vaccination for individual controls 
(A-D) and patients with CKD (E-H). * p<0.05 – paired t-test on log transformed titres. 
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Interestingly, the humoral response following first exposure to influenza A strains and all 
exposures to influenza B strains appeared short lived. Month 6 HAI titres were 
significantly higher than pre-vaccination levels only following repeat exposure to 
A/H3N2/Switzerland in both controls and patients with CKD, and after repeat exposure to 
A/H1N1/California in controls (summarised in Table 4-5 and Table 4-6). First exposure to 
any influenza strains contained in TIV and all exposures to influenza B strains did not 
yield significantly different HAI titres at month 6 compared to pre-vaccination levels in 
either controls or patients with CKD.  
The magnitude of strain-specific HAI titre change at month 6 from peak titres at day 28 
was assessed using the geometric mean antibody maintenance ratio (month 6/day 28 titre; 
AMR), where a value of 1 represents maintenance of titre and values less than 1 represent 
a reduction. Strain-specific AMRs were similar between controls and patients with CKD 
for both first and repeat exposures to vaccine antigens. 
When data were combined to give representative results for responses to all A/H1N1, 
A/H3N2 and B strains (summarised in Table 4-7 and Figure 4-6), both patient groups had 
significantly lower HAI GMTs at month 6 than day 28 post-vaccination to all 3 TIV 
strains. Interestingly, month 6 GMTs were significantly higher than pre-vaccination titres 
in controls for all TIV strains, but not in patients with CKD, where A/H1N1 titres at 
month 6 approximated pre-vaccination levels. Overall, strain-specific AMRs were similar 
between controls and patients with CKD (Table 4-7 and Figure 4-6). Higher strain-specific 
ARR was significantly associated with lower AMR for that strain (Pearson R: -0.54, 
p<0.0001 for A/H1N1; R= -0.68, p<0.0001 for A/H3N2 strains and R: -0.76, p<0.0001 for 
B strains). Strain-specific ARRs were significant predictors of AMR in a linear regression 
model that also included age, gender, CKD and CMV serostatus for each of the TIV 
153 
 
strains (p<0.0001). As such, this suggests that those individuals with greater change in 
HAI titre from baseline to peak are more likely to reduce titres by month 6 than those who 
do not mount as robust a response. This may simply reflect the short-lived nature of the 
response to TIV antigens, with greater “maintenance” of titre simply reflecting little 
change in HAI titre across the study for individuals with poor vaccine-induced responses. 
 
Figure 4-6 Summary of maintenance of humoral response to TIV antigens- comparison 
between controls and patients with CKD.  
Strain-specific HAI titres shown at day 28 and month 6 after vaccination for individual controls 
(A-C) and patients with CKD (D-F), together with strain-specific antibody maintenance ratios 
(AMR) – panels G-I. *p<0.05 – paired t-test on log transformed titres. Error bars show geometric 
mean and 95% CI. 
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In summary, older adults with and without chronic disease significantly reduce strain-
specific HAI titres from peak (day 28) to month 6 after vaccination with TIV. Although 
titres at month 6 were significantly higher than pre-vaccination titres for most strains, the 
significant inverse correlations between strain-specific ARR and AMR suggest that robust 
responses to TIV are relatively short-lived. This supports the current recommendation for 
routine annual influenza vaccination in this patient population. 
 
	
4.6 Clinical parameters of adequate TIV response 
A post-vaccination (day 28 onwards) strain-specific HAI titre of 40 or above is associated 
with 50% protection against disease with that influenza strain on a population level and 
will henceforth be referred to as the “protective titre” (31). Controls and patients with 
CKD had equivalent proportions of individuals with protective HAI titres against all 3 
influenza strains at baseline and day 28 post-vaccination (Table 4-8). Healthy individuals 
with HAI of 40 or above prior to vaccination are expected to be able to mount a 4-fold 
increase in titres post-vaccination. An adequate response to influenza vaccination is, 
therefore, defined as the conversion from a non-protective to protective titre or a 4-fold 
increase from baseline if starting titres are 40 or above. This approach allows first and 
repeat exposures to influenza antigens to be considered together. Adequate response to 
TIV as a whole is defined here as an adequate response to 2 of 3 antigens contained in that 
season’s vaccine. 
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Table 4-8 Adequate responses to seasonal TIV in SONIC study participants. 
N and % shown. Adequate response was defined as the conversion strain-specific HAI titre of <40 
pre-vaccination to HAI≥40 at day 28 or a 4-fold increase from baseline if starting titres are 40 ) – 
study participants are split by disease group and vaccination season.  
 
 
When responses to TIV as a whole were considered across all vaccination seasons, a 
surprisingly small proportion of all participants mounted an adequate response to the 
vaccine (less than 1 in 5) - Table 4-8. Patients with CKD generally performed worse than 
controls, with a lower proportion of individuals mounting an adequate response to 2 of 3 
vaccine antigens (12% versus 25%, Fisher’s exact 2-tailed p=0.32). The H1N1 influenza 
A strains appeared to be the most immunogenic overall using these clinical definitions (12 
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(43%) controls and 9 (27%) patients with CKD mounting adequate response, Fisher’s 
exact 2-tailed p=0.28) and the B strains were the least (4 (14%) controls and 3 (9%) 
patients with CKD mounting adequate response, Fisher’s exact 2-tailed p=0.69).  
When vaccination seasons were considered separately, patients with CKD in the 2015-16 
cohort had slightly greater protection to A/H3N2/Switzerland than controls at baseline 
(n=2 (20%) versus n=8 (62%) respectively, Fisher’s exact p=0.09) mirroring the pattern 
seen for absolute HAI titres. However, the number and proportion of individuals achieving 
an adequate response to this antigen were similar between the groups (n=5 (50%) in 
controls and n=6 (46%) in patients with CKD).  
Individuals that achieved protective HAI titres for any of the TIV strains at day 28 tended 
to maintain them at month 6 (Figure 4-7) and there were no significant differences 
between controls and patients with CKD. Overall, 80% (n=16) of controls maintained 
protective HAI titres to 2 of 3 TIV strains, compared with 67% (n=14) of patients with 
CKD (Fisher’s exact 2-tailed p=0.48). 
Overall, using clinical parameters of TIV humoral response, both patients with CKD and 
controls had poor responses to the vaccine as a whole, with less than 20% achieving 
adequate responses to 2 of 3 TIV antigens. Patients with CKD seemed to perform slightly 
worse compared to controls, but this did not reach statistical significance (possibly limited 
by sample size).  
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Figure 4-7 Proportion of individuals that maintained protective HAI titres (40 or more) at 
month 6 by TIV strain.  
Blue – controls, red – patients with CKD. 
 
 
4.7 Demographic and clinical characteristics of TIV 
responders  
Due to the small number of TIV “responders” and lack of significant differences in TIV 
responses between controls and patients with CKD, all study participants were considered 
together in the following comparison of “responders” (n=11) and “non-responders” 
(n=50). Unfortunately, the number of “responder” individuals was too small for 
meaningful multivariate predictive analysis using logistic regression. 
TIV responders were significantly younger (Table 4-9 and Figure 4-8 A), but with an 
approximately equal gender split, equivalent multimorbidity as measured by CCI and 
medication burden, smoking/alcohol exposure and prevalence of latent CMV (Table 4-9). 
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Table 4-9 Clinical characteristics of TIV responders versus non-responders.  
N and % shown. *and blue highlighting denotes unpaired t test on transformed data 2-tailed 
p<0.05. 
 
CMV-specific IgG titre was equivalent between CMV seropositive responders and non-
responders (Table 4-10). TIV responders generally had lower hsCRP and higher eGFR 
(Figure 4-8 B,C), but no significant differences were seen in any other biochemistry 
parameters, including HbA1c (also not altered when only individuals with DM were 
compared) and albumin (Table 4-10). No significant differences were seen between 
responders and non-responders in total white cell count, neutrophil count or NLR, 
however, Hb and lymphocyte counts seemed to be higher in CKD responders compared to 
non-responders (Figure 4-8 E,F). No differences were seen in levels of total IgA/M/G 
between responders and non-responders.  
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Figure 4-8 Clinical and laboratory parameters of TIV responders (R) versus non-
responders (NR). 
Age (A), hsCRP (B), eGFR (C & D), Hb (E) and lymphocyte count (F) shown. Teal colour 
represents TIV responders. Error bars show median +/- IQR. Dashed red lines in panel F represent 
limits of normal range. *unpaired t test on transformed data 2-tailed p<0.05; p values also shown 
for relationships approaching significance.  
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Table 4-10 Clinical laboratory characteristics of TIV responders versus non-responders.  
Median and IQR shown. * and blue colour denote unpaired t test on transformed data 2-
tailed p<0.05. 
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4.8 Pre-vaccination titres of pneumococcal serotype-specific 
IgG are similar in older adults with CKD and controls 
At baseline, patients with CKD had significantly greater coverage with PPV23 than 
controls, but duration from previous vaccination was similar, with a median of 
approximately 10 years (Table 4-2). Although controls and patients with CKD were 
matched for age across the whole study, those that had received a previous PPV23 vaccine 
were significantly older (median 69.5 years for vaccine naïve (IQR 3.8) and 78 years for 
revaccinees (IQR 9.3), Figure 4-9). This is expected, given contemporaneous guidelines 
for PPV23 to be given routinely at age 65.  
 
Figure 4-9 Comparison of age between PPV23 naïve individuals and those receiving 
repeat PPV23 vaccination.  
Grey symbols represent data from revaccinees. Error bars show median +/- IQR. *unpaired t test 
p<0.05. 
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No significant differences were seen in baseline serotype-specific anti-PnPS IgG titres 
between controls and patients with CKD (Table 4-11).  
When controls and patients with CKD were split by previous vaccination status, CKD 
revaccinees had a trend for lower baseline titres against serotype 3 compared to controls 
(unpaired 2-tailed t-test on log transformed data p=0.10), which may be a chance finding, 
but could also suggest poorer maintenance of Pn3-specific long-term humoral immunity in 
CKD.  Previously vaccinated controls and patients with CKD had significantly higher 
titres against serotype 4 than vaccine naïve individuals (unpaired t-test 2-tailed p=0.02 on 
log-transformed titres; geometric mean concentrations (GMCs) 0.06µg/ml (95% CI 0.03-
0.11) and 0.17µg/ml (95% CI 0.11-0.27) respectively). This is expected as natural 
exposure to this serotype is infrequent (285, 286). 
 
4.9 Patients with CKD and controls increase serotype-specific 
anti-PnPS IgG after vaccination with PPV23 
GMCs of serotype-specific anti-PnPS before and at day 28 after PPV23 vaccination, 
together with statistical differences within the data, are summarised in Table 4-11. PPV23 
vaccination significantly increased serotype-specific anti-PnPS IgG concentrations for all 
12 serotypes tested from baseline to day 28 in both controls (Figure 4-10) and patients 
with CKD (Figure 4-11) – summarised in Figure 4-12 A. 
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Table 4-11 Serotype-specific anti-Pneumococcal IgG titres before and after PPV23 
vaccination.  
 
 
 
 
 
Geometric mean concentrations 
(GMC) and 95% CI shown with 
unpaired t-test 2-tailed p value for 
log-transformed data.  
ARR: antibody response ratio, AMR: 
antibody maintenance ratio.  
*p<0.05 2-tailed paired t test on log 
transformed data: comparison of Day 
0 and Day 28 titres;  
~p<0.05 2-tailed paired t test on log 
transformed data: comparison of Day 
28 and Month 6 titre;  
#p<0.05 2-tailed paired t test on log 
transformed data: comparison of 
Month 6 and Day 0 titre. 
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Figure 4-10 Serotype-specific anti-PnPs IgG change from baseline to day 28 in individual 
control subjects.  
Range of assay: 0.01 -10 microgram/m (dashed lines): all values below 0.01 were assigned a value 
of 0.01, all values above 10 were assigned a value of 10. Red line denotes WHO long-term 
protective threshold of 0.35microgram/ml. *denotes p<0.05 paired t-test performed on log-
transformed data. 
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Figure 4-11 Serotype-specific anti-PnPs IgG change from baseline to day 28 in individual 
patients with CKD.  
Range of assay: 0.01 -10 microgram/m (dashed lines): all values below 0.01 were assigned a value 
of 0.01, all values above 10 were assigned a value of 10. Red line denotes WHO long-term 
protective threshold of 0.35 microgram/ml. * denotes p<0.05 – paired t-test performed on log-
transformed data. 
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Figure 4-12 Summary of PPV23 vaccine responses in SONIC study participants.  
Spider diagrams of A: anti-PnPS IgG geometric mean concentrations for controls (blue) and 
patients with CKD (red) at baseline (dashed lines) and day 28 (solid lines) post-vaccination with 
PPV23; B: serotype-specific geometric mean ARR for controls (blue) and patients with CKD 
(red). *denotes significant difference in ARR between patient groups (p<0.05).  
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The magnitude of humoral response to individual serotypes, as measured by the antibody 
response ratio (ARR: geometric mean of Day 28 titre/Baseline titre, summarised in Table 
4-11), was generally lower in patients with CKD than controls for all serotypes, reaching 
statistical significance only for serotype 19F (summarised in Figure 4-12 B). When the 
response to the whole vaccine was considered (calculated as the mean ARR of all 12 
serotypes tested), patients with CKD tended to have a lower PPV23 mean ARR than 
controls, which approached statistical significance (Table 4-11 and Figure 4-13). 
 
Figure 4-13 PPV23 whole vaccine (mean of 12 serotypes) ARR – comparison between 
patients with CKD and controls.  
Error bars denote geometric mean and 95% CI. Unpaired t test (on log transformed data) 2-tailed p 
value shown. 
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4.10 Demographic and clinical predictors of day 28 PPV23 
vaccine response 
When the SONIC study population was considered as a whole, a significant negative 
correlation was found between baseline anti-PnPS IgG concentrations and the magnitude 
of response (ARR) for 10 of 12 serotypes tested (1, 4, 6b, 7f, 9V, 14, 18c, 19A, 19F and 
23F; Pearson’s 2-tailed p<0.05 on log-transformed data). Age also negatively correlated 
with ARR for 7 of 12 serotypes tested (1, 4, 5, 6b, 9V, 14, and 19A) and mean ARR 
(Pearson’s 2-tailed p<0.05 on log-transformed ratios). Few significant relationships were 
seen between serotype-specific ARR and measures of renal disease (eGFR – positive 
correlation with 19F and 23F ARR only, Pearson p<0.05; ACR – not significant) and 
multimorbidity (CCI – negative correlation with ARR for serotypes 1 and 19F, Spearman 
p<0.05; medication burden – not significant). No significant relationships were seen 
between ARR and markers of inflammation (NLR and hsCRP) or glycaemic control 
(HbA1c).  
Individuals that had previously received PPV23 were significantly older than vaccine-
naïve individuals (Figure 4-9). Previous vaccination with PPV23 was generally associated 
with lower ARR for the vaccine as a whole and for most individual serotypes, reaching 
significance for half of all 12 tested - 1, 4, 5, 6b, 18c and 23F (summarised in Figure 4-14, 
panels A and C). 
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Figure 4-14 Impact of previous PPV23 vaccination and latent CMV infection on 
magnitude of humoral response to PPV23 vaccination in SONIC study participants.  
 
A: summary spider graph of serotype-specific ARR 
(geometric means shown) in vaccine naïve individuals and 
revaccinees; B: summary spider graph of serotype-specific 
ARR (geometric means shown)  in CMV seronegative and 
seropositive individuals; C: mean vaccine ARR in controls 
and patients with CKD, split by previous vaccination status; 
D: mean vaccine ARR in controls and patients with CKD, 
split by CMV serostatus; E: mean vaccine ARR for all 
SONIC participants, split by combination of previous 
vaccination status and CMV serostatus. Error bars denote 
geometric mean and 95% CI. *denotes p<0.05 – unpaired t-
test on log-transformed data 
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Interestingly, lower serotype-specific ARRs were generally seen in CMV seropositive 
compared to CMV negative study participants (summarised in Figure 4-14, panels B and 
D). Both CMV seropositivity and previous PPV23 vaccination were associated with lower 
mean ARR (whole vaccine response), but these variables did not have appear to have an 
additive effect (Figure 4-14, panel E). A significant interaction was present between these 
variables (univariate ANOVA p=0.004) - that is to say the impact of latent CMV infection 
in this study appeared to be different depending on whether or not the individual had 
previously been vaccinated with PPV23.  
In light of the above relationships within the data, several potential confounders are 
present in this study of PPV23 vaccine response in controls and patients with CKD: age, 
baseline anti-PnPS IgG concentration, CMV serostatus and previous PPV23 vaccination 
status. To examine the effect of these variables on the magnitude of the humoral response 
to PPV23 vaccination, I performed multivariate analysis using a linear regression model 
that contained age, gender, baseline serotype-specific IgG concentration (for individual 
serotypes only), CKD status, CMV serostatus and previous PPV23 vaccination status, 
together with their interaction term (both positive). Previous PPV23 vaccination and CMV 
seropositivity, either alone or in combination (p<0.001 for PPV23 status, p=0.003 for 
CMV status, p=0.004 for interaction term), were significant predictors of lower whole 
vaccine (mean) ARR, independent of age, gender or CKD status (adjusted R2 of 
model=0.31). This was not altered with substitution of CKD status by CCI or medication 
burden (as more comprehensive measures of multimorbidity). Interestingly, CMV 
seropositivity or previous PPV23 vaccination alone had a greater impact on mean ARR 
than if they were combined (interaction term): standardised Beta coefficients in the model 
were -0.62, -0.72 and -0.54 (adjusted), respectively. Neither CMV-specific IgG titre or 
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duration from last PPV23 vaccination were significant predictors of mean ARR in CMV-
seropositive individuals and PPV23 revaccinees, respectively. 
When this linear regression model (with addition of baseline anti-PnPS concentration) was 
applied to individual serotypes (Table 4-12), the most consistent significant predictor of 
ARR was the baseline serotype-specific IgG concentration, with CMV/PPV23 status 
reaching significance for only 2 serotypes (1, 18c), but approaching significance in 
another 4 (5, 6b, 9V and 23F). Age was also a significant predictor of ARR for serotypes 
4, 6b, 9V and 14. Interestingly, CKD status reached significance as a predictor for ARR of 
serotype 19F, but this is likely to be a feature of multimorbidity as CCI (collinear with 
CKD status) was also significant (p=0.03) when substituted, in turn, for CKD status and 
the model fit was unchanged with subsequent addition of CKD status.  
 
Table 4-12 Linear regression modelling of predictors of Pn serotype-specific GMRR.  
P values shown for predictor variables (top row) included in linear regression model of serotype-
specific GMRR (first column). Significant results (p<0.05) highlighted in bold. 
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In summary, PPV23 vaccination significantly increased serotype-specific IgG 
concentrations at day 28 in both patients with CKD and controls, but no independent 
effect of renal impairment on PPV23 humoral responses was seen in this study. Higher 
pre-vaccination anti-PnPS concentrations were associated with a significantly lower 
magnitude of vaccine-induced humoral response for most serotypes tested. Older age was 
also associated with poorer responses to serotypes 4, 9V and 14. Unexpectedly, both latent 
CMV infection and previous vaccination with PPV23, even if over a decade ago, were 
associated with poorer vaccine-induced responses, particularly to serotypes 1 and 18c. The 
association of previous PPV23 vaccination with lower serotype-specific ARR (in the face 
of comparable pre-vaccination serotype-specific IgG titres) is consistent with immune 
hyporesponsiveness to PPV23. It is surprising that this was observed even after 10 years 
had elapsed from previous PPV23 vaccination. As such, this warrants further investigation 
and consideration of the impact of vaccine efficacy. The potential impact of latent CMV 
infection on TI vaccines such as PPV23 also warrants further investigation in a larger 
cohort of older adults with and without chronic disease.  
 
4.11 Maintenance of PPV23 response  
Serotype-specific anti-PnPS IgG significantly reduced from levels achieved at day 28 
post-vaccination to month 6 in patients with CKD for 9 of 12 (75%) serotypes tested (1, 3, 
4, 5, 6b, 7f, 19A, 19F and 23F), but only 5 of 12 (42%) in controls (1, 4, 6b, 7f and 23F) 
as summarised in Table 4-11, Figure 4-15, Figure 4-16 and Figure 4-17. 
 
173 
 
Figure 4-15 Serotype-specific anti-PnPS IgG at day 28 and month 6 post-vaccination in 
individual controls.  
Range of assay: 0.01 -10 microgram/m (dashed lines): all values below 0.01 were assigned a value 
of 0.01, all values above 10 were assigned a value of 10. Red line denotes WHO long-term 
protective threshold of 0.35microgram/ml. *denotes p<0.05 paired t-test performed on log-
transformed data. 
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Figure 4-16 Serotype-specific anti-PnPS IgG at day 28 and month 6 post-vaccination in 
individual patients with CKD.  
Error bars denote geometric mean and 95% CI. Range of assay: 0.01 -10 microgram/m (dashed 
lines): all values below 0.01 were assigned a value of 0.01, all values above 10 were assigned a 
value of 10. Red line denotes WHO long-term protective threshold of 0.35microgram/ml. *denotes 
p<0.05 paired t-test performed on log-transformed data. 
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Figure 4-17 Summary of maintenance of PPV23 response in SONIC study participants.  
Spider diagrams of A: anti-PnPS IgG geometric mean titres for controls (blue) and patients with 
CKD (red) at day 28 (solid lines) and month 6 (dashed lines) post-vaccination with PPV23; B: 
serotype-specific geometric mean AMR for controls (blue) and patients with CKD (red). *denotes 
significant difference in AMR between patient groups (p<0.05). 
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The magnitude of PnPS-specific IgG change at month 6 from peak titres at day 28 was 
assessed using the antibody maintenance ratio (AMR: geometric mean of month 6 
titre/day 28 titre), where a value of 1 represents maintenance of titre and values less than 1 
represent a reduction. Serotype-specific AMR was generally lower in patients with CKD 
than controls for the majority of serotypes tested, reaching significance for serotype 3 
(Table 4-11, summarised in Figure 4-17). This mirrors the pattern seen at baseline where 
anti-Pn3 IgG was slightly lower in CKD revaccinees than controls.  
When maintenance of response to PPV23 was considered as a whole (using the mean 
AMR for all 12 serotypes tested), there was a downward trend in patients with CKD that 
approached statistical significance (Table 4-11). Interestingly, mean AMR was 
significantly lower than 1 in patients with CKD (one-sample unpaired t-test on log 
transformed data, 2-tailed p=0.001) but not in controls, suggesting that, overall, patients 
with CKD did not maintain peak anti-PnPS IgG levels to the vaccine as a whole at month 
6. This is similar to the findings described earlier with responses to TIV (summarised in 
Figure 4-6). 
Both patient groups had significantly higher anti-PnPS IgG concentrations at month 6 than 
pre-vaccination for all serotypes tested (Table 4-11), but revaccinees, per individual, had 
significantly fewer serotypes for which month 6 titres exceeded baseline (Mann Whitney 
2-tailed p=0.04). Indeed, month 6 titres were greater than baseline in at least 8 of 12 
serotypes tested for all 1st time PPV23 recipients, whereas this was not the case in 17 
revaccinees (40%, Fisher’s exact p=0.005).  
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4.12 Clinical predictors of PPV23 maintenance 
Serotype-specific ARR (peak response ratio) negatively correlated with AMR 
(maintenance ratio) for 11 of 12 serotypes tested (1, 3, 4, 5, 6b, 7f, 9V, 14, 19A, 19F and 
23F; Pearson’s 2-tailed p<0.05 on log-transformed data). As seen with responses to TIV, 
this may simply indicate that a robust response to PnPS is short-lived, with greater 
“maintenance” of titre reflecting little change in anti-PnPS IgG across the study for 
individuals with poor PPV23 responses. Age, multimorbidity as measured using CCI, 
glycaemic control (HbA1c), CMV-specific IgG titre and hsCRP were not significantly 
associated with serotype-specific or mean AMR in this study. Unlike with ARR, no 
significant differences in AMR were seen between PPV23 naïve individuals and 
revaccinees, or between CMV seronegative and seropositive individuals in this study. 
In keeping with the above relationships within the data, serotype specific ARR was a 
significant predictor of AMR for all serotypes except 18c in a linear regression model that 
also included age, gender and CKD status. CKD status was also a significant predictor of 
AMR for serotypes 3 and 19F in this model. However, when CKD status was substituted 
with its collinear variable CCI (a more comprehensive measure of multimorbidity), the 
new variable was also significant. No improvement in model fit was seen with subsequent 
addition of CKD status, suggesting that multimorbidity appears to explain the variability 
in AMR for serotypes 3 and 19F better than the presence or absence of renal impairment 
in this study. However, patients with CKD in this study were significantly more comorbid 
than controls, so a significant impact of CKD here cannot be ruled out.    
Overall, these data suggest that robust peak responses to PPV23 vaccination are not 
maintained at 6 months in older adults with and without chronic disease. No independent 
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effect of renal impairment was seen in this study, but reduction from peak for anti-PnPS 
IgG against serotypes 3 and 19 was greater in more comorbid individuals (who frequently 
had concomitant CKD). Overall, anti-PnPS IgG concentrations remained above baseline 
levels for all serotypes tested in both patient groups. However, significantly fewer 
revaccinees had month 6 anti-PnPS concentrations that exceeded pre-vaccination levels 
for 8 of 12 serotypes tested, compared to 1st time PPV23 recipients. This, together with 
reduced magnitude of peak response to PPV23, supports the hypothesis of PPV23-induced 
hyporesponsiveness.  
 
4.13 Clinical parameters of adequate PPV23 vaccine response 
There are two main clinical criteria to assess adequacy of the immune response to PPV23 
(Table 4-13).  
The AAAAI criteria were designed as a diagnostic tool for identifying/assessing 
immunodeficiency states (287) and are therefore more stringent than the WHO criteria 
(31), which were developed to assess antigen immunogenicity in vaccine development. 
Both criteria can be applied to 1st time vaccine recipients and revaccinees. AAAAI criteria 
were developed for use in children and adults under the age of 65, so may over-estimate 
immunodeficiency in the elderly.  
A serotype-specific anti-PnPS IgG titre of 0.35µg/ml is associated with long-term 
protection against infection with that specific pneumococcal serotype (31) and will 
henceforth be referred to as the “WHO protective threshold”.  
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Table 4-13 Clinical criteria to assess adequacy of PPV23 response. 
AAAAI: American Academy of Asthma, Allergy and Immunodeficiency; WHO: World Health 
Organisation. Table compiled from references (31, 54). 
 
At baseline, there were no significant differences between controls and patients with CKD 
in the number of individuals with anti-PnPS IgG concentrations above the protective 
threshold for any of the 12 serotypes tested (summarised in Table 4-14). No significant 
differences were seen when the study group was also split by previous vaccination status. 
Serotypes with the lowest proportion of study participants having anti-PnPS IgG 
concentration above the WHO protective threshold were 1, 3 and 4.  
The proportion of individuals with anti-PnPS IgG at or above the WHO protective 
threshold generally increased following vaccination in both controls and patients with 
CKD. However, the proportion of individuals with protective levels to 8 or more serotypes 
significantly increased at day 28 post-vaccination from baseline only in controls (Fisher’s 
exact p=0.002) and not in patients with CKD (Fisher’s exact p=0.32) - Table 4-14. 
Using WHO criteria for adequate response, significantly fewer patients with CKD had 
adequate responses to serotypes 1 and 3, with trends for reduced responses to serotypes 5 
and 19F (Table 4-13). Patients with CKD also had a significantly lower number of 
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serotypes for which an adequate response was achieved per person, compared to controls 
(median 3 (IQR 4) versus 5 (6), respectively, Mann-Whitney 2-tailed p=0.03). When 
response to PPV23 as a whole was considered, approximately 1 in 5 individuals (7 
controls (24%) and 6 patients with CKD (17%), Fisher’s exact 2-tailed p=0.54) had an 
adequate response to 8 of 12 serotypes tested.   
 
Table 4-14 WHO PPV23 vaccine response adequacy criteria – number of individuals with 
adequate response by serotype. 
N and (%) shown unless stated. Statistical comparisons performed between controls and patients 
with CKD. *denotes Fisher’s exact 2-tailed p<0.05, ~ denotes Mann-Whitney 2-tailed p<0.05. 
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Over 80% of controls and patients with CKD that had reached the WHO protective 
threshold at day 28 post-vaccination maintained protective levels of anti-PnPS IgG at 
month 6, without a significant difference seen between the groups (Figure 4-18). All but 
one individual (a control subject) that had protective levels of anti-PnPS to 8 or more of 
the serotypes tested maintained protective levels to 8 or more serotypes at month 6.  
 
Figure 4-18 Proportion of individuals that maintained anti-PnPS IgG concentrations at or 
above the WHO protective threshold at month 6.  
Blue – controls, red – patients with CKD.  
 
 
Using AAAAI PPV23-deficiency phenotype definitions, both controls and patients with 
CKD showed surprisingly poor humoral immune responses (Table 4-15) with 24 controls 
(86%) and all but 1 patient with CKD meeting criteria for moderate/severe deficiency 
phenotypes.  
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Table 4-15	AAAAI PPV23 deficiency phenotypes – comparison between controls and 
patients with CKD. 
This analysis does not account for infection status and baseline total immunoglobulins/subclasses. 
N (%) and Fisher’s exact 2-tailed p shown. P<0.05 considered significant.  
 
 
For diagnosis of specific antibody deficiency (one of the main primary immunodeficiency 
syndromes associated with isolated poor anti-polysaccharide responses), AAAAI vaccine 
criteria are combined with a history of recurrent respiratory infections and an otherwise 
normal adaptive immune system. Taking into account baseline immunoglobulin and IgG 
subclass levels, together with history of recurrent (2 or more) respiratory infections in the 
6 months following vaccination, one patient with CKD (but no controls) did fulfil AAAAI 
183 
 
humoral criteria for specific antibody deficiency, although this definition was developed 
for adults aged less than 65 years.  
PPV23 “responder” status was associated with significantly younger age compared with 
“non-responder” status for both WHO (median 67 years (IQR 9.5) in responders, 75 (11) 
in non-responders, Mann Whitney 2-tailed p=0.002) and AAAAI criteria (67 (9.5) in 
responders and 75 (11) in non-responders, p=0.03). AAAAI, but not WHO responders had 
lower CCI (median score=0 (IQR 3) versus 3 (4), Mann Whitney 2-tailed p=0.08) and 
higher eGFR (median 90 (IQR 42) versus 38 (53), Mann Whitney 2-tailed p=0.03) than 
non-responders in this study. However, no significant differences were seen between 
PPV23 responders and non-responders (either WHO or AAAAI definition) in proteinuria 
(ACR), inflammation (hsCRP) and glycaemic control (HbA1c). No significant differences 
in proportions of individuals seropositive for CMV were seen between responders and 
non-responders, as defined by either clinical criteria. 
Although both clinical adequacy criteria are designed to be used to assess both 1st and 
repeat vaccination responses, a greater proportion of non-responders had previously 
received PPV23 than responders (WHO criteria:  39/47 versus 6/13, Fisher’s exact 2-tailed 
p=0.01; AAAAI criteria: 43/55 versus 2/5, p=0.09). However, previous PPV23 recipients 
were significantly older than vaccine-naïve individuals (Figure 4-9), so this may simply 
reflect the difference in age between responders and non-responders. The absolute number 
of PPV23 responder individuals in this study, using either clinical criteria for adequate 
response, is too small for meaningful multivariate analysis using logistic regression. As 
such, it is not possible to tease out the independent effects of age and previous PPV23 
vaccination in this analysis. 
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In summary, using clinical criteria to assess vaccine response adequacy, the immune 
response to PPV23 is very poor in older adults with and without chronic disease with 
approximately only 1 in 5 fulfilling WHO criteria for adequate response to the whole 
vaccine and over 85% potentially fulfilling AAAAI criteria for humoral 
immunodeficiency. There is also a subtle reduction in the adequacy of immune response 
as defined by WHO criteria in patients with CKD compared to controls, with greatest 
divergence between the groups for serotypes 1 and 3. These two serotypes are associated 
with invasive pneumococcal disease, which confers a high mortality rate in older adults. 
At baseline, these two invasive serotypes had the lowest proportion of individuals with 
WHO protective titres. As such, even a subtle reduction in vaccine response adequacy to 
these serotypes, as seen in patients with CKD in this study, may have significant clinical 
consequences.  Advancing age and previous PPV23 were associated with PPV23 non-
responder status, as defined by either clinical criteria, but the independent impact of these 
variables is unclear. 
 
4.14 Relationship of TIV/PPV23 vaccine response to incidence 
of infection 
No significant differences were seen in baseline titres against any of the 3 flu strains 
contained in TIV or any of the 12 pneumococcal serotypes tested between individuals that 
did or did not report infections in the 6 months of study follow-up. Pneumococcal strain-
specific ARR or AMR were also equivalent between those that did or did not report 
infections, but ARR for influenza strain A/H3N2 was significantly higher in controls that 
reported infections than controls that did not (median 1.0 (IQR 3) and 2.7 (4), 
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respectively; unpaired t-test on log-transformed data 2-tailed p=0.04). However, this 
significance was lost when only respiratory infections were considered. No significant 
differences were seen in proportion of responders and non-responders for TIV or PPV23 
reporting infections in the 6 months of study follow-up. 
 
4.15 Discussion  
This Chapter describes the humoral response to both a T-dependent (TIV) and T-
independent vaccine (PPV23) in older adults with and without moderate/severe CKD. 
Although both controls and patients with CKD were able to increase strain-specific 
influenza HAI titres and anti-PnPS IgG at day 28 post-vaccination and largely to a similar 
degree, approximately 1 in 5 older adults with and without CKD fulfilled clinical criteria 
for adequacy of vaccine response for either TIV or PPV23. These poor responses in older 
adults with and without chronic disease are largely in keeping with previous observations 
of declining vaccine responses with advancing age (64, 275, 280). Indeed, age was one of 
the main predictors of poor vaccine responses, together with higher baseline antigen-
specific HAI or IgG titres (also previously reported for TIV (288) and PPV23 (55)). 
Multimorbidity and renal impairment were both generally associated with poorer vaccine 
responses, but an independent effect of renal impairment could not be conclusively 
elucidated.  
Multiple comparisons have been made between data from patients with CKD and controls 
in this chapter, without a formal Bonferroni correction. Although some of the significant 
findings may represent type I errors (false positives), most are probably due to genuine 
differences between the disease groups and associations between variables. 
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A history of previous PPV23 vaccination (even if over a decade ago) was associated with 
reduced humoral responses to repeat PPV23 in both controls and patients with CKD. This 
is consistent with immunological hyporesponsiveness to PPV23, which has previously 
been variably reported in older adults (55, 56, 58, 60, 66, 289). Several potential reasons 
for this variability exist, including differences in the definition of hyporesponsiveness and 
interpretation of its clinical significance between studies, together with differences in the 
number and combination of pneumococcal serotypes against which antibody responses are 
tested. For example, although in the study by Kawakami et al (55) a reduction in 
magnitude of response following repeat PPV23 to all 14 serotypes tested was noted in 
older adults, the authors conclude that this is due to higher pre-vaccination titres in 
revaccinees without multivariate analysis to examine the independent effect of previous 
PPV23 vaccination.  
As described in Chapter 1 (Introduction), one hypothesis for hyporesponsiveness in 
response to repeated exposures to plain polysaccharide vaccines is the depletion of 
antigen-specific memory B cells. Activation of these memory B cells may drive their 
differentiation into ASCs, without replenishing or increasing the size of the memory B cell 
population. This concept is supported by the results of an elegant study from Clutterbuck 
et al (25), where PPV23 vaccination induced a reduction in circulating memory B cell 
populations and also impaired subsequent memory B cell expansions in response to a 7-
valent pneumococcal conjugate vaccine (PCV-7). Although, anti-PnPS IgG concentrations 
generally remained above baseline levels for all serotypes tested in both patient groups in 
the SONIC study, month 6 titres exceeded baseline levels for at least 8 of 12 serotypes in 
all 1st time PPV23 recipients, whereas this was not the case in 40% of revaccinees. This is 
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consistent with a depletion of B cell antigen-specific memory in response to repeat 
exposure to plain polysaccharide antigens.   
There a number of weaknesses of the analysis of humoral PPV23 response in this study. 
Firstly, I did not characterise antigen-specific IgM, IgA or subclasses of IgG induced by 
vaccination in patients with CKD compared to controls, which may have yielded further 
insights into both the nature of the immune response to PPV23 in older adults and the 
differences between disease groups. I also did not evaluate the function of the antigen-
specific IgG produced e.g. using an opsono-phagocytic assay such as described in (290). 
However, the findings presented in this study, particularly the presence of 
hyporesponsiveness to pneumococcal polysaccharides even if previous exposure was over 
a decade ago, in addition to previous studies demonstrating diminished responses to 
PPV23 in the elderly, suggest that we may need to re-evaluate the role and effectiveness of 
PPV23 in this vulnerable patient group in the post-PCV13 era.  
An unexpected finding in this study is the independent effect of latent CMV infection on 
humoral responses to PPV23, with CMV-seropositive individuals demonstrating generally 
reduced responses. Although CMV-associated impairment in B cell responses has 
previously been reported with regard to T-dependent vaccines (96), this has not 
previously, to my knowledge, been shown for T-independent antigens. As such, this 
requires confirmation in a larger cohort of CMV seropositive and seronegative older 
adults.    
In this study, comprehensive interrogation of the humoral response to TIV was limited by 
the small sample size overall and heterogeneity of vaccine composition across the 3 years 
that the study was run, which further reduced sample size in “like-for-like” analysis. Even 
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when using clinical parameters of adequate vaccine response (thus maximising total 
sample size here), to observe a significant reduction in proportion of patients with CKD 
mounting an adequate response to TIV compared to controls of the same magnitude as 
demonstrated in this study (27% patients with CKD versus 43% controls) with 80% power 
at a confidence level of 5% would require a total sample size of approximately 280 
individuals (140 in each disease group). Therefore, I may not have seen a difference 
between patients with CKD and controls, when it exists, due to small sample size. I also 
did not evaluate vaccine-induced responses to other influenza antigens e.g. neuraminidase 
(NA), which may have yielded further insights into differences in responses to TIV 
between patients with CKD and controls. 
Despite the similarity of vaccine responses between the patient groups, individuals with 
CKD reported a significantly greater number of respiratory infections over the 6 month 
study follow-up period. This observation suggests that there may be other factors at play 
in the observed immunodeficiency state in CKD, other than Ab production. As described 
in Chapter 1 (Introduction), multiple defects in both innate and adaptive immune 
responses have been previously reported in patients with CKD/ESRD. In the next 3 
Chapters of this thesis, I will present results of cross-sectional lymphocyte phenotype 
analysis and neutrophil function, which demonstrate defects that may be responsible for 
the increased susceptibility to infection observed in this study.   
Another possibility for the observed lack of difference in vaccine response between the 
disease groups in this study, in the face of significantly greater infections reported by 
patients with CKD, is that the vaccines used here may not represent a good “mimic” of 
natural infection. The largest body of evidence regarding impaired vaccine responses in 
CKD/ESRD is with the hepatitis B vaccine (154, 179). The most commonly used 
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preparation is Engerix B (GSK, Belgium), which contains a non-infectious recombinant 
hepatitis B virus surface antigen (HBsAg) derived from genetically engineered 
Saccharomyces cerevisiae cells, with the vaccine containing less than 5 % yeast protein 
(291). This recombinant HBsAg is also adsorbed on aluminium hydroxide (alum), which 
acts as an adjuvant in the. Although Engerix B is a T-dependent vaccine, similar to 
seasonal TIV, the latter does not contain any adjuvants. As described in Chapter 1, Table 
1-5, alum exerts a number of immune effects including induction of local secretion of 
cytokines and chemokines, monocyte/macrophage recruitment and enhanced antigen 
presentation (292). The method of HBsAg manufacture may also mean that other PAMPs 
e.g. zymosan (interacts with TLR2/6) from Saccharomyces cerevisiae cells are 
incorporated into the vaccine. As such, the mechanisms of immune responses to the two 
T-dependent vaccines Engerix B and seasonal TIV are likely to be different. It is possible 
that defects in antigen presentation, TLR signalling and innate immune system activation 
are more prominent in CKD-associated immune dysfunction than lymphocyte response 
mechanics and therefore studies using Engerix B have shown more marked divergence in 
responses between patients with CKD and controls. Indeed, previous studies (albeit in 
dialysis populations) have shown reduced circulating numbers of DCs and impaired DC 
function (293, 294). Responses to TIV in this study may not, therefore, represent a true 
mimic of responses that could be elicited during natural infection. This could explain why 
vaccine responses appeared to be similar between the two disease groups, but self-reported 
infection rates were higher in patients with CKD compared to controls.   
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CHAPTER 5 
5 T LYMPHOCYTES IN OLDER 
ADULTS WITH CKD 
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5.1 Introduction 
T lymphocytes play a key role not only in direct pathogen killing, but also in helping B 
lymphocytes generate high affinity class-switched antibody (3). As I have used two 
vaccines as an “in vivo” antigen challenge in this study of older individuals with CKD, I 
thought it pertinent to examine the composition of the CD4+ T cell compartment alongside 
analysis of vaccine-specific IgG antibody.  
As described in Chapter 1 (Introduction), several previous studies have suggested that the 
changes in the T lymphocyte compartment seen in patients with CKD/on dialysis may be 
consistent with a hypothesis of accelerated “immune ageing” (142). However, these T cell 
phenotypes have also previously been reported in association with latent CMV infection 
(86). The design of this study provided a unique opportunity to explore these age- and 
CMV-associated T cell populations in a well-phenotyped cohort of older adults with and 
without CKD.  
In this Chapter I will present results of cross-sectional T lymphocyte phenotyping 
performed on patients with CKD and age-matched controls, either at the baseline study 
visit (pre-vaccination) or at month 6 after vaccination. These study timepoints were 
deemed suitable for cross-sectional phenotyping as they represent a “background” immune 
state, rather than one recently altered by the study vaccinations.  
During lymphocyte analysis, 2 individuals (1 patient with CKD and 1 control subject) 
were identified to have abnormally large proportions of B cells (>50% total lymphocytes), 
but with normal total circulating lymphocyte counts. Although there were no other clinical 
features to suggest a haematological malignancy, such expansions are in keeping with 
monoclonal B-cell lymphocytosis (MBL) - a pre-malignant condition with a 1-2% annual 
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risk of progression to chronic lymphocytic leukaemia (CLL) (295). Genetic mutations 
associated with CLL have been reported in MBL (296) and this condition, therefore, 
represents an abnormal immune system. In view of this, I chose to exclude these 2 
individuals from the final lymphocyte phenotyping analysis.  
 
5.2 Latent CMV infection has a greater impact on CD4+ and 
CD8+ T cell proportions than CKD 
 
Figure 5-1 shows representative gating for identification of CD4+ and CD8+ T cells from 
frozen PBMCs. T cell proportion of lymphocytes were equivalent between controls and 
patients with CKD (Figure 5-2). Proportions of CD4+ and CD8+ T cells were also 
equivalent between the disease groups, as was the CD4/8 ratio (less than 1 (or inverted) in 
1 control and 2 patients with CKD).  
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Figure 5-1 Representative gating strategy for identifying CD4+ and CD8+ T cells from 
frozen PBMCs.  
Scatter plots shown. Lymphocytes were identified based on forward scatter (FSC) and side-scatter 
(SSC) characteristics. Singlet lymphocytes were identified by FSC area and height and live 
lymphocytes were gated as APC-Cy7 negative. T cells were defined by the presence of surface 
CD3 and further sub-categorised based on CD4 and CD8 expression. 
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Figure 5-2 Basic T cell phenotyping – comparison between controls and patients with 
CKD. 
Total T cell, CD4+ and CD8+ proportions (A-C) and CD4/8 ratio (D) shown for controls (unfilled 
symbols) and patients with CKD (blue symbols). Error bars show median and IQR. Red dashed 
line in panel D denotes CD4/8 ratio of 1. 
 
 
Neither total T cell proportion of lymphocytes, nor CD4+ or CD8+ proportion were 
significantly associated with measures of CKD severity (eGFR, ACR), multimorbidity 
(CCI, medication burden), inflammation (hsCRP) or glycaemic control (HbA1c). 
However, lower CD4+ and higher CD8+ proportions of T cells were significantly 
associated with higher CMV-specific IgG titre (Figure 5-3). 
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Figure 5-3 Relationship of CMV-specific IgG titre with basic T cell phenotype. 
Linear regression statistics shown for relationships between CMV-specific IgG titre and 
proportions of CD4+ (A) and CD8+ (B) T cells, together with CD4/8 ratio. P value <0.05 
considered significant. 
 
As described in Chapter 3 (Characterisation of the study cohort), patients with CKD in this 
study had a slight excess of CMV-seropositive individuals (defined by a CMV-specific 
IgG titre ≥10 AU as previously described (180)) compared to controls (83% versus 63%, 
Fisher’s exact 2-tailed p=0.09). However, the titre of CMV-specific IgG in seropositive 
individuals was equivalent between the two patient groups, suggesting a similar CMV 
immune “imprint” (95). When study participants were split by CMV serostatus, both 
CMV seropositive patients with CKD and controls generally had higher CD8+ proportions 
T cells, mirrored by a reduction in CD4+ proportions and the CD4/8 ratio (Figure 5-4). No 
significant differences in CD4+ or CD8+ proportions of T cells were seen when CMV 
seropositive or seronegative individuals were compared by disease group. 
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Figure 5-4 Effect of the presence of latent CMV infection on basic T cell phenotypes.  
Comparisons between CMV seronegative and seropositive individuals in proportion of CD4+ (A) 
and CD8+ (B) T cell, together with CD4/8 ratio (C). Lilac colour represents data from CMV-
seropositive (+) individuals, unfilled symbols represent data from CMV-seronegative (-) 
individuals. Error bars show median and IQR. *denotes Mann Whitney 2-tailed p<0.05 
 
 
CMV serostatus was the only significant independent predictor of CD8+ proportion of T 
cells in a linear regression model that also included age, gender and CKD status 
(p=0.005). However, female gender was a significant predictor of CD4+ proportion of T 
cells (p=0.03) in addition to CMV serostatus (p=0.003) when the same linear regression 
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analysis was applied. Although a slightly higher proportion of patients with CKD were 
CMV seropositive than controls, there were no significant differences in the proportions of 
male and female participants that were CMV seropositive (n=26 for males, n=18 for 
females - 72% for both genders, Fisher’s exact 2-tailed p=1.0). However, CMV 
seropositive female participants had significantly higher CMV-specific IgG titres than 
seropositive males (Mann Whitney 2-tailed p=0.03; Figure 5-5) and this may explain the 
above linear regression findings.  
 
Figure 5-5 CMV-specific IgG titres in CMV seropositive individuals split by gender. 
Rose colour represents data from females. Error bars show median and IQR. *denotes Mann-
Whitney 2-tailed p<0.05.  
 
The outcomes of the above multivariate analyses were not altered by the substitution of 
CKD status by CCI as a more comprehensive multi-morbidity measure.  
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5.3 Latent CMV infection and female gender significantly 
influences TEMRA expansion in older adults with and 
without chronic disease 
 
Several strategies have previously been employed to assess immune ageing of the T cell 
compartment. These include evaluation of naïve versus memory subsets (surrogates for 
antigen experience) using expression of the surface markers CCR7 and CD45RA (297), 
the loss of co-stimulatory molecules e.g. CD28 and CD27 (298) and gain of surface 
markers associated with replicative senescence e.g. CD57 and KLRG1 (17). Each of these 
strategies were, in turn, employed in this study to assess T cell “ageing” in patients with 
CKD. 
Figure 5-6 shows the gating strategy for identification of naïve/memory populations of T 
cells. Here, CCR7+CD45RA+ cells were deemed “naïve”, CCR7+CD45RA+ - “central 
memory”, CCR7-CD45RA- - “effector memory” and CCR7-CD45RA+ - “terminally 
differentiated effector memory T cells” or TEMRA. 
No significant differences were seen in the proportions of naïve and memory subsets in the 
CD4+ or CD8+ T cell compartments between controls and patients with CKD (Figure 
5-7).  
 
 
 
199 
 
Figure 5-6 Representative gating strategy to identify naïve/memory T cell subsets. 
Naïve and memory T cell populations were defined by CCR7 and CD45RA expression as shown 
in A. CD4+ and CD8+ T cells were identified as in Figure 5-1, then gated as shown in B (top 
panels show representative scatter plots, bottom panels show density plots). CD8+ and CD4+ T 
cells had different patterns of expression of CCR7, hence the angle of the lower bound of the CD8 
naïve subset is different to CD4 to enable accurate gating. 
 
 
Markers of renal impairment/damage (eGFR, ACR) were not significantly associated with 
any of these naïve/memory subsets, except for central memory proportions of CD8+ T 
cells, which increased with declining eGFR (see Figure 5-8). Measures of multimorbidity 
(CCI, medication burden), glycaemic control (HbA1c) or inflammation (hsCRP) were also 
not associated with any of these naïve/memory T cell populations.  
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Figure 5-7 Naïve/memory T cell subsets in SONIC study participants. 
Naïve/memory T cell populations of CD4+ (A,C,E,G) and CD8+ (B,D,F,H) T cells shown for 
controls and patients with CKD based on CCR7 and CD45RA expression. Proportions of total 
CD4/8 T cells shown. Error bars show median and IQR. 
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Figure 5-8 Relationship between eGFR and central memory proportion of CD8+ T cells.  
Linear regression R2 and p value shown. MDRD eGFR shown in plot, but closely approximates 
CKD-EPI eGFR. P value <0.05 considered significant. 
 
 
However, CMV-specific IgG titre significantly correlated with the size of the TEMRA 
proportion of both CD4+ and CD8+ T cells across the whole study (Spearman’s coefficient 
0.27, p=0.035 and Spearman’s coefficient 0.26, p=0.045, respectively). When both 
controls and patients with CKD were considered together, CMV seropositive individuals 
had significantly higher TEMRA proportions (unpaired t test 2-tailed p=0.01) and slightly 
lower naïve proportions of CD8+ T cells than seronegatives (Mann Whitney 2-tailed 
p=0.06). The CD4+ TEMRA population was also slightly larger in CMV seropositive 
individuals than in seronegatives (Mann Whitney 2-tailed p=0.12).  
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Figure 5-9 CMV effect on naïve/memory T cell subsets in SONIC study participants. 
Naïve/memory subsets of CD4+ (A,C,E,G) and CD8+ (B,D,F,H) compared between CMV 
seronegative (-) and seropositive (+) individuals.	Lilac colour represents data from CMV 
seropositive individuals. Error bars show median and IQR. *denotes p<0.05 
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Interestingly, the central memory proportion of CD8+ T cells was significantly larger in 
CMV seropositive patients with CKD compared to CMV seropositive controls (Mann 
Whitney 2-tailed p=0.04), mirroring the correlation seen with eGFR. This suggests that 
renal impairment may have an independent effect on expansion of the central memory 
population of CD8+ T cells.  
CMV serostatus and gender were both significant predictors of the size of the TEMRA 
proportion of CD8+ T cells (p=0.004 and 0.01, respectively) in a linear regression model 
that also included age and CKD status. However, when this model was applied to TEMRA 
proportions of CD4+ T cells, gender emerged as a significant predictor independent of 
CMV serostatus (p=0.01). Female study participants generally had higher proportions of 
TEMRA cells in both CD4+ and CD8+ T cell compartments than males (Figure 5-10). 
Although CMV-specific IgG titres were significantly greater in female participants than 
males (Figure 5-5), gender remained a significant predictor of TEMRA proportions in both 
CD4+ and CD8+ T cells in CMV seropositive individuals, independent of age, CKD status 
and CMV-specific IgG titre. This suggests an independent gender effect on these T cell 
populations, the biological significance of which is unclear.   
No significant predictors of central memory proportions of CD8+ T cells were identified in 
a linear regression model that included age, gender, CKD status and CMV serostatus, 
either when all study participants or only CMV seropositive individuals were considered. 
This was not altered by substitution of CCI for CKD status as a more comprehensive 
measure of multimorbidity. 
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Figure 5-10 Gender effect on CD4+ (A) and CD8+ (B) TEMRA populations.  
Rose colour represents data from females. Error bars show median and IQR. *denotes p<0.05. 
 
 
5.4 Latent CMV infection and magnitude of humoral CMV-
specific response determine “senescent” T cell phenotype in 
older adults with and without chronic disease 
The loss of surface expression of CD27 and/or CD28 is associated with terminally 
differentiated T cells. This, together with gain of surface CD57 and/or KLRG1 expression, 
has been associated both with chronological immune ageing (17) and with latent CMV 
infection (88). Together, these 4 surface markers are associated with replicative 
senescence in T cells (17) and phenotypes using combinations of these markers will 
henceforth be referred to as “senescence”-associated, for brevity. These populations were 
assessed in the SONIC study, with representative gating shown in Figure 5-11. 
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Figure 5-11 Gating strategy to identify “senescence”-associated T cell subtypes.  
Representative gating shown for CD27/28 (A) and CD57/KLRG1 (B) after CD4/8 T cells were 
identified as in Figure 5-1. Left panels show representative scatter plots, right panels show density 
plots. 
No significant differences were seen between patients with CKD and controls in the 
proportions of CD4+ or CD8+ T cells either lacking CD28 alone or in combination with 
CD27, or the proportions expressing both CD57 and KLRG1 (Figure 5-12 A,C,E,G and 
Figure 5-13 A,C,E,G). 
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Figure 5-12 CD4+ T cell “senescence” phenotyping. 
Comparisons between controls and patients with CKD (A,C,E,G) and impact of latent CMV 
(B,D,F,H) – here +/- denotes CMV seropositive/negative. Error bars show median and IQR. 
*denotes p<0.05 
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Figure 5-13 CD8+ T cell “senescence” phenotyping. 
Comparisons between controls and patients with CKD (A,C,E,G) and impact of latent CMV 
(B,D,F,H) – here +/- denotes CMV seropositive/negative. Error bars show median and IQR. 
*denotes p<0.05. 
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However, CMV seropositive individuals had significantly higher proportions of CD28null, 
CD27-CD28-, CD57+KLRG1+ and CD28-CD57+ cells in both CD4+ and CD8+ T cell 
compartments (Figure 5-12 and Figure 5-13). Interestingly, CMV-specific IgG titre in 
seropositive individuals was significantly associated with all CD4+ “senescence”-
associated phenotypes (Figure 5-14), but none in the CD8+ T cell compartment (Figure 
5-15), although the CD27-CD28- proportion of CD8+ T cells approached significance 
(p=0.07). 
 
Figure 5-14 Associations between CMV-specific IgG titre in CMV seropositive 
individuals and CD4+ T cell "senescence"-associated phenotypes. 
Relationships between CMV-specific IgG titre and A: CD28null, B: CD27-CD28-, C: 
CD57+KLRG1+, D: CD28-CD57+ % of CD4+ T cells. Linear regression statistics shown. P <0.05 
considered significant. 
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Figure 5-15 Associations between CMV-specific IgG titre in CMV seropositive 
individuals and CD8+ T cell "senescence"-associated phenotypes. 
Relationships between CMV-specific IgG titre and A: CD28null, B: CD27-CD28-, C: 
CD57+KLRG1+, D: CD28-CD57+ % of CD8+ T cells. Linear regression statistics shown. P <0.05 
considered significant. 
 
 
There were no significant relationships between proportions of “senescence”-associated 
CD4+ or CD8+ T cell subsets and eGFR, ACR, HbA1c or hsCRP. However, several 
significant associations were seen between measures of multimorbidity (CCI and 
medication burden) and CD8+, but not CD4+ “senescence”-associated subsets, although 
the proportion of CD27-CD28- CD4+ T cells approached significance for both 
multimorbidity parameters (Table 5-1). 
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Table 5-1 Relationships between measures of multimorbidity and “senescence”-associated 
T cell subsets.  
Correlations between multimorbidity measures (top row) and “senescence”-associated T cell 
subsets (first column). Spearman R and 2-tailed p shown and highlighted in bold if p<0.05 
(deemed significant). 
	 CCI	 Medication	burden	
CD4+	 	 	
CD28null	%	 R=0.13	
p=0.33	
R=0.17	
p=0.19	
CD27-CD28-	%	 R=0.23	
p=0.08	
R=0.23	
p=0.08	
CD57+KLRG1+	%	 R=0.19	
p=0.15	
R=0.18	
p=0.17	
CD28-CD57+	%	 R=0.18	
p=0.19	
R=0.16	
p=0.26	
CD8+	 	 	
CD28null	%	 R=0.27	
p=0.04	
R=0.31	
p=0.02	
CD27-CD28-	%	 R=0.28	
p=0.03	
R=0.32	
p=0.01	
CD57+KLRG1+	%	 R=0.23	
p=0.08	
R=0.27	
p=0.04	
CD28-CD57+	%	 R=0.21	
p=0.10	
R=0.26	
p=0.05	
 
Multivariate analysis confirmed CMV serostatus as a significant predictor of all 
“senescence”-associated CD8+ T cell phenotypes independent of age, gender and CKD 
status (Table 5-2). This was not altered with substitution of CKD status by CCI or 
medication burden. CMV serostatus was also a significant predictor of all “senescence”-
associated CD4+ T cell phenotypes, but female gender was a significant co-factor in 
predicting expansions of CD28- and CD27-CD28- subsets. As with the CD8+ 
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compartment, these relationships were not altered by the substitution of CKD status by 
CCI or medication burden. 
Table 5-2 Multivariate analysis to identify predictors of T cell “senescence”-associated 
subsets.  
Linear regression p values shown for predictor variables of interest (first column) for individual 
“senescence”-associated T cell subsets (top row). Model included age, gender, CKD status and 
CMV serostatus. P value <0.05 considered significant (highlighted in bold). 
All	participants	
CD4	T	cells	 CD8	T	cells	
CD28null	
%	
CD27-	
CD28-	
%	
CD57+	
KLRG1+	
%	
CD28-	
CD57+	
%	
CD28null	
%	
CD27-	
CD28-	
%	
CD57+	
KLRG1+	
%	
CD28-	
CD57+	
%		
Gender	(M/F)	 0.009	 0.009	 0.49	 0.07	 0.36	 0.30	 0.36	 0.46	
CMV	serostatus	
(+/-)	 <0.0001	 <0.0001	 <0.0001	 <0.0001	 0.0003	 <0.0001	 0.004	 0.001	
 
 
As female CMV seropositive individuals in this study had a significantly higher CMV-
specific IgG titres (Figure 5-5) and the magnitude of this titre was significantly associated 
with expansions of CD4+ T cell “senescence”-associated subsets, the linear regression 
results may simply reflect a CMV-associated effect. However, neither CMV-specific IgG 
or gender were significant predictors of any of these subsets in CMV seropositive 
individuals only in a linear regression model that also included age, gender and CKD 
status. 
These findings suggest that latent CMV infection defines the “senescence”-associated 
phenotype of both CD4+ and CD8+ T cell compartments in older adults with and without 
chronic disease, independent of the degree of multimorbidity or, indeed, renal impairment. 
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5.5 CKD significantly affects CD4+ helper and regulatory T cell 
populations, independent of latent CMV infection 
I evaluated the proportions of CD4+ T cell helper and regulatory subtypes in a sample of 
study participants (limited by volume of blood collected and assay failure; n=18 per group 
for both patients with CKD and controls) based on surface chemokine receptor expression, 
which has been shown previously to approximate subtyping by transcription factor 
analysis and cytokine secretion (15, 16). As shown in Figure 5-16, CCR4-CCR6-CXCR3+ 
were defined as “Th1-like” CD4 T cells, CCR4+CCR6-CXCR3- as “Th2-like”, 
CCR4+CCR6+CXCR3- as “Th17-like” and CCR4-CCR6+CXCR3+ as “Th1Th17-like” (an 
atypical subset of Th1 cells previously shown to produce both IFN-g and IL-17) (16). 
“Tfh-like” CD4 T cells were identified by expression of CXCR5 (B cell follicle-homing 
receptor) as previously described (15). 
Regulatory CD4 T cells (Tregs) were identified by expression of the surface marker CD25 
and the lineage-specific intracellular transcription factor - FoxP3 - by two different gating 
strategies as shown in Figure 5-17. Initially, Tregs were defined as the CD25+FoxP3+ 
population after gating on CD4+ T cells (Figure 5-17 C) as per methods described in 
references (299-302) – hereafter referred to as CD25+FoxP3+ Tregs. During flow cytometry 
panel optimisation this population of cells was consistently negative for CD127 and this 
marker was therefore not used in subsequent analysis. Several authors have defined a more 
stringent gating strategy for Tregs (231, 303, 304), which I have also employed as shown in 
Figure 5-17D to enable wider comparisons with published data. Here, CD4+ T cells with 
the highest expression of CD25 were selected (CD25high) and then assessed for 
intracellular expression of FoxP3 – hereafter referred to as CD25highFoxP3+ Tregs.  
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Figure 5-16 Representative gating to identify “helper” CD4+ T cell sub-populations by 
surface chemokine receptor expression.  
Density plots shown. CD4 T cells were identified as per Figure 5-1 and “Tfh-like” CD4+ T cells 
were defined by surface expression of CXCR5 (A). Total CD4 T cells were then evaluated for 
surface CCR4 and CCR6 expression. Each quadrant from this gate was then evaluated for surface 
CXCR3 expression to define “helper” CD4+ T cell phenotypes as shown in B.  
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Figure 5-17 Representative gating to identify regulatory T cells. 
Scatter plots shown unless stated. Live singlet lymphocytes were identified based on forward and 
side scatter characteristics and viability stain (APC-Cy7). CD4+ T cells were identified and then 
evaluated for expression of CD25 and FoxP3 in two ways: A - CD25+FoxP3+ (with representative 
CD127 expression plot demonstrating lack of CD127 expression in this population); B - 
CD25highFoxP3+ density plots with histograms representing FoxP3 expression in patient samples 
and negative assay control. 
 
 
Patients with CKD had similar proportions of “Th1-”, “Th17-”, “Th1Th17-” and “Tfh-
like” CD4 T cells to controls, but a significantly greater proportion of “Th2-like” CD4 T 
cells (Figure 5-18), independent of CMV serostatus (Figure 5-19 B). 
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Figure 5-18 Helper CD4+ T cell subtypes in SONIC study participants.   
“Th1-like” (A), “Th17-like” (B), “Th1Th17-like” (C), “Tfh-like” (D) and “Th2-like” (E) subtypes 
as proportions of total CD4+ T cell population – comparison between controls and patients with 
CKD. Representative flow density plots from control and CKD individuals shown in panel F – for 
illustrative purposes, “Th2-like” population is gated as CCR4+ from CXCR3-CCR6- population. 
Error bars show median and IQR. *denotes p<0.05 
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Figure 5-19 Effect of latent CMV on CD4+ T cell helper subtypes. 
“Th1-like” (A), “Th2-like” (B), “Th17-like” (C), “Th1Th17-like” (D) and “Tfh-like” (E) subsets 
shown as proportions of total CD4+ T cells, compared between CMV seronegative (-) and 
seropositive (+) individuals. Error bars show median +/- IQR. *denotes Mann Whitney 2-tailed 
p<0.05. 
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Proportions of “Th2-” and “Th1-like” CD4 T cells had a significant reciprocal relationship 
(Pearson’s correlation coefficient -0.52, 2-tailed p=0.001), when controls and patients with 
CKD were considered together. Interestingly, proportions of “Th2-like” cells also 
positively correlated with proportions of “Th17-” and “Tfh-like” CD4 T cells (Pearson’s 
coefficient 0.63, 2-tailed p<0.0001 and Pearson’s coefficient 0.38, 2-tailed p=0.02, 
respectively). Expansions of the “Th2-like” phenotype in the CD4+ compartment were 
associated with a reduction in eGFR (Pearson’s correlation coefficient -0.36, 2-tailed 
p=0.03 for both MDRD and CKD-EPI eGFR), but less so with increasing proteinuria 
(Pearson’s coefficient 0.31, p=0.07 for baseline ACR). No significant associations were 
seen between any of the CD4+ helper subtypes and CCI, medication burden, HbA1c, 
hsCRP or CMV-specific IgG titre.  
CKD status was a significant predictor of “Th2-like” proportion of CD4+ T cells, 
independent of age, gender and CMV serostatus (p=0.02). The linear regression model fit 
was not improved by the addition of the collinear variables CCI or medication burden, 
suggesting that renal dysfunction alone is important in describing the expansion of this 
cell population.  No significant predictors were identified using this model for any of the 
other CD4+ helper subtype proportions.  
Patients with CKD had significantly greater proportions of Treg CD4+ T cells than controls, 
independent of gating strategy (CD25+FoxP3+ Tregs or CD25highFoxP3+ Tregs) and CMV 
serostatus (Figure 5-20). Expansions of Treg CD4 T cells were significantly associated with 
expansions of “Th2-like” CD4 T cells in this study (Figure 5-21), suggesting a common 
process driving expansions of both of these populations. Indeed, expansions of Tregs were 
significantly associated with reducing eGFR (Pearson’s coefficient -0.39, 2-tailed p=0.02 
for both gating strategies and MDRD eGFR and Pearson’s coefficient -0.35, 2-tailed 
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p≤0.04 for both gating strategies and CKD-EPI eGFR) and increasing proteinuria 
(Pearson’s coefficient 0.48, 2-tailed p<0.01 for both gating strategies and baseline ACR). 
No significant associations were seen between Treg proportion of CD4+ T cells (using 
either gating strategy) and HbA1c, CMV-specific IgG titre or hsCRP. Interestingly, 
CD25highFoxP3+ Treg proportion of CD4+ T cells was significantly associated with both 
CCI and medication burden (Spearman R=0.37, p=0.03 and R=0.47, p=0.004, 
respectively), but CD25+FoxP3+ Treg proportion only with medication burden (Spearman 
R=0.38, p=0.02). 
CKD status was the only significant predictor of both CD25+FoxP3+ Treg or 
CD25highFoxP3+ Treg proportion of CD4+ T cells in a linear regression model that also 
included age, gender and CMV serostatus (p=0.02 and 0.004 respectively). The addition 
of the collinear multimorbidity variable CCI (but not medication burden) to CKD status 
did improve model fit, suggesting that renal impairment and multimorbidity both have an 
impact on Treg populations. 
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Figure 5-20 CD4+ regulatory T cell subtypes. 
CD25+FoxP3+ Tregs: A, B, C and CD25highFoxP3+ Tregs: D, E, F, shown as proportions of total 
CD4+ T cell population – comparison between controls and patients with CKD (A ,D) with 
representative flow density plots (C, F) and impact of latent CMV (+ denotes seropositive) (B, E). 
For panel F, FoxP3 negative total CD4+ population is shown for illustrative purposes – FoxP3 
positive gate just on CD4+CD25high cells. Error bars show median +/- IQR. *denotes Mann-
Whitney 2-tailed p<0.05. 
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Figure 5-21 Relationships between Treg and “Th2-like” proportions of CD4+ T cells in 
SONIC study participants.  
Linear regression statistics shown for relationships between “Th2-like” proportions of 
CD4+ T cells and CD25+FoxP3+ Tregs (A) and CD25highFoxP3+Tregs (B). P value <0.05 
considered significant. 
 
	
	
5.6 T lymphocyte phenotypes associated with vaccine response 
Humoral responses to vaccines depend significantly on the function of B lymphocytes and 
their interaction with T lymphocytes, so it is reasonable to suppose that a difference in T 
cell phenotype might be seen between individuals with robust and with poor responses to 
TIV/PPV23. 
As described in Chapter 4 (Vaccine response), patients with CKD in this study had largely 
similar humoral responses to both a T-dependent (TIV) and T-independent (PPV23) 
vaccine compared to age and gender matched controls. Across the whole study, increasing 
age and lower baseline HAI titre or serotype-specific anti-PnPS IgG concentration were 
associated with higher peak responses (ARR) for both TIV and PPV23 vaccines. Previous 
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PPV23 vaccination status and, unexpectedly, latent CMV infection, were also associated 
with lower PPV23 ARR.  
For brevity and clarity of analysis, in this section I will evaluate relationships between 
TIV/PPV23 mean ARR (which is largely representative of trends seen with individual 
antigens) and T lymphocyte profiling as described earlier in this Chapter. As no significant 
differences in vaccine response were seen between controls and patients with CKD in this 
study, I have chosen to examine the SONIC study population as a whole to gain insight 
into potential cellular predictors of vaccine responses in older adults in general (with and 
without chronic disease). This approach also maximises sample size and allows a more 
powerful statistical analysis.   
 
5.6.1 Poor TIV responses correlate with expansions of “senescence”-
associated T cell subsets in older adults with and without chronic 
disease. 
Relationships between T cell phenotypes analysed in this study and the mean ARR of TIV 
and PPV23 are summarised in Table 5-3. Higher TIV mean ARR was significantly 
associated with T cell proportions of total lymphocytes and CD28null, CD27-CD28- and 
CD57+KLRG1+ proportions of CD4+ T cells (Figure 5-22 A, D-F). A significant inverse 
correlation was also seen with CD28null and CD27-CD28- proportions of CD8+ T cells and 
this approached significance for CD57+KLRG1+ proportions of CD8+ T cells (Figure 5-22 
G-I). These T cell phenotypes are associated with replicative senescence (17) and have 
previously been reported to be expanded in older adults (305) and in the context of latent 
CMV infection (86). Indeed, in this study of older adults with and without chronic disease, 
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CMV serostatus is a strong predictor of expansions of these populations. Although no 
significant relationship was seen between TIV mean ARR and CMV-specific IgG titre, the 
cellular relationships described suggest that latent CMV infection could still play a role in 
modulating T-dependent antigen responses in older adults. 
 
Table 5-3 Summary of correlations between T cell phenotypes and vaccine responses. 
Correlations between T cell phenotypes (first column) and TIV mean ARR (orange) and PPV23 
mean ARR (blue). Spearman correlation statistics shown. P value <0.05 considered significant – 
highlighted in bold.  
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In contrast to the above, and despite the strong association between latent CMV infection 
and PPV23 vaccine response, there were no significant correlations between any of the T 
cell “senescence”-associated phenotypes described earlier in this Chapter and PPV23 
mean ARR (Table 5-3). This may be a reflection of the T-independent nature of the 
antigens contained in the vaccine (i.e. that a difference truly does not exist) or due to the 
small sample size in this study. 
When naïve and memory T cell phenotypes were assessed using the surface markers 
CCR7 and CD45RA, expansions of the effector memory (CCR7-CD45RA-) population of 
CD8+ T cells were significantly related to higher TIV ARR (Figure 5-22 B). Similarly, 
expansions of central memory (CCR7+CD45RA-) CD8+ T cells approached significance 
(Figure 5-22 C). This could suggest that the humoral response to TIV observed in this 
study is supported by memory T cell responses, for example, directed against conserved 
influenza antigens, which afford a degree of cross-reactivity between different influenza 
strains e.g. nucleoprotein and matrix protein 1 (described in Chapter 1, Introduction). 
Indeed, it is highly likely that older adults would have established a sizeable pool of 
influenza-antigen memory lymphocytes from repeated exposure to multiple circulating 
influenza strains over their lifetime.  
No relationships were observed between naïve and memory populations of CD4+ or CD8+ 
T cells and PPV23 mean ARR, which is in keeping with the T-independent nature of 
antigens in this vaccine. 
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 Figure 5-22 Relationships between T cell phenotypes and TIV response. 
Relationships shown between TIV mean ARR and T cell % (A); CD8+ T cell central memory (B) 
and effector memory % (C); CD4+ T cell CD28null (D) CD27-CD28- (E) and CD57+KLRG1+ % (F) 
and CD8+ T cell CD28null (G) CD27-CD28- (H) and CD57+KLRG1+ % (I). Non-parametric 
correlation statistics shown. P value <0.05 considered significant – denoted by *. 
 
 
No significant relationships were seen between TIV mean ARR and proportions of CD4+ 
and CD8+ T cells (or CD4/8 ratio), or expansions of different helper and regulatory T cell 
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phenotypes in the CD4+ T cell compartment (Table 5-3). However, greater proportions of 
circulating “Tfh-like” (CXCR5+) and “Th1Th17-like” (CCR4-CCR6+CXCR3+) CD4+ T 
cells were significantly associated with higher PPV23 mean ARR (Table 5-3 and Figure 
5-23). This is unexpected, as TI responses classically do not engage Tfh cells as in TD 
germinal centre reactions. The secretory phenotype of CCR4-CCR6+CXCR3+ (“Th1Th17-
like”) T cells has previously been described as dominated by IFN-g, but also includes IL-
17 (15). Co-administration of IFN-g has previously been shown to improve murine 
immune responses, albeit to TD antigens (306), but it has also been shown to suppress 
APC function (307). The importance of IL-17 in driving antibody production is debated 
(308). As such, the associations between PPV23 mean ARR and expansions of “Tfh-like” 
and “Th1Th17-like” CD4+ T cells seen in this study require corroboration in larger studies 
of patients with CKD and also further interrogation as to their true functional phenotype.   
 
Figure 5-23 Relationships between PPV23 mean ARR and CD4+ T cell proportions of 
“Tfh-like” (A) and “Th1Th17-like” (B) cells.  
Non-parametric correlation statistics shown. P value <0.05 considered significant – denoted by *. 
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5.7 Discussion  
Robust antigen-specific T cell responses are fundamental for the clearance of pathogens 
and long-term health of the host. Given the increased susceptibility to infection seen in 
patients with CKD in both this study and previous literature (146, 149), together with 
previously reported impairments in responses to TD vaccine antigens (154, 179), I 
expected to see a difference in T cell phenotype between the two groups in this study. As 
such, it was surprising that the differences observed were minimal and that the main 
differences in T cell phenotypes observed within the study cohort were dependent on 
CMV serostatus. 
In this study, older patients with CKD demonstrated a T lymphopenia compared to age 
matched healthy controls, but with a preserved CD4/8 ratio, contrary to previous literature 
(214). I observed no contraction of naïve CD4+ or CD8+ T cell populations in patients with 
CKD (contrary to previous reports in patients with ESRD (186, 214)), and only an 
expansion of central memory CD8+ T cells, which appeared to be CMV-independent. 
TEMRA proportions of both CD4+ and CD8+ T cell compartments were also equivalent in 
patients with CKD in this study, compared to healthy age matched individuals, also 
contrary to previous literature on T cells in patients with ESRD (186). No differences in 
the size of the “senescence”-associated T cell populations (CD28null, CD27-CD28-, 
CD57+KLRG1+ or CD28-CD57+ proportions of CD4+ or CD8+ T cells) were seen between 
patients with CKD and controls in this study, again, contrary to previous reports (186, 215, 
218). 
There are several possible explanations as to why the findings of this study do not agree 
with previous literature. In this study, patients with CKD were well-matched for age and 
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CMV seropositive individuals had equivalent CMV-specific IgG titres – considered a 
surrogate for the immune “imprint” of CMV (95). As such, a strength of this study is the 
inherent controlling for the effects of age and latent CMV infection on the immune system 
as potential confounders. Previous studies in CKD/ESRD populations generally report the 
presence of latent CMV only as a binary variable (seropositive/seronegative), without 
consideration of the magnitude of the CMV-specific humoral response. Therefore, 
differences in immune cell profiles (particularly T cells), may have previously been 
ascribed to CKD, when they may, in reality, reflect differences in CMV-specific 
responses. This requires further interrogation in a larger cohort of patients with CKD and 
age-matched controls. Interestingly, when all study participants were taken into account, 
poor humoral responses to a T-dependent vaccine – TIV, were significantly associated 
with expansions of T cell populations associated with latent CMV infection in this study. 
This suggests that latent CMV infection may play a significant role in modulating 
responses to T-dependent antigens in older adults with and without chronic disease – a 
feature that has previously been observed by others (96, 309). 
Another possible explanation is that dialysis therapy (excluded in this study), rather than 
renal impairment, could be driving the T cell features previously described in patients with 
ESRD. As the sample size of this study is small, it is possible that I have not been able to 
see a difference when it actually exists. However, the strong relationships between latent 
CMV infection and “senescence”-associated and naïve/memory T cell populations in this 
study suggest this is less likely.   
Another important finding of this study is the expansion of “Th2-like” and Treg proportions 
of CD4+ T cells in patients with CKD, compared to age matched controls, which appears 
to be independent of latent CMV infection. Again, the majority of previous literature 
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suggests the presence of a Th1 skew in CKD/ESRD (302), with reductions in circulating 
regulatory T cell numbers and function (230). However, several studies have recently 
shown a similar CD4+ helper phenotype in patients with CKD/ESRD as seen here (226, 
227, 310), which could be related to vitamin D deficiency (310). I did not evaluate serum 
vitamin D levels in this study and therefore this could be a confounder here.  
Previous studies have largely used lineage-specific transcription factors and cytokine 
secretion profiles to define helper CD4+ T cell populations in patients with CKD/ESRD. 
The use of surface chemokine receptor profiling in this study may, in part, account for the 
different findings in this study. I did not perform any functional T cell assays to examine 
the cytokine profiles of the helper T cell populations defined by surface chemokine 
receptors, hence I cannot be totally sure that the “Th2-like” population are of the Th2 
functional phenotype.   
Interestingly, latent CMV infection has previously been shown to induce a Th1 dominant 
CD4+ T cell effector profile (311-313). Indeed, in this small study, there was a slight 
increase in the proportion of “Th1-like” CD4+ T cells in CMV seropositive individuals, 
compared to those that were seronegative, and a positive association between “Th1-like” 
expansions and the size of “senescence”- and CMV-associated populations. As such, 
previous literature demonstrating this in CKD may have been confounded by the effect of 
CMV on the immune system. This requires further interrogation in a larger cohort of 
patients with CKD and age-matched controls. 
Chronological ageing is associated with Th2 polarisation of the CD4+ T cell compartment 
in both humans (314) and mice (315), together with expansion of Treg populations (316). 
As such, the features associated with CKD in this study may well reflect the previously 
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postulated “accelerated immune ageing” process (142) that may be independent of CMV. 
Immune “ageing” and the development of proliferative senescence occurs as a result of a 
number of processes, which include telomere shortening, accumulation of DNA damage 
and proliferation in response to chronic antigen exposure (e.g. CMV) (79). Previous 
studies have proposed that immune dysfunction associated with CKD is related to the 
action of retained uraemic toxins (182). Although previous studies (317, 318) have shown 
telomere shortening in patients with ESRD compared to age-matched controls, the 
significant effect of CMV on telomere attrition (319) has not been accounted for. As such, 
I suggest that features of accelerated ageing in CKD, as seen in this study, could be driven 
by accelerated DNA damage and/or impairment of DNA repair mechanisms driven by the 
uraemic milieu, supporting evidence for which already exists in the literature (320, 321). 
As with previous results, multiple comparisons have been made between data from 
patients with CKD and controls in this chapter. Although some of the significant findings 
may represent type I errors (false positives), most are probably due to genuine differences 
between the disease groups and associations between variables. 
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CHAPTER 6 
6  B LYMPHOCYTES IN OLDER 
ADULTS WITH CKD 
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6.1 Introduction 
Upon activation with cognate antigen, B lymphocytes differentiate into antibody secreting 
cells (ASCs) and antigen-specific memory B cells. This process usually occurs as a result 
of interactions with T cells also specific for the antigen (T-dependent), but can also occur 
independently of T cell help. In this study of older individuals with CKD I have used two 
vaccines as an “in vivo” antigen challenge – one that is T-dependent (TIV) and one that is 
T-independent (PPV23), and have evaluated the humoral response to both vaccines in 
Chapter 4 (Vaccine response). As such, I thought it pertinent to also examine the 
composition of the B cell compartment alongside analysis of vaccine-specific antibody. 
As described in Chapter 1 (Introduction), previous studies have reported various B cell 
phenotypic and functional changes associated with severe CKD and/or dialysis treatment, 
including a generalised B lymphopenia, contraction of naïve B cell population and 
increased B cell apoptosis (232, 233, 235, 236). These features are similar to what has 
been described in association with immune ageing, suggesting the presence of an 
accelerated “ageing” process in the B cell compartment in renal disease. At present it is 
not clear whether the same features are present in pre-dialysis non-immune CKD. 
This Chapter presents results of B lymphocyte phenotyping performed on patients with 
CKD and age-matched controls. As with the analysis of T cell phenotype presented in 
Chapter 5 (T cells), samples from 2 individuals were also excluded from this analysis due 
to abnormally high B cell proportions of total lymphocytes – a feature consistent with the 
premalignant condition monoclonal B-cell lymphocytosis (previously reported to have 
tumour-associated genetic mutations (295)). Cross-sectional phenotyping was performed 
on PBMC samples with a minimum viability of 80% collected either at the baseline study 
232 
 
visit (pre-vaccination) or at month 6 post-vaccination. The final sample size of the cross-
sectional B cell phenotype analysis: 28 patients with CKD and 27 controls, was 
determined by practical constraints including assay failure and viability of stored samples. 
In this sample, a significantly greater proportion of patients with CKD were CMV-
seropositive than controls (n=24 versus 15, Fisher’s exact p=0.03). Although effects of 
latent CMV infection on the B cell compartment remain incompletely understood (93, 94, 
322), given the significant effects of CMV on the T cell phenotypes described in Chapter 5 
(T cells), CMV serostatus is included in the following analysis of B cells as a potential 
confounder, with unexpected results. 
Dynamic changes in circulating plasma cell/blast populations from pre-vaccination to day 
7 post-vaccination were also assessed in a subset of study participants as a surrogate for 
antigen-specific B cell responses (10 patients with CKD, 7 age-matched controls). To 
date, no studies have been performed in non-dialysis CKD patients to evaluate this, so our 
results represent a novel insight into this aspect of B cell function in renal impairment. 
 
6.2 Multimorbidity is associated with B lymphopenia in older 
adults, but preserved naïve/memory B cell proportions 
Circulating B lymphocytes were identified from frozen PBMCs by surface expression of 
CD19+ (Figure 6-1A) and further subcategorised into naïve and memory subtypes using 
the markers CD27 and IgD (Figure 6-1B) as per previously published methods (323, 324). 
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Figure 6-1 Gating strategy for identification of B cells and naïve/memory B cell subtypes. 
Singlet live lymphocytes were identified by forward/side scatter characteristics and viability dye 
(APC-Cy7) – scatter plots shown. B cells were defined by surface expression of CD19 (A) and 
naïve/memory subtypes by surface expression of IgD and CD27 (B – representative scatter plot 
shown in top panel, density plot shown in bottom panel). 
 
 
B cell proportion of total lymphocytes was significantly reduced in patients with CKD 
compared to controls (Figure 6-2). Contraction of the B lymphocyte pool was associated 
with reducing eGFR (Pearson’s correlation coefficient 0.31, 2-tailed p=0.02 for both 
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MDRD and CKD-EPI eGFR), but not degree of proteinuria (ACR), glycaemic control 
(HbA1c) or inflammation (hsCRP). However, B cell proportion of total lymphocytes was 
also inversely related to both CCI and medication burden (Spearman correlation 
coefficient -0.37, 2-tailed p=0.004 and Spearman correlation coefficient -0.42, 2-tailed 
p=0.001, respectively) and to CMV-specific IgG titre (Pearson R= -0.28, 2-tailed p=0.03). 
 
Figure 6-2 B lymphocytes in SONIC study participants. 
B cell proportions (A) in patients with CKD and controls. Representative flow density plots from 
one control and one patient with CKD shown in panel B. Error bars show median and IQR. * 
denotes p<0.05.  
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CCI, medication burden (both measures of multimorbidity) and CKD status were 
significantly collinear and, therefore, their independent contribution to a multivariate 
predictive model could not be reliably determined. They were each, however, in turn, 
significant predictors of B cell proportion of total lymphocytes in a linear regression 
model that also included age, gender and CMV serostatus. The model that included 
medication burden best explained the variability in B cell proportion of total lymphocytes, 
compared to CCI or CKD status (adjusted R2=0.23 versus 0.17 and 0.14, respectively). No 
additional improvement in this predictive model was seen with the subsequent addition of 
CKD (R2 did not increase), suggesting that, in this study, the presence or absence of renal 
impairment had no extra predictive effect on B cell proportion in addition to medication 
burden as a measure of multimorbidity.  
No significant differences were seen in the proportion of naïve/memory B cells between 
patients with CKD and controls (Figure 6-3).  
A greater degree of B lymphopenia was significantly associated with smaller naïve 
proportions (Pearson R: 0.29, p=0.03) and larger late memory proportions (Pearson R: -
0.33, p=0.01) of total B cells. This suggests that, in individuals from this study, as the 
proportion of circulating B cells declines, there is a shift within the B cell population 
towards a memory phenotype - features consistent with previously reported B cell changes 
associated with chronological ageing (83).  
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Figure 6-3 Naive/memory B cell phenotype assessment in patients with CKD and controls, 
based on CD27 and IgD expression.  
Naïve/memory B cell phenotypes shown as proportions of total B cells . Error bars show median 
and IQR. 
 
No significant associations were observed between naïve or memory B cell proportions in 
this study and eGFR (MDRD or CKD-EPI), ACR, HbA1c, CCI or medication burden, but 
the proportion of IgM memory B cells (CD27+IgD+) did inversely correlate with age 
(Pearson’s coefficient -0.36, 2-tailed p=0.006), CMV-specific IgG titre (Pearson’s 
coefficient -0.27, p=0.046) and hsCRP (Pearson’s coefficient -0.32, p=0.02). Indeed, 
linear regression analysis revealed both age and CMV serostatus to be significant 
predictors of IgM memory % of B cells (p=0.03 for both variables), independent of gender 
and CKD status, and when the collinear variables CCI or medication burden were 
substituted for CKD status in this model.  
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6.3 Multimorbidity is associated with a contraction of the Breg 
pool in older adults 
Regulatory B cells (Bregs) were defined by surface markers as CD19+CD24highCD38high as 
per previously published methods (85, 325) – gating shown in Figure 6-4 A. Breg 
proportions of total B cells were significantly reduced in patients with CKD compared to 
controls (Figure 6-4 B, C).  
Figure 6-4 Evaluation of Breg populations in patients with CKD and controls.  
Comparisons between controls and patients with CKD of Breg proportions of total B cells (A). 
Panel B shows representative flow contour plots for patients with CKD and controls – Bregs defined 
as CD19+CD24highCD38high. Error bars show median and IQR. *denotes Mann-Whitney 2-tailed 
p<0.05. 
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A smaller Breg proportion of total B cells was significantly associated with smaller naïve 
(Pearson R: 0.71, p<0.0001) and larger late memory proportions of total B cells (Pearson 
R: -0.86, p<0.0001), suggesting that contraction of the Breg pool is associated with a skew 
towards a B cell memory phenotype. This is consistent with the previously reported age-
associated decline in both naïve and Breg populations seen in healthy older adults (85).  
Lower Breg proportions of total B cells were significantly associated with elevated CCI 
(Spearman correlation coefficient -0.35, p=0.009), but not with medication burden, ACR, 
HbA1c, hsCRP or CMV-specific IgG titre. Declining eGFR was generally associated with 
lower Breg proportions of B cells, but this fell just short of statistical significance 
(Pearson’s correlation coefficient 0.26, 2-tailed p=0.052 for MDRD and 0.25, p=0.07 for 
CKD-EPI eGFR). 
CCI was a significant independent predictor of Breg proportion of total B cells in a linear 
regression model that also included age, gender and CMV status (p=0.04). The addition of 
the collinear variables CKD status or eGFR did not improve model fit (R2 unchanged). 
This suggests that, in this study, renal impairment does not appear to have an extra effect 
on Breg populations above that of CCI – a more comprehensive measure of multimorbidity.  
 
6.4 Renal impairment and magnitude of humoral response to 
latent CMV infection are associated with upregulation of B 
cell activation markers CD80/86, but not CD40 
Ligation of the B cell surface costimulatory molecule CD40 by its Tfh-derived ligand 
CD40L stimulates class switch recombination in activated B cells (3), leading to the 
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production of a robust long-lasting antibody response. B cells also express surface CD80 
and CD86, which act as ligands for the T cell co-stimulatory receptor CD28, thus playing 
a key role in their function as APCs. Having already examined the humoral response to 
vaccination in this study, together with naïve and memory B cell populations, I then went 
on to evaluate surface expression of CD40, CD80 and CD86 on B cells, as a surrogate for 
their capacity to interact with cognate T cells after activation. As both CD80 and CD86 are 
ligands for the T cell receptor of interest (CD28), I chose to use the same fluorochrome 
(PE-Cy7) for both, which enabled me to also interrogate the naïve/memory B cell 
populations in the same flow cytometry panel (see Chapter 2, Methods). In the rest of this 
analysis, I will therefore refer to expression of these surface markers as CD80/86 as it is 
not possible to distinguish between them in design of the flow cytometry panel. 
Representative gating and controls for this analysis are shown in Figure 6-5. 
Patients with CKD had equivalent proportions of B cells expressing CD40 compared to 
controls, but significantly higher proportions expressing CD80/86, which translated into 
greater proportions of B cells expressing all of these markers (CD40+CD80/86+) – shown 
in Figure 6-6. 
Expansions of CD80/86+ populations of B cells were significantly associated with reduced 
B cell proportion of total lymphocytes, contraction of naïve and regulatory proportions of 
B cells and expansions of switched and late memory proportions (Figure 6-7) – features 
previously reported in association with an “ageing” immune system (83, 85). 
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Figure 6-5 Representative gating for identification of CD40 and CD80/86 expression on B 
cells.  
Lymphocytes were first identified by forward and side scatter characteristics, then gated on 
singlets and live cells (as shown previously). CD19+ cells were then examined for expression of 
both CD40 and CD80/86. FMO controls were initially used to define gate position, but this was 
very closely approximated by gating on CD19- lymphocytes (mainly T cells). Hence, this “internal 
control” was used in subsequent analyses and an example is shown in panel A (scatter plots 
shown). Panel B shows representative results from controls and patients with CKD, percentages 
shown denote double positive (CD40+CD80/86+) proportion of total B cells (contour plots 
shown). 
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Figure 6-6 Expression of co-stimulation markers CD40 and CD80/86 on B cells from 
patients with CKD and controls.  
Proportions of B cells expressing surface CD40 (A), CD80/86 (B) or both (C). *denotes unpaired 
t-test 2-tailed p<0.05. Error bars show median and IQR. 
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Figure 6-7 Relationships between CD80/86+ B cell proportions and other B cell subsets. 
Correlation shown between CD80/86+ B cell proportions and total B cell % (A), proportions of 
naïve (B), IgM memory (C), switched memory (D), late memory (E) and regulatory B cells (F). 
Linear regression statistics shown and best fit line plotted with 95% CI, p value<0.05 deemed 
significant and denoted by *. 
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I then went on to investigate whether the observed increase in the proportion of B cells 
expressing CD80/86 could be accounted for by a subtle skew towards a B cell memory 
phenotype in patients with CKD. Indeed, when all study participants were considered, the 
proportion of B cells expressing CD40 reduced with loss of IgD, whereas CD80/86 
expression followed the opposite pattern, with significantly increased proportions of 
antigen-experienced B cells expressing these markers than naïve cells (Figure 6-8 A, B). A 
significant inverse correlation was also observed here between proportions of B cells 
expressing CD40 and CD80/86 (Figure 6-8 C). Patients with CKD had significantly higher 
proportions of B cells expressing CD80/86 than controls in IgM memory and late memory 
subtypes and this approached significance for naïve B cells (Mann-Whitney 2-tailed 
p=0.1) - Figure 6-8 E. This suggests the presence of a disease effect on CD80/86 
expression that appears to be independent of antigen experience. When expression of both 
CD40 and CD80/86 was considered, patients with CKD had higher proportions of all 
naïve/memory populations expressing these markers than controls (Figure 6-8 F).  
Measures of renal function (MDRD or CKD-EPI eGFR), but not kidney damage (baseline 
ACR) significantly correlated with CD80/86+ proportion of B cells (Figure 6-9). 
Interestingly, no significant associations were seen between CD80/86+ B cell proportion 
and measures of multimorbidity (CCI, medication burden), systemic inflammation (hsCRP 
or NLR) or glycaemic control (HbA1c). These relationships suggest that the degree of 
renal impairment, rather than systemic inflammation or the presence of multimorbidity, 
had a greater impact on expansions of CD80/86+ populations in the B cell compartment in 
this study of older adults with and without chronic disease. 
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Figure 6-8 Expression of CD40 and CD80/86 on B cell populations depending on antigen 
experience. 
Results shown from all study participants in A, B, C; comparisons between controls and patients 
with CKD shown in: D-F.  CD40+ B cell populations by naïve/memory subtypes shown in A and 
D. CD80/86+ B cell populations by naïve/memory subtypes shown in B and E. Panel C shown 
linear regression statistics and best fit line (with 95% CI) of relationship between CD40+ and 
CD80/86+ proportions of total B cells in all study participants. Panel F shows the distribution of 
CD40+CD80/86+ B cells by naïve/memory subtypes compared by disease group. Error bars show 
median and IQR unless stated. *denotes Mann-Whitney 2-tailed p<0.05. 
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Figure 6-9 Relationships between CD80/86+ proportions of B cells and markers of renal 
disease. 
Linear regression statistics and best fit line (with 95% CI) shown for relationships between 
CD80/86+ proportions of B cells and A: MDRD eGFR, B: CKD-EPI eGFR, and C: baseline ACR. 
P value <0.05 considered significant and denoted by *.  
 
Contraction of CD4+ and expansion of CD8+ proportions of T cells (together with 
reductions in the CD4/8 ratio) were significantly associated with expansions of CD80/86+ 
B cells in both controls and patients with CKD (Figure 6-10).  
 
Figure 6-10 Relationships between CD80/86+ B cell proportions and basic T cell subsets. 
Linear regression statistics and best fit line (with 95% CI) shown for relationships between 
CD80/86+ proportions of B cells and CD4+ (A) and CD8+ (B) proportions of total T cells, together 
with their ratio (C). *denotes statistical significance (p<0.05). 
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Given the integral role of CD80/86 interaction with T cell CD28, I then examined the 
relationships between this B cell population and T cell phenotypes lacking surface 
expression of CD28, as described in Chapter 5 (T cells). Positive correlations between 
CD80/86+ proportions of B cells and expansions of CD28null and CD27-CD28- populations 
of CD4+ T cells fell just short of significance (Figure 6-11), but no significant 
relationships were seen with CD28null or CD27-CD28- proportions of CD8 T cells. This 
suggests that the observed expansion of CD80/86+ populations of B cells seen in patients 
with CKD in this study may be compensatory to downregulation of their ligand CD28 on 
CD4 T cells. 
 
Figure 6-11 Relationships between CD80/86+ B cell proportions and CD28null (A) and 
CD27-CD28- (B) CD4+ T cell populations.  
Linear regression statistics and best fit line (with 95% CI) shown. P value <0.05 considered 
significant. 
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As the loss of surface expression of CD28 on CD4 T cells is strongly associated with 
latent CMV infection (91, 92, 326), I then investigated the relationship between the size of 
CD80/86+ B cell populations and presence of latent CMV infection in this study. CMV 
seropositive patients with CKD tended to have greater proportions of CD80/86+ B cells 
than seronegative individuals (statistical analysis limited by sample size, n=3 seronegative 
patients with CKD) and also compared to CMV seropositive controls (Figure 6-12 A). 
This may suggest a different CMV-associated effect on this B cell population in the 
presence of renal impairment, compared to healthy individuals. 
However, I observed significant positive correlations between CMV-specific IgG titre and 
CD80/86+ % of B cells when CMV seropositive controls and patients with CKD were 
considered together (Figure 6-12 B) or separately (Figure 6-12 B, C). As such, the 
magnitude of the humoral CMV-specific response appears to be associated with CD80/86+ 
B cell expansions in older adults with and without chronic disease.  
CKD status was the only significant predictor of CD80/86+ B cell % in a linear regression 
model that also included age, gender and CMV-specific IgG titre (p=0.047). When CKD 
status was substituted by CCI or medication burden, none of the variables in the model 
approached significance at the 0.05 level, which suggests that the effect of renal 
impairment is greater than that of concomitant multimorbidity. However, when CMV 
seropositive individuals were evaluated separately, CMV-specific IgG was the only 
significant predictor of CD80/86+ B cell expansions independent of age, gender and CKD 
status (p=0.03).  
These findings suggest that both renal impairment and the magnitude of the humoral 
immune response to latent CMV infection (resulting in expansions of CD4 T cell 
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populations lacking the costimulatory receptor CD28) could have an effect on expanding 
populations of CD80/86+ B cells in older adults. This appears to be independent of the 
degree of systemic inflammation (hsCRP) and multimorbidity/polypharmacy in this study.  
 
Figure 6-12 Relationship between CD80/86 expression on B cells and latent CMV 
infection.  
CD80/86+ proportions of total B cell proportion compared by CMV serostatus (+/-) and disease 
group are shown in panel A (unpaired t test 2-tailed p values shown). The relationship between 
CD80/86+ proportion of B cells and CMV-specific IgG titre is shown in B for all CMV-
seropositive participants, in C for only CMV-seropositive controls and in D for only CMV-
seropositive patients with CKD (linear regression statistics and best fit line with 95% CI shown). 
Error bars show median +/- IQR unless stated. P value <0.05 considered significant and denoted 
by *. 
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6.5 Generation of circulating plasma blasts/cells at day 7 post-
vaccination is maintained in patients with CKD 
A sample of study participants were assessed for generation of circulating ASCs at day 7 
(10 patients with CKD and 7 age-matched controls). ASCs were defined as CD19+CD20-
CD38high as per previously published methods (327, 328) with representative gating shown 
in Figure 6-13 A, B. Unfortunately, the detection of the surface proteoglycan CD138 (the 
hallmark of mature plasma cells (329), differentiating them from plasmablasts) was very 
variable after cryopreservation of PBMCs in this study (infact, completely abrogated in 
some post-vaccination samples during assay development as shown in Figure 6-13 C), 
thus limiting its utility in flow cytometry analysis of frozen samples here. As such, the 
CD19+CD20-CD38high ASC population described in this analysis will, henceforth, be 
referred to as plasma blasts/cells (PB/PC) as I was not able to confidently determine 
CD138 expression in frozen samples. 
Both patients with CKD and controls were able to expand circulating PB/PC populations 
at day 7 post-vaccination, approximately to the same degree (Figure 6-14). 
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Figure 6-13 Representative plasma blast/cell gating strategy. 
Lymphocytes were first identified by forward and side scatter characteristics, then gated on 
singlets and live cells (as shown previously). CD19+ cells were then examined for surface 
expression of CD20 and CD38, with plasma blasts/cells defined as CD20-CD38high. Panels A and 
B show representative flow scatter plots for samples from controls and patients with CKD, 
respectively. Panel C shows abrogation of CD138 staining in PBMC samples used in assay 
development: cells from a healthy laboratory donor were taken at day 7 after TIV received as part 
of routine care for that individual; cells were stained immediately after isolation (left scatter plot) 
and an aliquot was frozen at -80∘C and analysed at a later stage with the same flow cytometry 
technique (right scatter plot).  
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Figure 6-14 Change in circulating plasma cell/blast proportion of B cells from pre-
vaccination (day 0) to day 7 post-vaccination. 
Change in circulating plasma cell/blast B cell populations in individual controls (A) and patients 
with CKD (B) from baseline to day 7 after vaccination. Panel C compares the magnitude of change 
in these populations in patients with CKD and controls. Error bars show median and IQR. 
*denotes p<0.05 
 
 
No significant relationships were seen between the fold change in circulating PB/PC 
proportions of B cells (PB/PC FC) at day 7 and age, CCI, medication burden, eGFR, 
ACR, HbA1c or hsCRP. Interestingly, CMV seropositivity was associated with lower 
PB/C FC (Figure 6-15 A) and CMV-specific IgG titre significantly correlated with PB/PC 
FC (Spearman’s R= -0.69, 2-tailed p=0.002). Interestingly, PB/PC FC also significantly 
inversely correlated with the proportion of CD4+ T cells lacking CD28 (Figure 6-15 B) – 
a population known to be expanded in latent CMV infection – but not with any other B 
cell or T cell phenotypes assessed in this study. 
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Figure 6-15 Impact of latent CMV infection on change in circulating plasma blast/cell 
populations at day 7 post-vaccination.  
A – comparison of magnitude of change in these cell populations between CMV negative and 
seropositive individuals (error bars show median +/- IQR, dashed red line denotes fold change of 
1). B – relationship between the magnitude of change in circulating plasma cell/blasts and CD28null 
CD4+ T cell proportion (linear regression statistics and best fit line with 95% CI shown) – a 
phenotype significantly associated with latent CMV infection. *denotes p<0.05.  
 
 
CMV-specific IgG titre (but not the binary variable of CMV serostatus), approached 
significance as a predictor of PB/PC FC in a linear regression model that also included 
age, gender and CKD status/CCI (p=0.09). The model fit was not improved with the 
addition, in turn, of CD28null CD4+ T cell % or measures of multimorbidity. These 
relationships suggest that latent CMV infection has a significant impact on the generation 
of plasma cells/blasts at day 7 post-vaccination, independent of renal impairment or 
multimorbidity.  
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6.6 B lymphocyte phenotypes associated with vaccine response 
Antigen-specific antibody production is the main function of B cells. Hence, I felt it was 
important to evaluate the relationship between circulating B cell phenotype and measures 
of vaccine response as described in Chapter 4 (Vaccine response). For brevity and clarity 
of analysis, I will use the mean ARR for both TIV (TD vaccine) and PPV23 (TI vaccine), 
which are largely representative of trends seen with individual antigens, as the read-out of 
vaccine response. The relationships between vaccine response and cross-sectional B cell 
phenotyping as described earlier in this chapter are summarised in Table 6-1. 
Table 6-1 Summary of relationships between B cell populations and vaccine response. 
Relationships shown between B cell populations (first column) and TIV mean ARR (orange) and 
PPV23 mean ARR (blue). Spearman correlation statistics shown. P value <0.05 considered 
significant – highlighted in bold. 
 
As seen with T cells in Chapter 5 (T cells), there appeared to be a split between the B cell 
phenotypes associated with robust TIV and PPV23 responses. Higher B cell proportions of 
total lymphocytes were significantly associated with higher PPV23 mean ARR, but not 
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mean ARR for TIV (Figure 6-16 A, B). However, higher TIV mean ARR was 
significantly associated with lower naïve and higher switched and late memory 
proportions of B cells, whereas no relationships were seen between these variables and 
PPV23 mean ARR (Figure 6-16 C-H). This could suggest that the magnitude of the 
humoral response to TIV observed in this study is determined by memory B cell 
responses, either directed against serotype-specific antigens previously encountered 
through environmental or vaccination exposure, or directed against conserved influenza 
antigens, which afford a degree of cross-reactivity between different influenza strains e.g. 
nucleoprotein and matrix protein 1 (described in Chapter 1, Introduction). This is in 
keeping with subtle association between mean TIV ARR and expansions of CD8 T cell 
memory populations described in Chapter 5 (T cells). TIV mean ARR (but not that of 
PPV23) also negatively correlated with the proportion of B cells expressing CD40 (Figure 
6-16 I, J), which may reflect the high expression of this marker on naïve B cells seen in 
this study. Interestingly, no significant relationships were seen between mean ARR to 
either vaccine and the proportion of B cells expressing CD80/86 or both CD40 and 
CD80/86.  
In contrast to the associations seen between TIV and PPV23 ARR and cross-sectional 
lymphocyte phenotypes, the relationships between vaccine response and dynamic changes 
in circulating plasma blasts/cells (PB/PC FC) following vaccination were similar for TIV 
and PPV23. PB/PC FC from baseline to day 7 post-vaccination (equivalent between 
controls and patients with CKD) was significantly associated with both TIV and PPV23 
mean ARR (Figure 6-17 A, B). 
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Figure 6-16 Relationships between vaccine responses (mean ARR) and B cell cross-
sectional phenotype.  
Relationships shown between TIV mean ARR (orange symbols) and B cell % (A), naïve % of B 
cells (C), switched memory % of B cells (E), late memory % of B cells (G) and CD40+ % of B 
cells (I); PPV23 ARR (blue symbols) and B cell % (B), naïve % of B cells (D), switched memory 
% of B cells (F), late memory % of B cells (H) and CD40+ % of B cells (J). Non-parametric 
correlation statistics shown. Significance set at 0.05 level – denoted by *. 
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Figure 6-17 Relationships between vaccine responses (mean ARR) and dynamic changes 
in circulating plasma blasts/cells (fold change from baseline to day 7 post-vaccination) in 
subset of SONIC participants.  
Relationship between fold change in circulating plasma cells/blasts and A – TIV mean ARR 
(orange symbols), B – PPV23 mean ARR (blue symbols); non-parametric correlation statistics 
shown. *denotes p<0.05.    
 
Interestingly, both latent CMV infection and previous PPV23 vaccination status were 
associated with a smaller PB/PC FC at day 7 post-vaccination (Figure 6-18 A, B) and, 
unlike what was seen for PPV23 mean ARR, their effect appeared to be additive (Figure 
6-18 C). These findings are in keeping with the associations between “senescence”- or 
CMV-associated T cell phenotypes and TIV mean ARR described in Chapter 5 (T cells). 
These findings also support the hyporesponsiveness observed in the earlier analysis of 
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humoral response to PPV23 (Chapter 4, Vaccine response) and highlight the importance 
of previous PPV23 vaccination in determining subsequent PPV23 response.  
Figure 6-18 Effect of latent CMV (A) and previous PPV23 vaccination (B) on dynamic 
change in circulating plasma cells/blasts at day 7 post-vaccination. 
The additive effect of both CMV and previous PPV23 is shown in panel C. Error bars denote 
median and IQR. +/- denotes CMV seropositive/negative. *denotes p<0.05 (deemed significant).  
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6.7 Discussion  
In this study I have performed a cross-sectional analysis of B cell phenotype in patients 
with CKD compared to age-matched controls. In line with previous literature (233, 235), I 
found a reduced circulating number and proportion of B cells in patients with CKD, often 
reported as a feature of accelerated “ageing” of the immune system. However, due to the 
marked difference in multimorbidity between controls and patients with CKD, the 
independent effect of renal impairment here could not be reliably determined. These 
results are still clinically relevant, as older individuals with non-immune renal disease 
invariably have multiple comorbidities that are likely to have contributed to the 
development of renal impairment. 
As with previous results, multiple comparisons have been made between data from 
patients with CKD and controls in this chapter. Although some of the significant findings 
may represent type I errors (false positives), most are probably due to genuine differences 
between the disease groups and associations between variables. 
Reduced circulating B cell proportion of total lymphocytes was significantly associated 
with other B cell features previously reported in association with immune ageing (83, 85) 
when all study participants were evaluated together: contraction of naïve (CD27-IgD+) and 
regulatory B cell proportions (CD24highCD38high) and expansion of late memory B cell 
populations (CD27-IgD-). Although patients with CKD were found to have significant 
reductions in Breg proportions, no significant differences in naïve/memory proportions of 
B cells were seen between patients with CKD and controls, contrary to previous findings 
in ESRD (142, 233, 239). This may reflect the inherent immune activating effect of 
dialysis therapy, rather than renal impairment itself or that the study sample was too small 
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for a difference to be seen. It could also be that CKD and its associated comorbid state do 
not affect all aspects of the B cell population equally. Interestingly, expansions of late 
memory (CD27-IgD-) B cells have been associated with chronic immune activation as seen 
in chronic viral infections such as human immunodeficiency virus (HIV) and hepatitis C 
(330). The lack of differences in the size of this B cell population between older adults 
with and without CKD in this study could, therefore, be related to an equivalent immune 
“imprint” of latent CMV, but this requires further investigation. 
Although the CD24highCD38high surface phenotype of B cells has been associated with 
secretion of IL-10, a canonical regulatory B cell cytokine (85), I cannot confirm this 
function from the data available in this study. As such, the contraction of the 
CD24highCD38high population of B cells observed in patients with CKD in this study may 
represent a reduction in the circulating population of immature B cells, also previously 
described to have this surface marker pattern (331). This requires further investigation 
with interrogation of cell function in a larger cohort of patients with CKD.  
Patients with CKD in this study had greater proportions of B cells expressing the CD28 
ligands CD80/86 than controls. The expression of CD80 or CD86 on B cells has not 
previously been evaluated in CKD arising from non-immune mechanisms, but one study 
in dialysis patients has shown downregulation of CD86 expression on circulating 
macrophages, suggesting the presence of a defect in APC function (332). Indeed, the 
majority of literature on B cell CD80/86 expression in CKD patients focuses on 
upregulation of these surface ligands as markers of renal damage and disease activity in 
systemic lupus erythematosus, such as in references (333, 334), and the use of the 
monoclonal CTLA4-like antibody, belatacept, which reduces T cell CD28 interaction with 
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its APC ligands CD80/86, in addition to conventional immunosuppression to improve 
patient and organ outcomes in renal transplantation (335, 336).  
The findings of greater proportions of B cells expressing CD80/86 in patients with CKD 
than controls are in keeping with what has been observed in some chronic inflammatory 
states e.g. murine models of inflammatory arthritis (337), but, interestingly, the 
observations in this study do not correlate with hsCRP. Downregulation of CD4 T cell 
CD28 was associated with expansion of CD80/86+ proportions of B cells, suggesting that 
this may be a compensatory mechanism. A novel finding in this study is the effect of both 
renal impairment and the magnitude of the humoral immune response to latent CMV 
infection in this upregulation of CD80/86 on B cells, which appeared to be independent of 
multimorbidity. This is an interesting finding that warrants further investigation. 
Despite the phenotypic differences seen in the B cell compartment in patients with CKD, 
the generation of circulating ASCs (PB/PCs) following vaccination appeared equivalent 
between patients with CKD and controls in a small sample of the study population. This 
suggests equivalent differentiation/mobilisation of effector B cells following antigen 
exposure in patients with CKD compared to controls. The sample size for this particular 
analysis was small and may not have picked up a difference if it exists, but this is unlikely, 
given that differences in vaccine antibody responses are marginal between all patients with 
CKD and controls in this study. 
Higher PB/PC FC was significantly associated with the a more robust vaccine response as 
measured by mean ARR for both PPV23 and TIV.  Interestingly, PB/PC FC was 
significantly altered by the presence of latent CMV infection and previous PPV23 
vaccination, with a stepwise reduction in PB/PC FC observed with addition of these two 
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factors. The presence of hyporesponsiveness to PPV23 has already been observed in the 
serotype-specific IgG response in this study, as described in Chapter 4 (Vaccine response). 
The role of latent CMV infection in determining vaccine responses is gaining attention 
(96, 309) and may represent a therapeutic target in improving immune responses. Indeed, 
a recent study from our group has shown an effect of therapeutic CMV suppression on 
responses to a TD vaccine (97). 
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CHAPTER 7 
7 NEUTROPHIL FUNCTION IN 
OLDER ADULTS WITH CKD 
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7.1 Introduction 
As described in Chapter 1 (Introduction), few studies have examined neutrophil function 
in non-dialysis CKD populations and those that have, have shown conflicting results (184-
187, 244). In dialysis populations, neutrophils are often described as “primed” or “over-
active” and having an exaggerated oxidative burst response to multiple stimuli, but with 
generally impaired phagocytosis (183, 184). Multiple studies have alluded to the 
contribution of materials in dialyser membranes to this observation (188, 338), hence it is 
not clear what the effect of renal impairment per se is in these patients.  
As neutrophils represent the first line of defence against pathogens, I felt it was vital to 
examine this cell population in this study of older patients with CKD (who have increased 
pathogen susceptibility) and also to evaluate the relationship between innate and adaptive 
immune system defects.  
In this Chapter, I will describe results from functional neutrophil assays performed on 
samples from patients with CKD and age-matched controls. Assessment of neutrophil 
function evolved during the course of this study. Initially, only assessment of phagocytosis 
and oxidative burst were performed on whole blood samples (PhagoTestTM and 
PhagoBurstTM assays), but as differences emerged between patients with CKD and 
controls, further functional assays were incorporated into the analysis, including 
generation of NETs and assessment of migration. This approach allowed us to sequentially 
interrogate different, but related, aspects of neutrophil function in patients with CKD, like 
peeling back the layers of an onion. The sample size for each functional assessment is 
presented together with results from that assay in this Chapter and was determined by 
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practical constraints including availability of donors, volume of blood collected and assay 
failure.  
 
7.2 Neutrophil phagocytosis is preserved in older adults with 
CKD 
Both neutrophil phagocytosis (PhagoTestTM) and oxidative burst (PhagoBurstTM) assays 
(described in Chapter 2, section 2.2.16) were performed in tandem on samples from 65 of 
66 SONIC patients. The majority of samples were analysed at the baseline timepoint of 
the study – 33 patients with CKD and 27 controls, with the remainder (samples from 3 
patients with CKD and 2 controls) analysed at the day 7 timepoint due to assay failure at 
baseline. Exclusion of day 7 samples did not alter the relationships in neutrophil function 
observed between patients with CKD and healthy controls, hence they are included in the 
final analysis. Both PhagoTest™ and PhagoBurst™ assays are optimised for whole blood 
samples with neutrophils in the normal range. Four SONIC subjects (all patients with 
CKD) had abnormal neutrophil counts on the day these assays were performed (1 low, 3 
high) and are, therefore, excluded from the final analysis. One control individual 
developed pulmonary fibrosis and two patients with CKD were diagnosed with metastatic 
carcinoma during the course of the study (thus fulfilling exclusion criteria) and their 
samples were subsequently excluded from analysis of immune function. The final sample 
size for analysis of PhagoTestTM and PhagoBurstTM assays is 30 patients with CKD and 28 
controls.  
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The proportion of neutrophils ingesting opsonised killed FITC-labelled E.coli in the 
PhagoTestTM assay was equivalent in patients with CKD to that of controls (Figure 7-1 A). 
The flow cytometer underwent repair after data acquisition for the 2015 cohort, therefore, 
the MFI in the FITC channel from these patients was not directly comparable to 
subsequently acquired data. This parameter was, therefore, standardised by dividing the 
result from stimulated samples by that of the negative control and allowed the 
phagocytosis index (PI) - the product of the phagocytosing neutrophil % and the FITC 
MFI of the neutrophil gate – to be calculated for use across the whole SONIC study. As 
such, no significant difference in PI was observed between patients with CKD and 
controls, suggesting that the number of bacteria engulfed per cell is equivalent between the 
two groups. No significant relationships were observed between % phagocytosing 
neutrophils or PI and eGFR, ACR, hsCRP, CCI or medication burden. 
Overall, these results suggest that renal impairment in older adults is not associated with a 
demonstrable defect in neutrophil phagocytosis of heat killed opsonised bacteria compared 
to older adults without renal impairment. 
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Figure 7-1 Results of neutrophil phagocytosis assay (PhagoTestTM) – comparison between 
controls and patients with CKD.  
A – proportion of neutrophils undergoing phagocytosis following stimulation with heat killed 
opsonised FITC-labelled E Coli; B –Standardised phagocytosis index (log10) – product of % 
neutrophils undergoing phagocytosis and standardised FITC MFI of the neutrophil gate. Error bars 
show median and IQR. 
 
 
7.3 Reduced neutrophil oxidative burst is associated with 
declining health status and renal impairment in older 
adults 
Neutrophil oxidative burst (as measured by intracellular oxidation of DHR-123 in the 
PhagoBurstTM assay) was assessed in response to fMLP, opsonised heat killed E. coli and 
PMA. The bacterial metabolite, fMLP, activates neutrophils through interaction with cell 
surface G-protein coupled receptors to stimulate superoxide production through activation 
of NADPH oxidase (339). Opsonised E. coli stimulate neutrophils through a number of 
PRRs, including TLRs and receptors for the Fc portion of immunoglobulin (340). PMA 
stimulates NADPH oxidase activation through direct stimulation of protein kinase C 
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(PKC), without interaction with surface receptors (341). The use of these 3 stimuli in the 
PhagoBurstTM assay allowed me to test responses to both biological (receptor-mediated) 
and mitogenic stimuli in neutrophils from the same individual.  
The proportion of neutrophils generating reactive oxygen species (hereafter described as 
“oxidative burst %” for brevity) in response to fMLP and opsonised killed E. coli (but not 
the mitogen PMA) was significantly reduced in patients with CKD compared to controls 
(Figure 7-2 A-C), suggesting an impairment in receptor-mediated neutrophil activation. 
Although statistically significant, the absolute reduction in median oxidative burst % in 
response to E. coli was very small in patients with CKD (0.2%) and may not be 
biologically significant.  
However, the neutrophil oxidative burst capacity (defined as FITC MFI of neutrophil gate) 
was significantly reduced in response to all 3 stimuli in patients with CKD (Figure 7-2 D-
F), suggesting that neutrophils from older patients with CKD are not able to generate as 
much ROS per cell as those from healthy older adults, regardless of the type of activating 
“signal” they receive. This could limit neutrophil ability to kill ingested bacteria, thus 
contributing to the increased susceptibility to infection seen in the CKD patient 
population. FITC MFI has been standardised for use across the entire SONIC cohort by 
dividing the result from stimulated samples by that of the negative control sample, to 
account for changes in cytometer settings after data acquisition for the 2015 cohort. 
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Figure 7-2 Oxidative burst function of neutrophils as assessed by PhagoBurstTM assay.  
Proportion of neutrophils from patients with CKD and controls that produced reactive oxygen 
species (oxidative burst %) is shown in response to A – fMLP, B – E Coli and C – PMA. 
Oxidative burst capacity per cell (standardised FITC MFI) is shown in response to D – fMLP, E – 
E coli and F – PMA. Error bars show median and IQR. *denotes p<0.05. 
 
 
Oxidative burst % of neutrophils in response to fMLP and E. Coli significantly correlated 
with one another (Spearman r=0.44, 2-tailed p=0.001) and also with eGFR (both MDRD 
and CKD-EPI eGFR: Spearman r=0.36, 2-tailed p=0.005 and r=0.26, p=0.04, 
respectively) and CCI (Spearman r= -0.33, p=0.01 for both fMLP and E. Coli). Only 
oxidative burst % in response to fMLP significantly correlated with medication burden 
(Spearman r= -0.30, p=0.02). No significant correlations were seen between oxidative 
burst % of neutrophils in response to fMLP or E. coli and ACR, hsCRP or HbA1c.  
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Interestingly, oxidative burst % in response to PMA correlated significantly only with 
hsCRP (Spearman r= -0.28, p=0.04) and not with measures of renal disease (eGFR, ACR), 
glycaemic control (HbA1c) or multimorbidity (CCI, medication burden). PMA % 
response was also not related to oxidative burst % in response to fMLP or E. coli, which is 
not unexpected given their different mechanisms of neutrophil activation.   
CCI was a significant independent predictor of oxidative burst % in response to fMLP and 
E. Coli (p≤0.02) in a linear regression model that also included age and gender. CCI and 
CKD status/eGFR were significantly collinear and their independent contribution to a 
multivariate predictive model could, therefore, not be reliably determined. However, the 
fit of the above linear regression model was not improved by the addition of CKD status 
or eGFR, suggesting that declining health status was a more prominent predictive factor of 
neutrophil oxidative burst % in response to fMLP and E. Coli than renal impairment alone. 
No significant predictors were identified when this model was applied to oxidative burst 
% in response to PMA.  
In contrast to oxidative burst %, neutrophil oxidative burst capacity (standardised FITC 
MFI) in response to all 3 stimuli was significantly associated with eGFR, CCI and 
medication burden (Table 7-1). Oxidative burst capacity in response only to E. Coli was 
also significantly associated with ACR and hsCRP, and HbA1c was significantly 
associated with oxidative burst capacity in response to all stimuli except fMLP. 
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Table 7-1 Relationships between neutrophil oxidative burst capacity in response to the 
stimuli listed and measures of multimorbidity, renal disease severity, glycaemic control 
and inflammation.  
Correlations between neutrophil oxidative burst capacity to different stimuli (top row) and 
demographics/laboratory parameters of study participants. R denotes Pearson correlation 
coefficient, r denotes Spearman correlation coefficient. Statistically significant results highlighted 
in bold (p<0.05).  
	 fMLP	 E	Coli	 PMA	
CCI	 r:	-0.28	
p=0.03	
r:	-0.58	
p<0.0001	
r:	-0.45	
p=0.001	
Medication	burden	 r:	-0.32	
p=0.02	
r:	-0.56	
p<0.0001	
r:	-0.41	
p=0.002	
eGFR	MDRD	 R:	0.36	
p=0.006	
R:	0.59	
p<0.0001	
R:	0.38	
p=0.006	
eGFR	CKD-EPI	 R:	0.34	
p=0.008	
R:	0.59	
p<0.0001	
R:	0.37	
p=0.006	
ACR	 R:	-0.21	
p=0.12	
R:	-0.45	
p<0.001	
R:	-0.27	
p=0.06	
HbA1c	 R:	-0.16	
p=0.22	
R:	-0.37	
p=0.005	
R:	-0.36	
p=0.009	
hsCRP	 R:	-0.12	
p=0.36	
R:	-0.26	
p=0.05	
R:	-0.25	
p=0.07	
 
ACR and HbA1c did not have a linear relationship with neutrophil oxidative burst 
capacity, so were excluded from multivariate analysis. Significant collinearity precluded 
inclusion of CCI, medication burden and CKD status in the same multivariate analysis, but 
each variable, in turn, was a significant predictor of neutrophil burst capacity in response 
to each of the 3 stimuli in a linear regression model that also included age and gender. The 
best fitting model for responses to fMLP contained medication burden (adjusted R2 0.04), 
rather than CCI or CKD status, and the model fit was not improved with subsequent 
addition of CKD status. The best fitting model for responses to both E. Coli and PMA 
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contained CKD status (adjusted R2 0.31 and 0.11, respectively) and only the E. coli model 
was improved by the subsequent addition of CCI or medication burden.  
This multivariate analysis suggests that, although reduced oxidative burst % and oxidative 
burst capacity per cell was identified in patients with CKD compared to controls in this 
study, it is not possible to confidently surmise that this is due to renal impairment alone, 
outside the context of associated multimorbidity. 
 
7.4 Generation of NETs in response to PMA is reduced in 
patients with severe CKD compared to healthy controls 
The generation of NETs is largely dependent on the production of ROS as a result of 
NADPH oxidase activation in stimulated neutrophils (342). In view of the oxidative burst 
defects seen in neutrophils from patients with CKD earlier in the study, I then went on to 
assess their ability to generate NETs. This fluorimetric assay (described in Chapter 2: 
Materials and Methods) used the mitogen PMA as the stimulating factor. Although not a 
true “biological” mimic, responses to PMA (which directly activates NADPH through 
actions on PKC) give an indication of the capacity of neutrophils to generate NETs after 
stimulation through other mechanisms, as many intracellular signalling pathways 
downstream of surface receptors converge on PKC activation (339).  
This assay was performed on samples collected at the month 6 study timepoint from the 
2016 cohort and the baseline timepoint from the 2017 cohort. These timepoints were 
considered equivalent in terms of cross-sectional assessment of a quiescent immune state. 
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The final sample size for this analysis was 18 patients with CKD and 17 age and gender-
matched controls.   
There was no significant difference in extracellular DNA concentration (representing 
NETs) either at background levels (RPMI-PS control) or following PMA stimulation in 
patients with CKD when compared to controls (Figure 7-3 A). In vitro generation of NETs 
was visualised using fluorescent microscopy in a sample of patients with CKD and 
controls (representative images shown in Figure 7-3 B). The fold change in extracellular 
DNA following PMA stimulation (representative of NETs generation) was overall lower 
in patients with CKD (Mann Whitney 2-tailed p=0.07, Figure 7-3 C), but with one outlier 
in the CKD group. When the CKD group was split by renal function into stages G3 and 
G4 (based on average of eGFR over the first 3 study visits), G4 patients (severe CKD) 
generated significantly fewer NETs compared to healthy controls (Figure 7-3 D).  
The magnitude of NETs generation in response to PMA was significantly associated with 
eGFR (Pearson R: -0.34, 2-tailed p=0.05 for both MDRD and CKD-EPI eGFR), but not 
ACR, HbA1c, hsCRP, CCI or medication burden. Interestingly, there were also no 
relationships between NETs production and any of the oxidative burst indices discussed 
earlier in this Chapter. This may be due to the small sample size or because of the 
contribution of other biological processes such as autophagy, now increasingly recognised 
to be important in NETs generation (343). No significant predictors of the magnitude of 
NETs generation were identified in a linear regression model that included age, gender 
and CKD status/eGFR. 
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Figure 7-3 Neutrophil generation of NETs in patients with CKD and controls.  
A – extracellular DNA (NETs) at background and after PMA stimulation; B – representative 
fluorescent microscopy images of neutrophils from patients with CKD (x20 magnification) - NETs 
marked with white arrows; C – fold change in extracellular DNA (NETs): split by disease group; 
D – fold change in extracellular DNA (NETs) compared with controls by CKD severity. Error bars 
show median and IQR. *denotes Mann Whitney 2-tailed p<0.05. 
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7.5 Reduced neutrophil migration towards fMLP, but not IL-8 
in patients with CKD 
The bacterial metabolite fMLP can stimulate different functions in neutrophils depending 
on the concentration of fMLP the cell is exposed to. Two different fMLP receptor 
subtypes exist, which activate different intracellular signal transduction pathways. Low 
fMLP concentrations activate intracellular signalling responsible for the chemotactic 
response through interaction with the high affinity formyl peptide receptor (FPR). High 
fMLP concentrations (as seen at sites of infection) stimulate signal transduction that leads 
to superoxide production and release of lysozyme through interaction with the low affinity 
receptor subtype: FPR like 1 (FPRL1) (339). In view of the impaired oxidative burst 
following fMLP stimulation seen in neutrophils from patients with CKD earlier in the 
study, I then went on to investigate neutrophil chemotaxis to fMLP. I also used the 
chemoattractant IL-8 (CXCL8) to evaluate neutrophil migration to a receptor-mediated 
inflammatory, rather than a microbial stimulus (344).  
Analysis of neutrophil migration was performed on samples collected from 10 patients 
with CKD and 8 age and gender-matched controls from the 2017 cohort, at either day 28 
or month 6 post-vaccination (considered equivalent in terms of a quiescent neutrophil 
state).   
Gradients of fMLP and IL-8 significantly altered migration of neutrophils from all 
individuals tested when compared to the negative control (RPMI) – Figure 7-4, showing 
induction of stimulation with the reagents used. 
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Figure 7-4 Neutrophil migration results from all individuals tested towards RPMI 
(negative control), fMLP and IL-8.  
A – chemokinesis (speed); B – chemotaxis (velocity); C – chemotactic index (accuracy). Error 
bars show median and IQR. *denotes Mann Whitney 2-tailed p<0.05. These results demonstrate 
that reagents used in the assay significantly altered neutrophil migration. 
 
 
Slightly reduced velocity (chemotaxis) and accuracy (chemotactic index, CI) of neutrophil 
migration towards fMLP (Mann Whitney 2-tailed p=0.08 and 0.12, respectively; Figure 
7-5 B, C and G), but not IL-8, were seen in patients with CKD compared to healthy 
controls (Figure 7-5 D-F). 
Accuracy of neutrophil migration (CI) towards fMLP, but not IL-8, was significantly 
associated with degree of proteinuria (ACR, Spearman r: -0.55, p=0.02) and medication 
burden (Spearman r: -0.51, p=0.03). CCI, eGFR, HbA1c and hsCRP were not significantly 
associated with either fMLP or IL-8 CI. 
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Figure 7-5 Neutrophil migration – comparison between patients with CKD and controls. 
A-C: migration indices in response to fMLP; D-F: migration indices in response to IL-8; E: 
representative cell tracking plots for patients with CKD and controls in response to fMLP 
(brightfield microscopy, x40 magnification). Error bars show median and IQR. 
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Medication burden was a significant predictor of neutrophil migratory accuracy (CI) to 
fMLP, independent of age and gender in a linear regression model (p=0.01). The model fit 
was not improved with the addition of ACR or eGFR (collinear with medication burden), 
suggesting that polypharmacy was a stronger predictor of neutrophil migration accuracy 
towards fMLP than measures of renal disease.  
Although the sample size for this analysis is small, the findings suggest reduced neutrophil 
responsiveness to stimulation by bacterial metabolites in older adults with CKD and other 
comorbidities, compared to healthy older adults. 
Interestingly, although no significant differences were seen in neutrophil phagocytosis, 
oxidative burst response/capacity or NETs generation between individuals reporting 
infections and those that did not, neutrophil migratory accuracy (chemotactic index) 
towards IL-8 (but not fMLP) was significantly lower in those who did report infections 
during the course of the study (Mann Whitney 2-tailed p=0.03, Figure 7-6). 
Figure 7-6 Accuracy (chemotactic index) of neutrophil migration towards IL-8 (A) and 
fMLP (B) – comparison between individuals that reported 1 or more infection. 
Pink symbols denote individuals reporting one or more infections (+1) and black symbols denote 
those that did not (0). Error bars show median +/- IQR. *denotes Mann Whitney 2-tailed p<0.05. 
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7.6 Discussion  
Overall, the results presented in this Chapter represent a comprehensive assessment of 
multiple aspects of neutrophil function in a well-characterised cohort of patients with 
CKD and age and gender matched controls.  
Phagocytosis of heat killed opsonised E. coli was similar in neutrophils from older adults 
with CKD compared to cells from age-matched controls, contrary to previous literature in 
ESRD populations (183, 184). This may reflect the inherent effect of dialysis therapy in 
driving neutrophil dysfunction (which was excluded from this study) and/or differences in 
experimental techniques. Indeed, a recent study using the PhagoTestTM assay method in 
non-dialysis CKD patients showed similar results to SONIC (194).  
Several functional defects that could result in reduced pathogen clearance were identified 
in patients with CKD: reduced proportion of cells generating ROS in response to 
physiological stimuli (fMLP and E. coli, although the biological effect of the small 
relative reduction to the latter may not be significant), reduced oxidative burst capacity in 
response to both physiological and mitogenic stimuli, reduced capacity to generate NETs 
in severe CKD (stage G4) in response to PMA and reduced migratory accuracy towards 
the bacterial metabolite fMLP. All but one of these parameters (migratory accuracy) were 
significantly associated with reducing eGFR, with variable inverse associations with ACR, 
a marker of kidney damage. However, due to the difference in multimorbidity between the 
two study groups, the effect of renal impairment alone cannot be reliably elucidated. 
Indeed, decreasing health status (measured using either CCI or medication burden) is the 
strongest predictor of neutrophil dysfunction in this study.  
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Previous studies of neutrophil oxidative burst function in CKD or dialysis have shown 
both increased and decreased function. These variations may be explained, in part, by 
immune activating effects of dialysis therapy, variations in patient selection and different 
experimental techniques. The findings of this study suggest that previously observed 
increased neutrophil ROS burst in ESRD patients may, indeed, be a treatment effect. 
Interestingly, a recent study examined neutrophil oxidative burst in non-dialysis CKD 
patients using the PhagoBurstTM assay, but the authors report only equivalent oxidative 
burst % responses to PMA (which is also seen in this study) and not the physiological 
stimuli included in the assay kit, without analysis of oxidative burst capacity per cell 
(MFI), concluding that neutrophil oxidative burst function is preserved in CKD.  
Literature on neutrophil migration in non-dialysis CKD is limited, but impaired neutrophil 
migration towards fMLP was recently reported following treatment of cells with FGF23 – 
a key biomarker associated with CKD (345) and another elegant study  elegantly 
demonstrated FGF23-mediated impairment of selectin-mediated slow rolling and 
chemokine-induced neutrophil migratory arrest (essential for neutrophil movement out of 
the vasculature and into inflamed tissue) in non-dialysis patients with CKD (346). The 
findings of this study are in keeping with this literature, but I did not investigate the 
contribution of FGF23. 
Interestingly, individuals reporting infections during the course of this study had lower 
neutrophil migratory accuracy to IL-8. This finding is comparable to that seen in patients 
with COPD who have a greater susceptibility to respiratory infections (347).  
Other systemic non-autoimmune chronic inflammatory disease states e.g. COPD have 
been associated with a number of neutrophil functional defects, including impaired 
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migratory accuracy and reduced generation of NETs (72), mirroring the findings of this 
study in patients with CKD (a systemic disease associated with chronic inflammation). 
This may suggest that chronic low-grade inflammation, regardless of origin, could be 
driving neutrophil dysfunction. There were, however, no significant relationships between 
the inflammatory marker hsCRP and neutrophil function parameters in this study. I did not 
measure systemic levels of other pro-inflammatory cytokines e.g. IL-6 or TNF-a, which 
may have yielded a different relationship to that seen with hsCRP. However, in contrast to 
the findings of this study in patients with CKD, studies of oxidative burst in neutrophils 
from patients with COPD have shown enhanced production, potentiating excessive tissue 
damage associated with infection and neutrophil phagocytosis is often impaired (72). 
As described in Chapter 1 (Introduction), neutrophil function also declines with age.  
Neutrophils from older adults frequently exhibit reduced phagocytosis, reduced killing 
ability, impaired NETs generation (74) and impaired chemotactic accuracy (75). As such, 
neutrophil dysfunction seen in this study of patients with CKD is largely in keeping with 
defects reported in association with chronological ageing, supporting the accelerated 
ageing hypothesis of CKD.  
Although several functional defects were found that could contribute to reduced pathogen 
clearance, this was not formally tested in a cell-mediated bacterial killing assay, which 
could yield further insights into neutrophil dysfunction associated with CKD. The sample 
size of the whole study is relatively small and the sequential addition of new functional 
assays reduced this further, thus limiting the power of the analysis. As such, confirmation 
of the findings observed in this study should be sought using a larger cohort of patients 
with CKD and age-matched controls. Further insights into the nature of and mechanisms 
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underlying neutrophil dysfunction in CKD could also be gained from assessment of 
neutrophil phenotype and quantification of immature granulocytes (shown to be a major 
contributor to neutrophil dysfunction associated with sepsis and thermal injury (259)), 
which was not performed in this study.  
Several groups have proposed environmental factors such as the retention of various 
uraemic solutes as a possible mechanism for neutrophil dysfunction observed in patients 
with CKD (182). However, without a complete understanding of the nature of neutrophil 
dysfunction, it is not possible to confirm the responsible mechanism. Also, as reviewed 
elegantly in (72), current literature on neutrophil function in advancing age and chronic 
illness is prospective and it is unclear which factor came first: the altered neutrophil 
function, the chronic illness, the ageing or the low-grade inflammation. 
As with previous results, multiple comparisons have been made between data from 
patients with CKD and controls in this chapter. Although some of the significant findings 
may represent type I errors (false positives), most are probably due to genuine differences 
between the disease groups and associations between variables.  
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CHAPTER 8 
8 GENERAL DISCUSSION 
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8.1 Major study findings and contribution to understanding of 
CKD-associated immune dysfunction 
In this thesis I have described the findings of a prospective observational study of the 
immune system and responses to external antigen challenge (vaccination) in older adults 
with and without chronic kidney disease. 
Contrary to previous literature documenting poor vaccine responses associated with ESRD 
(171, 179), only subtle reductions in the magnitude of the antibody increase at day 28 after 
vaccination with TIV and PPV23 were seen in patients with CKD compared to controls in 
this study. This may be due to the small sample size of the study, but also that a difference 
does not exist. Indeed, different studies report variable TIV and PPV23 responses in adults 
with CKD (176, 178, 179, 277, 278). The strongest evidence for a reduced vaccine 
response in the CKD population is with the hepatitis B vaccine (HBV) (179). The most 
common HBV vaccine in use is Engerix B (GSK, Belgium), which is adjuvanted with 
alum, unlike seasonal TIV, which is not. Therefore, although both vaccines are T-
dependent, the mechanics of immune responses elicited to HBV vaccination are likely to 
be different to that seen with TIV. Also, the use of TIV and PPV23 as surrogates for 
natural pathogen encounter in this study may be flawed as they represent a suboptimal 
mimic of natural infection. The responses seen with specific “narrow” antigen exposures 
in CKD may be largely preserved and significant immune defects may be revealed with 
activation of the whole immune response as occurs with natural infection. Indeed, despite 
the small sample size, patients with CKD did report a significantly greater number of 
respiratory infections than controls, in the face of only subtle differences in humoral 
vaccine responses. As such, future studies of immune responses in CKD could use 
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vaccines adjuvanted with agonists of the innate immune system (e.g. TLR9 (348, 349)) or 
live attenuated vaccines e.g. Salmonella Typhi Ty21a (350) as a better mimic of natural 
infection.  
An important finding in the response to PPV23 in this study was hyporesponsiveness to 
repeat vaccination, with reduced mean ARR in both controls and patients with CKD who 
had previously received PPV23, even with a median time lag of 10 years. This 
phenomenon has been reported previously, but its clinical relevance remains under debate, 
as discussed earlier in this thesis. However, the finding of Pn-specific IgG titre reduction 
in 8 out of 12 serotypes tested to below pre-vaccination levels at month 6 in 40% of 
PPV23 revaccinees in this study suggests that repeat PPV23 vaccination may not be 
beneficial in older adults with or without chronic disease. Previous studies have shown 
only marginal reductions in morbidity and mortality with PPV23 vaccination in older 
adults (281) and the findings of this study suggest that this may need to be revisited in the 
post-PCV era.   
8.1.1 Lymphocyte phenotypes 
Cross-sectional analysis of lymphocytes in this study revealed a preserved T cell 
proportion of lymphocytes, but a global B lymphopenia in patients with CKD compared to 
controls, in keeping with previous findings (215). No significant CKD-associated 
differences in naïve/memory T or B cell phenotypes were seen, in contrast to previous 
studies (182). This may be due to the small sample size in this study or that the difference 
does not exist. Unexpectedly, the size of circulating “senescence”-associated T cell 
populations (defined by loss of surface CD27/28 and/or gain of CD57/KLRG1) was 
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similar between patients with CKD and controls, which is not in keeping with the 
hypothesis of accelerated immune ageing in CKD. 
I also demonstrated an expansion of “Th2-like” populations of T cells in patients with 
CKD compared to controls, contrary to several (but not all (226, 227)) previous studies 
that report a polarisation towards a Th1 phenotype (182, 224). This could be due to the 
heterogeneity in experimental methods used e.g. surface chemokine receptor phenotyping 
used in this study, compared to intracellular transcription factor analysis and/or functional 
assays performed by other groups. On a physiological level, dialysis therapy rather than 
renal impairment itself may drive Th1 polarisation (182, 224), explaining this finding in 
studies of patients with ESRD. 
Treg populations were seen to be expanded in patients with CKD compared to controls in 
this study, independent of CMV. Previous studies have reported both increased and 
decreased circulating Tregs in association with CKD (221, 229, 230). Expansions of Tregs 
may induce excessive immunosuppressive effects, thus impairing immune responses to 
antigen and resulting in greater susceptibility to infection. 
Contraction of the Breg population in patients with CKD in this study is a novel finding 
and supports the hypothesis of accelerated immune ageing, as these features have 
previously been described in healthy older adults (85). Although antigen-specific cellular 
responses were not comprehensively interrogated in this study, I did demonstrate an 
equivalent expansion of circulating plasma cells/blasts at day 7 post-vaccination in both 
patients with CKD and controls, which significantly correlated with higher day 28 ARRs 
to both vaccines. This is a novel finding in CKD and suggests preserved capacity to 
generate ASCs to TIV/PPV23, although this requires confirmation in a larger cohort.  
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8.1.2 Contribution of latent CMV infection to lymphocyte phenotype 
and vaccine response  
The dominance of latent CMV infection, rather than health status, on shaping the memory 
T cell phenotype in both patients with CKD and controls is an important finding. Although 
expansion of CD28null T cells and the late differentiated TEMRA populations are known to 
be driven by chronic antigen exposure as seen in latent CMV infection (88), the 
interaction between CMV and chronological ageing/associated comorbidity is still 
debated. The lack of difference in relative “senescence”-associated T cell populations (e.g. 
CD28null, CD57+KLRG1+, TEMRA) seen in this study between patients with CKD and 
controls, may be due, in part, to a similar magnitude of the immune effect of CMV in the 
two groups. Previous studies demonstrating expansions of CD28null T cell populations in 
patients with CKD, independent of CMV, have frequently assessed the presence of the 
virus in a binary fashion, without quantitative assessment of CMV-specific IgG (217). In 
this study, CMV seropositive individuals with CKD and controls had equivalent titres of 
CMV-specific IgG, which is frequently used as a surrogate of the CMV “imprint” on the 
adaptive immune system (95). Previous studies may not have “controlled” for the 
magnitude of CMV-associated effect, which could manifest as a difference between 
controls and individuals with CKD. 
Interestingly, our group has previously shown higher CMV-specific IgG titres in a 
younger cohort of CMV seropositive adults with CKD compared to age-matched controls, 
suggesting an effect of CKD on CMV immune responses (180). As it is unlikely that latent 
CMV infection directly causes CKD, one explanation for this observation is that CKD-
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induced immune dysfunction results in impaired host control of CMV infection, resulting 
in increased frequency of subclinical reactivation and hence, increased antigen exposure, 
which drives the expansion of CMV-specific memory T cell populations to levels greater 
than seen in the general population. A possible explanation for the lack of difference seen 
in CMV-specific IgG titres between the disease groups in this study is that CKD could a 
different effect on the immune system depending on the age of the host, in keeping with 
the observation of reduction in the magnitude of relative risk increase of infection between 
individuals with CKD and the general population with increasing age. Latent CMV 
infection is also associated with Th1 polarisation of CD4+ T cells and previous studies 
have not adequately controlled for this (302, 351). The parity of CMV-associated immune 
“imprint” between the disease groups in this study may also account for the findings of 
“Th2-like” cell expansions in patients with CKD, contrary to previous data. As such, 
future studies of lymphocyte phenotype and function in patients with CKD should not 
only consider the presence of latent CMV infection, but also the magnitude of the CMV-
specific humoral response. 
Another novel and important finding is the effect of latent CMV infection on vaccine 
responses. CMV seropositivity was associated with lower day 28 mean ARR for PPV23 in 
all study participants, with previous PPV23 vaccination adding only a small extra 
reduction in responses in these individuals. Expansions of CMV-associated T cell 
populations (e.g. CD28null) were also associated with poorer TIV responses as measured 
using day 28 mean ARR. Latent CMV infection and previous PPV23 vaccination 
appeared to have an additive effect on reducing the magnitude of plasma blast/cell 
expansions at day 7 post-vaccination, even when examined in a small sample of study 
participants. These findings suggest that latent CMV infection could play a greater role in 
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impairment of immune responses seen in older adults with and without chronic disease 
than previously thought. Indeed, a recent study from our group in vasculitis patients (some 
with renal impairment) showed improved responses to PCV13 with reduced CMV 
reactivation episodes following 6 months of antiviral treatment (97).  
In addition to CMV, latent infections with other viruses, e.g. Epstein-Barr virus (EBV), 
herpes simplex virus (HSV), varicella zoster virus and polyomaviruses, are more prevalent 
with increasing age. Indeed, an estimated 5-10 individual viruses make up the persistent or 
chronic virome in adults (352, 353). Individual players in this persistent virome exhibit 
different cellular tropisms for latency. For example, CMV reservoirs (e.g. haematopoietic 
stem cells, monocytes/macrophages, vascular endothelium) are located throughout the 
entire body, with systemic potential for reactivation, whereas HSV is limited to 
craniofacial and/or anogenital sensory neurones and exhibits localised reactivation in the 
immunocompetent host (353, 354). Despite these differences, there is increasing evidence 
that viral reactivation at a local level can alter systemic immune responses (353-355). As 
such, it is possible that the effects on the adaptive immune system seen in association with 
latent CMV in this study are also impacted on by other latent viral infections, or a 
common factor that predisposes an individual to multiple latent viral infections.  
 
8.1.3 Neutrophil function 
In this study I have identified multiple functional defects in neutrophils from patients with 
CKD, including reduced oxidative burst capacity to multiple stimuli, together with 
reduced generation of NETs and impaired migratory accuracy to fMLP (which failed to 
reach statistical significance, possibly limited by sample size). As neutrophils form the 
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first line of defence against microbial invasion, these features may contribute the observed 
increased susceptibility to infection.  
In contrast to previous reports of impaired neutrophil phagocytosis in ESRD (183, 185), I 
found no difference in the phagocytic capacity of neutrophils between individuals with 
mild-moderate CKD and controls. Oxidative burst in neutrophils from patients with CKD 
has previously been reported to be both increased (184, 186) and decreased (187), with 
significant variations between studies in terms of experimental techniques used and 
participant selection. Interestingly, a recent study (194) using the same experimental 
technique (PhagoBurst© assay) reported preserved responses to PMA in terms of 
proportions of neutrophils producing ROS (similar to findings of this study), but did not 
interrogate this further through analysis of oxidative burst capacity per cell (MFI), where 
the most striking differences between controls and patients with CKD were seen in this 
study.  
Impaired neutrophil migration towards fMLP was recently reported following treatment of 
cells with FGF23 – a key biomarker associated with CKD (345), supporting the findings 
of this study. Interestingly, individuals reporting infections during the course of the study 
had significantly lower neutrophil migratory accuracy to IL-8, even in this small study 
sample. This finding is comparable to that seen in patients with COPD who have a greater 
susceptibility to respiratory infections (72).  
The neutrophil dysfunction seen in this study of patients with CKD is largely in keeping 
with defects reported in association with chronological ageing (72), supporting the 
accelerated immune ageing hypothesis of CKD. Several groups have proposed 
environmental factors such as the retention of various uraemic solutes as a possible 
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mechanism for neutrophil dysfunction observed in patients with CKD (182). Indeed, the 
uraemic milieu (particularly the presence of FGF23) has been shown to alter function of 
healthy neutrophils (345, 346). Another possible mechanism for CKD-associated 
neutrophil dysfunction is an alteration in cell metabolism. Indeed, mitochondrial 
dysfunction has previously been demonstrated in CKD (356). Overall, further 
comprehensive assessment of neutrophil function and phenotype in larger cohorts of 
patients with CKD is required to fully characterise the nature of CKD-associated 
neutrophil effects. 
 
8.2 Strengths and weaknesses 
This study has several strengths. Patients with CKD were well controlled for age and 
gender and the study selection criteria excluded several potential confounders, including 
dialysis therapy and immunosuppressive/modulatory comorbidities. Although the 
significantly higher prevalence of DM seen in patients with CKD than controls is a 
potential confounder in the analysis of CKD impact on the immune system in this study, 
the findings and conclusions remain highly applicable to the older population of CKD 
patients, who are usually multimorbid. As such, CKD and its associated comorbidities in 
older age could be considered a phenotype of “unhealthy ageing” and insights gained from 
this study may be relevant to the study of immune processes in “healthy ageing”. Another 
key strength of this study is the concurrent assessment of multiple aspects of the innate 
and adaptive immune systems in the same individual and in the context of clinical data 
such as infection incidence over the course of the study. 
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The main weakness of this study is the small overall sample size. Although the 
recruitment target of 100 individuals was achieved, a substantial number of participants 
withdrew from the study prior to vaccination, much of which was beyond my control. I 
also found that the older, comorbid individuals in my target CKD recruitment pool were 
frequently reluctant to commit to extra hospital visits, due to transport difficulties and 
multiple already scheduled hospital visits. However, the sample size of this study is 
representative of previous literature (214, 239). The study population was mostly of White 
ethnicity, and therefore findings may not be applicable to more ethnically diverse CKD 
populations.  
Multiple comparisons have been made between data from patients with CKD and controls 
in this thesis. Although some of the significant findings may represent type I errors (false 
positives), most are probably due to genuine differences between the disease groups and 
associations between variables. 
Although the study design eliminated a number of clinical confounders, I did not assess 
levels of vitamin D, hepcidin and FGF23 (previously shown to be associated with 
immunomodulation in CKD). I also did not assess the systemic inflammatory milieu 
beyond characterisation of hsCRP levels, but it is unlikely that pro-inflammatory cytokine 
characterisation in this study would have added significantly to what is already known in 
CKD, particularly as it would not be possible to identify the cell types responsible for their 
secretion.  
Weaknesses of the evaluation of humoral vaccine response in this study include lack of 
functional assessment of antibody produced e.g. affinity, avidity and opsonisation 
capacity, together with the lack of characterisation of antigen-specific IgA, IgM and 
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subclasses of IgG produced, which could yield further insights into the phenotype of the 
immune response to TIV/PPV23 in older adults with CKD. However, in relation to 
antibody functionality in CKD, previous work from our group has shown that cell-
independent serum killing of Salmonella Enteritidis is preserved in older patients with 
CKD compared to controls, suggesting that this patient population are able to make 
functional antibody (180).  
A weakness of the evaluation of lymphocytes in this study is the lack of assessment of 
cellular function, including proliferation and cytokine secretion profiles following 
stimulation, together with assessment of Treg and Breg suppressive capacity.  
 
8.3 Future perspectives 
The work presented in this thesis could be extended in several ways, including the 
evaluation of lymphocyte function (as described above) in addition to phenotype. The 
hypothesis of “uraemic milieu-mediated” neutrophil dysfunction (and its potential 
mechanisms) could also be explored through assessment of alterations in function of 
neutrophils isolated from healthy young individuals that are treated with serum/plasma 
from patients with CKD in this study.  
In view of the observed significant CMV-associated immune effects in this study, further 
work in the field of CKD-associated immune dysfunction could evaluate this in more 
detail, for example in a larger cohort of patients with CKD and controls. Given recent 
findings of improved TD vaccine responses following valacyclovir treatment in an 
immunosuppressed patient cohort, future work could also investigate the effect of CMV 
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suppression on vaccine responses/incidence of infection in patients with non-inflammatory 
CKD. The quantification of CMV reactivation e.g. urine CMV PCR in subjects recruited 
to this study could yield further insights into the biology of CMV latency and its effect on 
the adaptive immune system in health and disease. As discussed earlier, CMV represents 
only one of a number of possible players in the latent human virome that have potential to 
shape immune responses. Further work in this study could characterise the full extent of 
the latent virome in each individual and evaluate their virus-specific immune responses.   
As highlighted earlier, TIV and PPV23 may not represent adequate mimics of natural 
infection, therefore future studies should consider using other vaccines, responses to 
which are known to more closely mimic natural infection (e.g. live attenuated), or the 
concomitant use of agents that stimulate innate immune responses (e.g. CpG DNA – a 
TLR9 agonist). 
Given the complex and important interplay between innate and adaptive immune systems,  
further work in characterising the immune dysfunction associated with renal impairment 
should include assessment of APCs. The function of professional APCs such as DCs is 
key to generating effective and long-lasting memory responses to antigen. DCs have 
previously been largely examined in dialysis populations with reported depletion of 
circulating plasmacytoid dendritic cells (which express TLR7 and TLR9) and dysfunction, 
both of which are transiently exacerbated by haemodialysis treatment (293). As such, the 
effect of renal impairment alone on DCs remains unclear.  
It is also important to note that the study of immune cell populations in CKD has largely 
been limited to evaluation of peripheral cells, without assessment of structural or 
organisational changes in secondary lymphoid organs e.g. lymph nodes, or in bone 
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marrow. Further insights into the nature of CKD-associated immune dysfunction may be 
gained by examination of immune cell interactions in lymph nodes and immune cell 
populations in bone marrow, for example long-lived plasma cells. Recent studies have 
shown local immunomodulatory effects of adipose tissue on B cell populations (357), 
which may also be of interest in CKD, where adipokines such as leptin are thought to 
contribute to the chronic inflammatory state.  
The characterisation of immune dysfunction in CKD remains incomplete, but this study 
highlights the complexity of factors that may be at play, with evidence of both innate 
immune dysfunction and adaptive immune differences in patients with CKD. Latent CMV 
infection appears to have an important role in shaping the adaptive immune phenotype and 
vaccine responses in older adults with and without chronic disease, which raises the 
possibility that CMV suppression could be a possible therapeutic option to improve 
adaptive immune responses in this patient population, a concept supported by previous 
studies in both humans (97) and mouse models (358). The finding of significant 
hyporesponsiveness to repeat PPV23 in older adults with and without chronic disease in 
this study suggests a need for re-evaluation of the pneumococcal vaccination strategy in 
this patient group, particularly in the post-PCV13 era. Only when the nature of immune 
dysfunction in CKD is clearly defined can we start truly looking for CKD-associated 
causal mechanisms.  
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